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Summary 
 
Cardiovascular disease is the leading cause of mortality in Western countries. For 
the reconstruction of arteries with large caliber currently available synthetic grafts offer a 
reasonable solution and proven clinical efficacy. However, for small sized (<6 mm) grafts these 
materials generally give poor performance, due to anastomotic intimal hyperplasia and surface 
thrombogenicity.  The production of functional blood vessels by tissue engineering techniques 
is already possible, however due to the associated costs and lengthy production, the 
development of new materials appropriated for small diameter blood vessel replacements is 
still required. 
This thesis is a contribute for the improvement of bacterial cellulose for small blood vessel 
replacements. Among the strategies developed over the years to modify materials for vascular 
devices, pre-coating with the tripeptide Arg-Gly-Asp (RGD) improves endothelialization thus 
lowering thrombogenicity. In this work, bifunctional recombinant proteins, with a Cellulose-
Binding Module – CBM, from the cellulosome of Clostridium thermocellum - and cell binding 
sequences - RGD, GRGDY – were successfully cloned and expressed in the bacteria 
Escherichia coli. These RGD-containing cellulose-binding proteins were purified and used to 
coat bacterial cellulose fibres. Bacterial cellulose (BC) secreted by Gluconacetobacter xylinus is 
a material with unique properties and promising biomedical applications. CBMs adsorbs 
specifically and tightly on cellulose. Thus, they are a useful tool to address the fused RGD 
sequence (or other bioactive peptides) to the cellulose surface, in a specific and simple way. 
In this thesis the effects of chimeric proteins containing a CBM fused to adhesion peptides on 
the cell adhesion/biocompatibility properties were studied using mouse embryo fibroblasts 
(3T3) and human microvascular endothelial cells (HMEC) cultures. The results obtained 
demonstrated that the recombinant proteins containing adhesion sequences were able to 
significantly increase the attachment and spreading of fibroblasts and HMECs to BC surfaces, 
specially the RGD sequence. The results also showed that the RGD decreased the ingrowth of 
the HMEC cells through the BC and stimulated the early formation of cordlike structures by 
these endothelial cells. 
The blood compatibility of native and RGD-modified BC was also studied. The clotting times 
(aPTT, PT, FT and PRT) and whole blood clotting results demonstrate the hemocompatibility of  
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BC. A significant amount of plasma protein adsorbed to BC fibres, albumin presenting a higher 
BC affinity than γ-globulin or fibrinogen. According to analysis carried out by intrinsic 
tryptophan fluorescence, the BC adsorbed albumin, fibrinogen and γ-globulin do not undergo 
major conformational modifications. Although the presence of the adhesion peptide on bare-BC 
surface increases the platelet adhesion, when the material was cultured with human 
microvascular endothelial cells a confluent cell layer was readily formed, inhibiting the 
adhesion of platelets.  
Once the recombinant protein contains a bacterial CBM, the biocompatibility of native and 
RGD-CBM treated BC – to analyze whether the presence of the recombinant protein gives rise 
to any immunologic reaction – was investigated through in vivo studies in sheep. The fate of 
long term subcutaneous BC implants - 32 weeks - was analysed. Histological results showed 
that BC trigger a biological response typically observed for high surface-to-volume implants. 
After 1 week of implantation the presence of an inflammatory infiltrate suggests an 
acute/subacute inflammatory reaction that advance to a chronic inflammation confined to the 
implantation site and associated to the proliferation of small blood vessels. The presence of 
giant cells was observed at latter periods (16 and 32 weeks) and a narrow fibrous capsule was 
present surrounding the implant. BC tubes with small diameter (3mm ID) were produced and 
its mechanical properties evaluated.  
Overall, this work reports the successful functionalization of bacterial cellulose scaffolds with a 
CBM fused to adhesion peptides, leading to improved blood compatibility and increasing its 
potential use as blood vessels replacement. 
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Resumo 
As doenças cardiovasculares estão entre as principais causas de morte em países ocidentais. 
Para a reconstrução de artérias de grande calibre, os enxertos sintéticos actualmente 
disponíveis oferecem uma solução razoável e com eficácia clínica comprovada. No entanto, 
como enxertos de pequeno calibre (<6 mm) estes materiais geralmente apresentam  mau 
desempenho, devido a formação de hiperplasia íntima anastomótica e trombogenicidade 
superficial. A produção de vasos sanguíneos funcionais por meio de técnicas de engenharia de 
tecidos já é uma realidade, no entanto, devido aos elevados custos e longo tempo de 
produção, o desenvolvimento de novos materiais adequados para a substituição de vasos 
sanguíneos de pequeno diâmetro é ainda necessário. 
O objectivo geral desta tese foi o melhoramento da matriz de celulose bacteriana (CB) para o 
seu potencial uso como substituto de pequenos vasos sanguíneos. Entre as estratégias 
desenvolvidas ao longo dos anos destinadas à modificação de materiais usados como 
substitutos vasculares, o pré-revestimento com o tripeptídeo Arg-Gly-Asp (RGD) tem melhorado 
a endotelialização, reduzindo assim a trombogenicidade dos biomateriais. Neste trabalho, 
proteínas recombinantes bifuncionais, contendo um módulo de ligação à celulose (Cellulose – 
Binding Module – CBM) – do celulossoma da bactéria Clostridium thermocellum - e 
sequências conhecidas por promover a adesão de células (RGD, GRGDY) foram clonadas e 
expressas com sucesso na bactéria Escherichia coli, sendo posteriormente purificadas e 
usadas no revestimento de fibras de CB. Os CBMs adsorvem fortemente e especificamente à 
celulose, assim apresentam-se como uma ferramenta útil para direccionar de maneira simples 
e específica a sequência RGD (ou outros péptidos bioactivos) às superfícies de celulose. 
Nesta tese, os efeitos sobre a adesão celular/biocompatibilidade das proteínas quiméricas 
produzidas foram estudados usando culturas de fibroblastos de ratinhos (3T3) e células 
microvasculares humanas (HMEC). Os resultados obtidos demonstraram que as proteínas 
bifuncionais foram capazes de aumentar significativamente a adesão e o alongamento de 
fibroblastos e HMECs, além de promover uma distribuição uniforme das células sobre a matriz 
de celulose. A presença do RGD estimulou a formação antecipada de estruturas tipo-capilares 
em HMECs, porém diminuiu a invasão destas células na CB.  
A hemocompatibilidade da CB nativa e RGD-modificada também foi estudada. Os resultados 
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mostraram que uma quantidade significativa de proteínas plasmáticas adsorvem às fibras da 
CB, sendo que a albumina apresentou uma maior afinidade pela CB do que a γ-globulina ou 
fibrinogênio e que estas mesmas proteínas quando adsorvidas à celulose parecem não sofrer 
grandes alterações conformacionais. A presença do RGD na superfície da CB não-
endotelializada aumentou a adesão de plaquetas, porém quando este material foi revestido 
com células endoteliais, a adesão de plaquetas foi fortemente inibida.  
Uma vez que a proteína recombinante contém um CBM bacteriano, a biocompatibilidade da 
CB nativa e a tratada com RGD-CBM - para analisar se a presença desta proteína é capaz de 
originar alguma reação imunológica - foi investigada através de estudos in vivo, em ovelhas. Os 
implantes foram avaliados quanto à reação inflamatória, invasão celular e angiogênese. Os 
resultados histológicos mostraram que a CB provoca uma resposta biológica tipicamente 
observada em implantes que apresentam uma grande relação superfície x volume. Uma 
semana após a implantação a presença de um infiltrado inflamatório sugeriu uma reação 
inflamatória aguda/subaguda que progrediu para uma inflamação crónica, porém limitada ao 
local do implante, e associada à proliferação de pequenos vasos sanguíneos. A presença de 
células gigantes foi observada em períodos tardios e uma cápsula fibrosa delgada estava 
presente ao redor do implante. Não houve diferença significativa no grau de inflamação entre a 
CB tratada com RGD-CBM e a nativa. Nesta tese, tubos de CB com pequenos diâmetros foram 
produzidos e suas propriedades mecânicas avaliadas.  
De modo geral, este trabalho relata a funcionalização bem sucedida de matrizes de celulose 
bacteriana através do uso de peptídeos de adesão ligados a um CBM, resultando em uma 
melhor hemocompatibilidade e assim, aumentando seu potencial como substitutos de vasos 
sanguíneos.
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Chapter 1 
Figure 1. The arterial blood vessel (Sarkar et al. 2007 [10]) 
Figure 2. Metabolic and synthetic functions of endothelial cells: secretion of mediators that are able to influence 
cellular function throughout the body. LDL, low-density lipoprotein (Galley and Webster, 2004 [9]). 
Figure 3. Schematic representation of endothelial functions related to procoagulation and anticoagulation. NO, 
nitric oxide; PAF, platelet activating factor; PGI2, prostacyclin; t-PA, tissue plasminogen activator; TXA2, 
thromboxane A2; UK, urokinase; vWF, von Willebrand factor; WPb, Weibel–Palade body; AT III, Antithrombin III. 
Adapted from Michiels, 2003 [15]. 
Figure 4. Mechanisms of clotting factor interactions. Clotting is initiated by either an intrinsic or extrinsic pathway 
with subsequent factor interactions which converge upon a final, common path (Ratner et al., 1996[18]). 
Figure 5. Vascular prostheses. (a) Tissue engineering blood vessel (non-exogenous scaffold) produced by 
L’Heureux and colleagues  [55], (b) Dacron, (c) ePTFE.  
Figure 6. Endothelial cell interact by integrin family of cell-matrix receptors with the wall bound RGD-sequence and 
adhere to the vascular graft. Adapted from Walluscheck et al., 1996 [108]. 
Figure 7. Publications and patents on bacterial cellulose.  
Figure 8. Bacterial cellulose pellicle produced by ATCC 10245 G. xylinus strain in static culture. 
Figure 9. Scanning eletron microscopy of bacterial cellulose. Fibroblasts adhered on bacterial cellulose 
membranes after 24h in culture (Left, 1000x); detail of BC membranes surface (Right, 10.000x). 
 
Chapter 2 
Figure 1. Gluconacetobacter xylinus (ATCC 53582) cultured on liquid Hestrin-Schramm medium after 7 days. The 
medium was inoculated with the culture and added to the 24-well polystyrene plate (1 mL/per well) and 
incubated statically at 30 oC. 
Figure 2. Construction of the gene fusion encoding adhesion peptide and the Linker-CBM. (A) Construction 
containing one copy of the adhesion peptide at the N-terminal of the CBM; (B) Construction containing two copies 
of the adhesion peptide. 
Figure 3. Analysis by SDS-PAGE of recombinant protein expression and nickel column protein purification. 1-
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Molecular weight marker (250 kD, 150 kD, 100 kD, 75 kD, 50 kD, 37 kD, 25 kD, 20 kD); 2-Insoluble fraction; 3-
Soluble fraction; 4- Column filtrate; 5 to 9-Eluted fraction with 300 mM of Imidazole. (A) CBM; (B) RGD–CBM; (C) 
RGD–CBM–RGD; (D) GRGDY–CBM; (E) GRGDY–CBM–GRGDY. 
Figure 4. Fluorescent microscopy showing the binding of recombinant proteins to cell membranes. The arrows 
point with respect to some of the fluorescent cells. (A) RGD–CBM; (B) GRGDY–CBM; (C) CBM. 
Figure 5. Photographs showing the effect of the recombinant proteins on cell (fibroblasts 3T3) attachment to 
polystyrene plate. (A) RGD–CBM, (B) RGD–CBM–RGD, (C) GRGDY–CBM, (D) GRGDY–CBM–GRGDY, (E) CBM, (F) 
Buffer, and (G) Control. The photographs were taken at 1, 5, 24, and 48 h after addition of cells. 
Figure 6. MTS assays of fibroblast culture on polystyrene plates treated with the recombinant proteins (CBM, 
RGD–CBM, RGD–CBM–RGD, GRGDY–CBM, and GRGDY–CBM–GRGDY). The MTS test was developed at 1, 5, 24, 
and 48 h after addition of cells. 
Figure 7. Analysis by SDS-PAGE of the interaction between the recombinant proteins with the cellulose sheets. 
Line 1, 10, and 11 - Molecular weight marker (250 kD, 150 kD, 100 kD, 75 kD, 50 kD, 37 kD, 25 kD, 20 kD); 
line 2, 3 - RGD–CBM; line 4, 5 - RGD–CBM–RGD; line 6, 7 - GRGDY–CBM; line 8, 9 - GRGDY–CBM–GRGDY; line 
12, 13 - CBM. Lines 3, 5, 7, 9, and 13 represent the proteins after the interaction with BC sheets. 
Figure 8. MTS assays of fibroblast culture treated with the recombinant proteins (CBM, RGD–CBM, RGD–CBM–
RGD, GRGDY–CBM, and GRGDY–CBM–GRGDY) at the bacterial cellulose pellicles. The MTS test was developed at 
2, 24, and 48 h after addition of cells. 
 
Chapter 3 
Figure 1: MTS assays of HMEC-1 culture on BC–H pellicles treated with the recombinant proteins (CBM, RGD–
CBM, RGD–CBM–RGD, GRGDY–CBM and GRGDY–CBM–GRGDY) and buffer. The MTS assay was developed at 2, 
24, 48 hours and 7 days after cells addition. Results are expressed in absorbance values at 490nm. 
Figure 2: MTS assays of HMEC-1 culture on BC–L pellicles treated with the recombinant proteins (CBM, RGD–
CBM, RGD–CBM–RGD, GRGDY–CBM and GRGDY–CBM–GRGDY) and buffer. The MTS assay was developed at 2, 
24, 48 hours and 7 days after cells addition. Results are expressed in absorbance values at 490nm. 
Figure 3: MTS assays of HMEC-1 culture on BC–H pellicles treated with CBM, RGD–CBM and buffer. The MTS 
test was developed at 15, 30, 60, 90 and 120 minutes after addition of cells. Results are expressed in 
absorbance values at 490nm. 
Figure 4: Fluorescence photographs of endothelial cells stained with LIVE/DEAD® Viability/Cytotoxicity Kit for 
mammalian cells. Live cells are stained in green and dead cells are stained in red. BC–L treated with RGD–CBM 
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(a), CBM (b) and buffer (c). Controls with cells on polystyrene, live (d) and dead (e). Images were acquired using 
objectives 40x (scale 50µm). 
Figure 5: Apoptosis was quantitatively evaluated by the TUNEL assay. The HMEC cells were seeded on the BC–L 
and after 24h of incubation the TUNEL assay was performed. Bars represent the percentage of apoptotic cells 
evaluated by the ratio between TUNEL–stained cells and DAPI–stained nuclei in every culture. Experiments were 
repeated three times with identical results.  
Figure 6: Effect of RGD on the HMEC cell invasion through bacterial cellulose pellicles. Invasion was quantified in 
a double–chamber assay using medium complemented with 20% FBS as a chemoattractant. Bars represent the 
number of invasive cells. 
Figure 7: Images (a), (b) and (c) – optical microscopy photographs showing the effect of the RGD on the assembly 
of endothelial cells into capillary–like structures. BC–L treated with RGD–CBM (a), CBM (b) and buffer (c). Image 
was acquired using objective 20x (scale 200µm). Image (d) – Fluorescent microscopy image showing HMECs 
cells cultured at 14 days on BC–L pellicle treated with RGD–CBM recombinant protein. Nuclei were visualized by 
staining with DAPI (blue) and f–actin with Alexa Fluor 546-phalloidin (red). Image was acquired using objective 
20x (scale 100µm). 
Figure 8: SEM micrographs of bacterial cellulose. BC treated with RGD–CBM (a, b); CBM (c, d) and buffer (e, f). 
The arrows remark cells with elongated morphology. (a), (c) and (e) scale 50µm; (b), (d) and (f) scale 5µm. 
Figure 9: Immunocytochemical analyses using anti–vWF antibody. The results showed that HMEC cells cultured 
after 14 days on BC–L treated with recombinant proteins or buffer stained positively for vWF. (a) RGD–CBM, (b) 
CBM and (c) buffer. Image was acquired using objective 20x (scale 100µm). 
 
Chapter 4 
Figure 1: Plasma protein adsorption onto the bacterial cellulose membrane untreated or treated with the 
recombinant proteins (RGD-CBM or CBM) and controls (ePTFE and polystyrene). (a) Platelet–poor plasma; (b) 
human serum albumin; (c) human γ–globulin and (d) human fibrinogen. 
Figure 2: Comparison of the adsorption isotherms for the binding human serum albumin (HSA), human fibrinogen 
(HFG) and human γ–globulin (IG) on BC. 
Figure 3: Percentage of desorbed proteins on BC at each concentration tested after treatment with 1wt% aqueous 
solution of SDS. Human serum albumin (HSA), human fibrinogen (HFG) and human γ–globulin (IG). 
Figure 4: Steady–state fluorescence emission spectra of (a, b) human serum albumin, (c, d) human fibrinogen 
and (e, f) human γ–globulin adsorbed on BC and in solution. (a, c, e) and (b, d, f)  excitation wavelength of 295 
nm and 270, respectively, collected from 305 to 400 nm. 
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Figure 5: Comparison of anticoagulation time (aPTT, PT and FT) of BC membranes untreated or treated with the 
recombinant protein (RGD–CBM) and the controls (ePTFE, polystyrene and glass microspheres). The coagulation 
times of PPP non–contacted with the materials (pre–incubation control) were also analysed. 
Figure 6: Clotting kinetic profiles of the absorbance at 405nm as a function of time for PPP incubated with 
polystyrene, BC (hydrated and lyophilized), glass microspheres and ePTFE (a). Citrated PPP (without the addition 
of calcium) serves as a negative control. The data was averaged over five independent experiments. The half-max 
time of each profile (b) was calculated as a measure of the clotting time. 
Figure 7: The effect of BC, ePTFE, polystyrene and glass microspheres on thrombus formation in whole blood at 
0, 5, 15, 25 and 35 min. 
Figure 8: Relative number of platelets adhered on ePTFE and BC membrane untreated or treated with the 
recombinant proteins (RGD–CBM or CBM).  
Figure 9: SEM images of BC membrane and ePTFE surface after contact with PRP for 2 hours. Column II (scale 
bar 5µm) is the magnified images of Column I (scale bar 20µm). 
Figure 10: SEM images of the adhered platelets on endothelialized BC untreated or treated with recombinant 
proteins and ePTFE. The bare BC and ePTFE were used as controls. The captions without “bare” indicate the 
cultured HMEC surface. Column II and IV (scale bar 10µm) is the magnified images of Column I and II (scale bar 
30µm), respectively. 
Figure 11: Densities of adhered platelets on endothelialized BC untreated or treated with recombinant proteins 
and ePTFE. The bare BC and ePTFE were used as controls. 
 
Chapter 5 
Figure 1. Bacterial cellulose produced by G. xylinus (ATCC 53582) grows around the silicon tube, when an air flow 
is injected through the tube. a) Schematic picture of the cultivation system; b) Bacterial cellulose tube. 
Figure 2.MTS assays of fibroblast cultures at the dense or porous side of BC membrane. The MTS assay was 
developed at 2, 72 and 7 days after cell seeding. Results are expressed as absorbance values at 490 nm. 
Figure 3. Fluorescent microscopy images showing fibroblast cultured 7 days on BC pellicle. (a) Dense and (b) 
porous side of RGD–treated BC; (c) Dense and (d) porous side of untreated BC.Nuclei were visualized by staining 
with DAPI (blue) and f–actin with Alexa Fluor 546-phalloidin (red). Actin and nuclei combined images were 
acquired using objectives 10x (scale 200µm); Nuclei images were acquired using objectives 20x (scale 100µm). 
Figure 4. CryoSEM micrographs of bacterial cellulose cultured with fibroblasts after 14 days. (a) Dense and (b) 
porous side of RGD–treated BC; (c) Dense and (d) porous side of untreated BC. Scale 10µm. 
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Figure 5. CryoSEM micrographs of bacterial cellulose tubes. Visualization through a longitudinal cut of (a) Inner 
side (b) outer side. Visualization through a transversal cut of (c) Inner side (d) outer side. Scale 60µm 
(longitudinal images), scale 10µm (transversal images). 
Figure 6. Tensile stress-strain curves of the lengthwise of BC tubes with an inner diameter and wall thickness of 3 
mm and 1 mm, respectively. 
Figure 7. Histomorphology of bacterial cellulose membrane implanted subcutaneously in sheep and surrounding 
tissue reaction. Once there were no significant differences in biological responses by the host, the images 
represent the results for both groups of the post-implantation times analyzed. (a) 1, (b) 2, (c) 4, (d) 8, (e) 16 and 
(f) 32 weeks post-implantation. (a, b, c, d), (e) and (f), 40x, 100x and 400x ampliation, respectively (Hematoxylin - 
eosin staining). The solid arrows indicate the fibrous capsule formation. The dashed arrow on image (f) indicates 
small blood vessels formation. (*) Bacterial cellulose. 
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Aims and thesis outline 
 
Bacterial cellulose (BC) produced by Acetobacter microorganisms, is a glucose polymer with 
unique properties, including high water holding capacity, high crystallinity, an ultrafine fiber 
network, and high tensile strength, thus holding great potential for biomedical applications. The 
aim of this work was the development of a new approach to functionalise BC, through 
recombinant proteins containing adhesion peptides conjugated with a cellulose binding-
module. The use of recombinant proteins containing a CBM domain, exhibiting high affinity 
and specificity for cellulose surfaces, allows the control on the interaction of this material with 
cells. To achieve this aim, bifunctional recombinant proteins with CBM – from the cellulosome 
of Clostridium thermocellum – and cell binding sequences (RGD, GRGDY) were cloned and 
expressed in Escherichia coli. Thereafter, the potential use of these recombinant proteins in 
improving biocompatibiity/blood compatibility was studied. 
Chapter 1 presents a revision of these subjects, namely 1) The role of endothelium and the 
tissue engineering of small diameter vascular grafts; 2) properties and biomedical applications 
of bacterial cellulose. 
Chapter 2 describes the strategies used to produce the bifunctional recombinant proteins 
containing bacterial CBM from C. thermocellum fused to a RGD or GRGDY sequences. In this 
chapter a mouse embryo fibroblasts culture was selected and used in 
adhesion/biocompatibility in vitro assays as animal cells model to test our strategy in modified 
bacterial cellulose. 
Once the general aim of this work is the improvement of BC as scaffold to the production of 
small vascular graft chapter 3 describes the in vitro study of the effect of these chimerics 
proteins in Human microvascular endothelial cell cultured on BC. 
Although BC is promising material for vascular replacements, to our knowledge only very 
recently a first publication was dedicated to evaluate the thrombogenic properties of this 
biomaterial. However, further characterization is necessary, not only to confirm the promising 
hemocompatibility of BC, but also to better understand the BC-blood interaction, through more 
comprehensive characterization. Thus chapter 4 describes a blood compatibility study of BC. 
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Biocompatibility is one main requirement for any biomedical material. In chapter 5 we 
complete the in vitro biocompatibility study using fibroblast cultures. Also, the fate of long term 
subcutaneous implants in sheep – 32 weeks – was analysed to evaluate the in vivo 
biocompatibility of BC membranes. Once the chimeric protein used in this work contains a 
bacterial CBM the biocompatibility of BC membranes treated with the RGD–CBM protein was 
investigated. Finally we developed preliminaries studies on the mechanical properties of BC 
tubes. 
In the last chapter of this thesis (chapter 6) are presented the general conclusion of this work 
and the future perspectives. 
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Tissue Engineering of small diameter vascular 
grafts 
 
The prevalence of atherosclerotic arterial disease is increasing in an ageing society [1], the 
cardiac and peripheral vascular diseases figuring among the major cause of death in the 
Western world [2]. Vascular grafts are thus required for coronary and peripheral bypass 
surgeries. Autologous grafts remains the most used treatment, saphenous veins and 
mammary arteries being preferably used. However, autologous vessels are not available in over 
10% of the patients as a result of preexisting vascular disease, amputation or previous harvest 
for prior vascular procedures. Moreover, a second surgical procedure is needed to obtain the 
vessel [3, 4].  
The ideal vascular graft must meet a number of requirements: appropriate mechanical 
attributes that mimic the mechanical properties of a native vessel, being capable of 
withstanding long-term hemodynamic stress without material failure, good suturability and easy 
handling during the surgical procedure, appropriate permeability to water, solutes and cells. 
Furthermore, it should exhibit physiological properties such as vasoconstriction/relaxation, 
induce acceptable postimplantation healing not resulting in inflammation, hyperplasia, or 
fibrous capsule formation, leading to the integration of the graft into the body. Finally, a fully 
biocompatible graft should be nonimmunogenic and resistant to both thrombosis and infection 
[3] (TABLE 1).  
Unfortunately, no conduit to date possesses all of these qualities and attributes. Although 
acceptable patency rates are achievable using current commercially available prosthetic 
material, such as polyethylene terephthalate (PET, Dacron) or expanded polytetrafluoroethylene 
(ePTFE), which performs well as large-caliber replacements, small-diameter (less than 6 mm) 
prosthetic conduits have unacceptably poor patency rate. This is the result of low-flow 
conditions within a narrow conduit and compliance mismatch between prosthesis and native 
artery. Intimal hyperplasia and the inherent thrombogenicity of prosthetic materials are further 
major contributing factors [5]. 
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Table 1. Characteristics and desirable features of the ideal vascular graft. 
Biocompatible 
No healing disturbances 
Non-toxic 
Non-allergic 
No induction of malignancies 
Minimally traumatic to blood compounds 
Non-thrombogenic 
Resistant to infection 
Compliant 
Flexible, elastic, without kinking 
Resistant to myointimal hyperplasia 
Vasoactivity 
Appropriate permeability 
Easy processing 
Adequate physical and chemical properties, mechanical 
durability 
Readily available in a variety of sizes and lengths 
No need for special storage or preparation procedures 
Easy to suture 
Sterilisation 
Optional 
Capable of local drug delivery 
Low costs 
(Adapted from Teebken and Haverich, 2002 [6]) 
 
The endothelium 
The whole circulatory system has a common basic structure and consists of three different 
layers (FIGURE 1), from innermost to outermost: first, the tunica intima, constituted exclusively 
of endothelial cells (ECs) which are only one layer thick, supported by a basement membrane 
and delicate collagenous tissue, is the only layer of vascular tissue which comes into contact 
with blood; second, an intermediate muscular layer which is named the tunica media, 
composed of many layers of smooth muscle cells (SMCs) and an outer supporting tissue layer 
called the tunica adventitia. This last layer is composed primarily of loosely woven collagen 
fibers and can also contain small capillaries to provide nutrients to the outer layers of the 
tunica media [7]. Endothelial cells, as the inner lining of blood vessels, are strategically located 
between circulating blood and blood cells and the vascular smooth muscle [8]. Endothelial cell 
structure and functional integrity are important in the maintenance of the vessel wall and 
circulatory function. Furthermore, as a barrier, the endothelium is semi-permeable and 
regulates the transfer of small and large molecules. Endothelial cells are dynamic and have 
both metabolic and synthetic functions. They exert significant autocrine, paracrine and 
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endocrine actions and influence smooth muscle cells, platelets and peripheral leucocytes [9]. 
Endothelial cells have a main role in maintaining a nonthrombogenic blood – tissue interface 
and regulate thrombosis, thrombolysis, platelet adherence, vascular tone and blood flow 
(FIGURE 2). The endothelium is indispensable for body homeostasis; an uncontrolled 
endothelial cell response is involved in many disease processes, including atherosclerosis, 
hypertension, pulmonary hypertension, sepsis and inflammatory syndromes. These diseases 
are related to endothelial injury, dysfunction and activation [9]. 
 
 
Figure 1. The arterial blood vessel (Sarkar et al. 2007 [10]) 
 
Physiological functions of the endothelium: 
Anti-thrombotic functions. Under normal conditions the endothelium maintains an 
equilibrium between the anticoagulant and procoagulant phenotype (FIGURE 3). The 
anticoagulant activity of the endothelium is geared at restricting the generation of thrombin. At 
their surface, ECs are lined with a very fine and fragile layer called the glycocalyx, consisting of 
glycoproteins, glycosaminoglycans and proteoglycans. Globally, the glycocalyx provides an 
anticoagulant layer because of its negative electrical charge that repels circulating platelets and 
that allows the interactions with vitamin K-dependent coagulation factors. Also heparan sulfate 
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and dermatan sulfate, two glycocalyx glycosaminoglycans, potentiate the activity of two 
anticoagulant enzymes, antithrombin III and heparin cofactor II [11]. ECs produce 
thrombomodulin (TM) that is either attached to the membrane or released into the circulation. 
Because TM binds to the same site on thrombin that would normally bind to fibrinogen, 
platelets or factor V, all of these functions carried out by thrombin are blocked. TM converts 
thrombin from a procoagulant protease into an anticoagulant and slows down the clotting 
process. The thrombin/TM complex plays a role as a cofactor in the activation of the zymogen 
protein C (PC) into activated protein C (APC), which degrades factor V and VIII [12].  
 
  
Figure 2. Metabolic and synthetic functions of endothelial cells: secretion of mediators that are 
able to influence cellular function throughout the body. LDL, low-density lipoprotein (Galley and 
Webster, 2004 [9]). 
 
In vivo, the initiation of coagulation in response to trauma occurs via the exposure of tissue 
factors to blood. Tissue factor is the receptor for factor VII and is procoagulant. It is inhibited by 
tissue factor pathway inhibitor (TFPI), which is synthesized mainly by endothelial cells under 
basal conditions and is bound to the endothelial cell surface. Tissue factor expression leads to 
the activation of factor X, which then combines with factor Va to convert prothrombin to 
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thrombin [13, 14]. 
The anti-thrombotic functions of ECs also include antiplatelet activity. ECs produce substances 
such as prostacyclin I2 (PGI2) and nitric oxide (NO), both synergistically increase cAMP content 
in platelets, hence preventing their aggregation. In addition, endothelium also displays 
ectonucleotidases at its luminal surface. These enzymes hydrolyse ATP and ADP, both potent 
platelet aggregating agents, into AMP and adenosine [15-17]. 
Pro-thrombotic functions. The endothelium normally promotes blood fluidity, unless there 
is an injury. With damage, the normal response is to promote coagulation at the wound site 
while containing the coagulation response and not allowing it to propagate beyond this site. 
At least two mediators released by activated endothelial cells favour platelet activation. The first 
one is the lipid mediator platelet-activating factor (PAF), synthesized by endothelial cells 
stimulated by thrombin, histamine, or cytokines. PAF is a potent platelet activator and can 
promote platelet adhesion to endothelial cells. The second is the von Willebrand factor (vWF) 
synthesised by EC and stored in vesicles (Weibel-Palade bodies) and secreted upon stimulation 
by thrombin. Moreover, vWF binds and stabilizes coagulation factor VIII and is a specific factor 
required for the binding of platelets to exposed extracellular matrix (ECM) components when 
the vessel wall is damaged [15]. 
Tissue factor is a glycosylated intrinsic membrane protein that is expressed on the surface of 
adventitial vascular wall cells and is exposed to flowing blood during vascular injury or 
endothelial denudation. Endothelial cells do not normally express the primary trigger of the 
coagulation system, tissue factor. However, when exposed to thrombin, cytokines, or 
lipopolysaccharides (LPS), endothelial cells synthesize and express tissue factor at their 
surface. Tissue factor, when bound to factor VIIa, is the major activator of the extrinsic pathway 
of coagulation [15, 18]. 
Fibrinolityc activity. During vessel repair a fibrin matrix is formed. The fibrin matrix acts as a 
barrier preventing further blood leakage and provides a structure for new microvessels to 
infiltrate in damaged or activated tissue [7]. The fibrinolytic system is responsible for 
proteolysis and solubilization of the formed clot, allowing its removal. The endothelium 
participates in fibrinolysis by releasing tissue-type plasminogen activator (t-PA) and urokinase, 
allowing the transformation of plasminogen into plasmin, which degrades thrombi by digesting 
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the fibrin network. t-PA is constitutively released while urokinase is only synthesized by 
activated endothelial cells [11]. It must be noted that the natural inhibitor of t-PA, plasminogen 
activator inhibitor type 1 (PAI-1) is also constitutively secreted by endothelial cells. The balance 
of t-PA and PAI-1, which is normally in favor of PAI-1 is also altered by cytokines [19]. 
 
 
 
Figure 3. Schematic representation of endothelial functions related to procoagulation and 
anticoagulation. NO, nitric oxide; PAF, platelet activating factor; PGI2, prostacyclin; t-PA, tissue 
plasminogen activator; TXA2, thromboxane A2; UK, urokinase; vWF, von Willebrand factor; WPb, 
Weibel–Palade body; AT III, Antithrombin III. Adapted from Michiels, 2003 [15]. 
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Host defence and inflammation. Endothelial cells play key roles in host defence and 
inflammation by regulating lymphocyte and leukocyte movement into tissues. At the time of 
inflammation, due to either tissue injury or infection, several processes occur to facilitate the 
infiltration of leukocytes into the tissue. Among these are vasodilatation, increased blood flow 
and release of histamine and inflammatory cytokines. Due to these processes the endothelial 
cells become activated and interactions with leukocytes occur. The different steps in leukocyte 
sequestration into the surrounding tissue are tethering, rolling of the leukocyte along the vessel 
wall, firm adhesion to the endothelial cells, and transmigration though the vascular wall. All 
these sequential steps in the adhesion cascade are mediated through the intricately regulated 
expression of adhesion molecules [20]. 
Regulation of vasomotor tone. The endothelium is a significant contributor to the 
regulation of vasomotor tone, under the influence of physical and chemical factors originating 
from the vascular lumen or the surrounding tissues. ECs produce and release vasodilator 
substances such as NO and prostacyclin, and vasoconstrictor mediators such as endothelin 
and platelet activating factor (PAF). The production of NO by the endothelium is constitutive 
and modulated by different stimuli, whereas the synthesis of other mediators (prostacyclin, 
endothelin and PAF) is inducible [11]. 
Transport functions. The endothelium is an important barrier to the free passage of 
molecules and cells from the blood to the underlying interstitium and cells. Specific 
mechanisms are responsible for the transport of essential circulating blood macromolecules 
across endothelial cells to the subendothelial space, to meet the metabolic needs of the 
surrounding tissue cells. In addition, the junctions between endothelial cells (the so called 
`tight' junctions) act as a selective barrier to the egress of molecules from the circulation [9]. 
Angiogenesis. Vascular endothelial growth factor (VEGF) is an angiogenic factor produced by 
a variety of cells, including endothelial cells, with specific receptors on the endothelium. 
Angiogenesis – the formation of new blood vessels from pre-existing endothelium – is mediated 
by VEGF. VEGF contributes to the inflammatory response through stimulation of the release of 
adhesion molecules, metalloproteinases and NO, via the transcription factor activator protein-1 
(AP-1) [9]. 
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Coagulation cascade 
Initiation of clotting occurs either intrinsically by surface-mediated reactions, or extrinsically 
through factors derived from tissues. The two systems converge upon a final common path, 
which leads to the formation of an insoluble fibrin gel when thrombin acts on fibrinogen. 
Coagulation proceeds through a “cascade” of reactions by which normally inactive factors 
become enzymatically active following surface contact, or after proteolytic cleavage by other 
enzymes. The newly activated enzymes in turn activate other normally inactive precursor 
molecules. Figure 4 presents a scheme of the clotting factor interactions involved in both the 
intrinsic and extrinsic systems and their common path.  
In the intrinsic system, contact activation refers to reactions following adsorption of contact 
factors onto a negatively charged surface. This pathway is initiated when factor XII adsorbs to 
surfaces such as artificial materials, leading to spontaneous cleavage of factor XII into its active 
form factor XIIa. Factor XIIa converts both prekallikrein and factor XI into their active forms, 
kallikrein and factor XIa respectively, with high-molecular-weight kininogen (HMWK) as a 
cofactor. Factor XII, in turn, is a substrate for kallekrein, creating a short reciprocal activation 
loop, which leads to rapid contact activation. A middle phase of intrinsic clotting begins with 
the first calcium-dependent step, the activation of factor IX by factor XIa. Factor IXa 
subsequently activates factor X. Factor VIII is an essential cofactor in the intrinsic activation of 
factor X, and factor VIII first requires modification by an enzyme, such as thrombin, to exert its 
cofactor activity. In the presence of calcium, factors IXa and VIIla form a complex on 
phospholipid surfaces (as expressed on the surface of activated platelets) to activate factor X. 
This process is slow in the absence of appropriate phospholipid surfaces and serves to localise 
the coagulation to the cell surface [18, 21].  
The extrinsic system is initiated by the activation of factor VII after interaction with the tissue 
factor, which is located in the tissue adventitia and comes in contact with blood only after 
vascular injury. When factor VII interacts with tissue factor, in the presence of calcium ions, 
factor VIl is converted to a serine protease (factor VIIa) by minor proteolysis [22]. 
The common path begins when factor X is activated by either factor VIla-tissue factor or by the 
factor IXa—VIlla complex. The cofactor V, like factor VIII, is activated by thrombin to factor Va, 
which together with factor Xa, forms the complex factor Xa-Va that cleaves prothrombin (factor 
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II) to thrombin in the presence of calcium and phospholipids. Next, thrombin acts on fibrinogen 
and small peptides from fibrinogen are released. Then, these fibrin monomers polymerize to 
become a gel. Factor XIII is either trapped within the clot and is activated by thrombin. The 
factor XIIa stabilizes the fibrin polymer network and a insoluble fibrin network is formed [18]. 
 
 
Figure 4. Mechanisms of clotting factor interactions. Clotting is initiated by either an intrinsic or 
extrinsic pathway with subsequent factor interactions which converge upon a final, common path 
(Ratner et al., 1996[18]). 
 
Types of vascular grafts 
Autografts  
Autografts (or autologous graft) are any tissues transplanted from one part of the body to 
another location in the same individual. The use of venous and to some extent arterial 
autografts is well established in peripheral vascular surgery. For the reconstruction of small 
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diameter arteries, as required for lower-extremity bypass and coronary artery bypass grafting 
procedures, an autologous vein graft is typically used (e.g., saphenous vein); in the case of the 
coronary artery, an autologous arterial graft may alternatively be used (i.e., internal thoracic 
artery, gastroepiploic artery, inferior epigastric artery, radial artery) [23, 24]. Although venous 
and arterial autografts currently yield the best results (Table 2), disadvantages include the need 
for multiple surgical procedures, with increased risk and cost to the patient. In addition, vein 
grafts have thin walls that may be damaged when exposed to increased flow and pressure, as 
the ones present in the arterial circulation. Furthermore, suitable vessels are not available in all 
patients due to disease, amputation, or previous vessel harvest [25]. Grafting of tubes derived 
from skin, fascia, pericardium, and dura have been investigated in animal studies and in 
isolated human cases, and the results were not encouraging due to early thrombosis and 
aneurysm formation, although autografts from small intestine have shown some promise [6].  
 
Allografts 
Fresh or cryopreserved allografts (surgical transplantation of tissue between two genetically 
dissimilar individuals of the same species) have also been used in the clinic as coronary artery 
bypass conduits. These grafts are considered superior to artificial protheses and relatively 
resistant to infection, enjoy minimal thromboembolic complications, and do not require 
anticoagulation. Limitations include their reduced availability and durability due to calcification, 
aneurismal dilatation, and rupture. Fresh allografts undergo rapid rejection, while 
cryopreserved allografts have a longer but still limited clinical life [6, 26].  Allografts appear to 
be a useful choice for (1) the individual with a real need for revascularisation and who is 
burdened with a limited life expectancy not exceeding the functional life of the allograft, (2) 
urgent replacement of a major vessel damaged by trauma, [27] in situations where 
immunosuppression is contraindicated as in an infected surgical field, and (3) in patients 
whose immune system is already compromised. The allograft probably should not be used (1) 
simply for the relief of intermittent claudication, (2) in the above mid-calf location, and [27] in 
other anatomic locations where synthetic grafts perform better [26]. 
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Table 2. Methods for blood vessel replacement. 
 Autograft  Allograft Xenograft Prosthesis 
 Vein Artery Different sources Different sources Plastic 
Authors [28-32] [33, 34] [35-38] [39, 40] (Vinion N)[41]; (Teflon)[42]; 
(Dacron)[43, 44]; (seeded 
ePTFE)[45]; (Polyurethane)[46]. 
Examples Great saphenous vein, 
arm veins, popliteal 
vein, superficial femoral 
vein 
Internal and external iliac 
artery, superficial femoral 
artery, internal thoracic 
artery 
Artery, great saphenous vein, 
(Dacron - externally reinforced) 
umbilical vein, cryopreserved vein 
segments 
Bovine carotid/ internal 
thoracic artery 
Knitted crimped sealed Dacron; 
externally 
Reinforced expanded PTFE 
Availability Limited; diameter <1 to 
>6 mm, segment length 
<1m 
Very limited; diameter, <1 
to >8mm segment length 
cm 
Limited/good; diameter 4-6mm, 
segment length <1 m; special 
storage (e.g. cooling, liquid 
nitrogen) 
Good; diameter 4-8mm, 
segment length <40 cm; 
special storage (e.g. cooling, 
liquid nitrogen) 
Very good; diameter 6 to 
>30mm, segment length <1m 
Long-term 
results 
Complete healing, 
degeneration and 
aneurysms are rare, 
intima hyperplasia 
Very good No complete healing, degenerative 
disease; calcifications (Dacron 
reinforcement!); transmission of 
disease 
Degeneration, calcification, 
intima hyperplasia; 
transmission of disease (?) - 
PERV, BSE 
Intimal hyperplasia, thrombosis, 
obstruction, suture aneurysms 
5-year patency ∼75% (great saphenous 
vein); ∼65% (arm veins) 
∼95% ∼60% (umbilical vein) ∼59% (bovine xenografts) ∼40% (PTFE); ∼80% (EC seeded 
PTFE) 
Compliance 
mismatch 
+ + (+) (+) - 
Biocompatibility + + (+) + + 
Handling - (preparation, additional 
wound complications) 
- (preparation, additional 
wound complications) 
(+) (+) + 
Legend: favourable +; less favourable (+); unfavorable - ; PERV = porcine endogenous retro virus; BSE = bovine spongiform encephalitis. Adapted from 
Teebken and Haverich, 2002 [6]. 
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Xenografts 
In contrast to heart valve prostheses, tissue of xenogenic origin for small-diameter vascular 
grafts is rarely used. In 1964, Rosenberg and colleagues developed arteries derived from 
bovine sources. These authors created scaffolds, consisting mainly of collagen, by means of 
enzymatic cellular extraction using a solution of 1% ficin [39]. However, long-term results were 
not encouraging, due to aneurysm formation, infection, and a high incidence of thrombosis. 
The antigenicity has a deleterious effect on subsequent endothelialisation. For these reasons 
use of xenografts cannot be recommended for peripheral vascular reconstruction [6]. 
 
Tissue Engineered Grafts 
The most common tissue engineering approach involves the use of exogenous scaffolds into 
which cells are seeded and cultured. These scaffolds provide structural support and allow cell 
growth, migration, differentiation and cellular ECM production. Ideally, these scaffolds would 
degrade at the same rate as the natural tissue proliferate and synthesize new ECM. Tissue 
engineering scaffolds can be made of either natural or synthetic materials. 
Natural protein scaffolds. Natural protein scaffolds utilize the components of native ECM 
and create fully biological grafts. Natural protein scaffolds can be composed of collagen, 
elastin, fibronectin, or protein hydrogels [47]. Historically, the first adhesive gels were made 
from collagen [48]. Collagen gels have been shown to yield a high percentage of 
circumferentially aligned cells, which closely resembles alignment in natural blood vessels. 
However, these scaffolds do not provide sufficient initial mechanical strength to support normal 
hemodynamic loading [49]. To improve mechanical properties and increase collagen fiber 
alignment, collagen has been cross-linked with elastin providing the vessels with a greater 
elasticity and better mechanical properties [50]. Although the collagen/elastin gels did provide 
better structural characteristics than pure collagen ones, they still could not withstand the 
pressures experienced by small diameter arteries [49]. Another advantage is that both collagen 
and fibrin allow direct cellularization by cell entrapment during the gelation, because this 
occurs under physiological conditions [3]. On the other hand, natural protein scaffolds are 
often difficult and expensive to manufacture [47]. 
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Decellularized tissues. After the removal of the original cellular component through 
sequential protease treatments and detergent extractions, decellularized conduits of natural 
matrix structures from tissues ranging from cadaveral arteries to umbilical veins and small 
intestinal submucosa (SIS) xenografts have been tested for their potential to replace vascular 
matrix and encourage the ingrowth of host cells postimplantation [51]. The use of these 
natural biomaterials has typically required chemical or physical pretreatment aimed at (1) 
preserving the tissue by enhancing the resistance of the material to enzymatic or chemical 
degradation, (2) reducing the immunogenicity of the material, and [27] sterilizing the tissue. 
Multiple crosslinking techniques have been explored in an attempt to find the ideal procedure 
to stabilize the collagen-based structure of the tissue while maintaining its mechanical integrity 
and natural compliance. Decellularized tissues have the advantage of being entirely composed 
of natural ECM, providing mechanical, chemical and biological advantages over synthetic 
materials, and thus holding tremendous potential for use in tissue engineering therapies [3]. 
The decellularization of vascular tissue has the benefit of retaining the structure and 
composition of a native vessel; however, decellularization can adversely impact the tissue, 
resulting in reduced ultimate tensile strength and compliance. Significant shrinkage is typically 
observed in decellularized vessels, presumably as a result of proteoglycans being removed 
from the tissues by the detergent treatment. Decellularized xenografts undergo aneurysm 
formation, infection, and thrombosis. In addition, their residual antigenicity can impair 
subsequent reendothelialization. Another decellularized tissue that has been used for tissue 
engineering with good deal of success is the matrix derived from small intestinal submucosa 
(SIS). In addition to the typical ECM components, this scaffold was found to contain a number 
of growth factors that enhance neovascularization and infiltration of host cells upon 
implantation [51], promoting site-specific remodeling and regeneration by host [3]. 
Biodegradable synthetic scaffolds. Synthetic scaffolds serve as temporary structures 
subsequently replaced by native tissue as they are gradually removed from the implant site 
through biodegradation [52]. It can be created from a variety of polymers such as polyesters, 
polyanhydrides, and polyphosphazenes [52]. The most common aim of the use of synthetic 
polymers as scaffold in tissue engineering is to support tissue growth and remodeling. 
However, the chemicals and reactions necessary to synthesize these polymer scaffolds are 
often incompatible with cell survival and cells cannot be directly entrapped during scaffold 
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formation. Instead, cells must be seeded into the completed scaffolds, posing difficulties in 
achieving uniform cell distribution and attachment. The scaffold degradation rate must be 
appropriate to the regrowth of the new tissue, in order to maintain the graft structure and 
mechanical properties, and to avoid failure [3]. Polyglycolic acid (PGA) is most commonly used 
as tissue engineering scaffold but is resorbed rapidly. Attempting to improve the mechanical 
properties and further regulate cell phenotype via interactions with the polymer, numerous 
other polymers have been copolymerized with PGA, such as poly-L-lactic acid [3]. Although 
synthetic scaffolds provide initial mechanical strength and structure, compliance mismatch 
with native vessels has proven difficult to overcome, which can lead to thrombosis formation 
and failure of the graft [53]. The compliance of vascular grafts once the scaffold has resorbed 
is the result of cell generated ECM [54]. However, it has been shown that ECM production is 
inhibited in cells that are in contact with synthetic polymers [50]. This finding has led many 
researchers to investigate alternatives to synthetic polymer scaffolds. 
Non-exogenous scaffolds. Researchers are developing alternative approaches that avoid 
the use of exogenous scaffolds. In 1998, L’Heureux and colleagues [55] reported a completely 
biologic vessel generated from human umbilical cord-derived SMCs and ECs, as well as human 
dermal fibroblasts (FIGURE 5a). Briefly, human SMCs and fibroblasts were grown on culture 
plates in the presence of elevated ascorbic acid (to induce significant collagen synthesis) to 
form a sheet with associated extracellular matrix. After sufficient time, the sheet was rolled 
over a mandrel to form a vascular wall media derived mainly from SMCs. In the same manner, 
a sheet of skin fibroblast was grown and wrapped around the media to produce the adventitial 
layer. After maturation, these two layers fused into a single cohesive layer. Then, the tubular 
support was removed and endothelial cells were seeded in the lumen. The resulting construct 
showed well-defined multilayer organization in addition to abundant ECM deposition; SMCs 
demonstrated a reversion to the contractile phenotype by reexpressing desmin (a marker lost 
under culture condition). The endothelium expressed von Willebrand factor, incorporated 
acetylated-LDL, produced prostacyclin, and inhibited platelet adhesion in vitro, thus exhibiting 
properties similar to the ones performed by the endothelium of native arteries. These 
engineered vessels meet the fundamental requirements for grafting: high burst strength 
(>2000 mm Hg), good surgical handling, suturability, and a functional endothelium. However, 
although these tissue-engineered blood vessels are more compliant than ePTFE grafts, they are 
apparently much less compliant than the small-caliber vessels they are designed to replace, 
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which could potentially lead to complications related to the issue of compliance mismatch, 
which often leads to anastomotic intimal hyperplasia. In spite of this, short-term grafting 
experiments in canine model were extremely promising. 
In another study from the same group, human tissue engineered vessels (TEVs) were 
xenografted in immunosuppressed canine model for short term and in immunosuppressed rat 
and primate models for long-term evaluations [53]. The TEVs were antithrombogenic and 
mechanically stable though 8 months in vivo. It should be noted that in this study, the 
fabrication process of TEVs differed from the previous study conducted by the same group [55] 
in the exclusion of the SMC layer, whose early senescence is associated with decreased burst 
pressures in human models [56]. However, the presence of a smooth muscle-specific α-actin-
positive cell population within the TEV suggests the regeneration of vascular media. Moreover, 
the long time to produce these TEVs (approximately 28 weeks) would limit the application of 
these vessels in urgent clinical settings. More recently, this group published another study [57] 
comparing the mechanical properties of completely human TEVs to human saphenous vein 
and mammary artery. The results demonstrated that the sheet-based tissue engineering 
approach can consistently produce vessels with mechanical properties similar or superior to 
those of native vein. 
Campbell and co-workers use a method whereby a mandril of foreign material is surgically 
implanted in the peritoneal cavity of the recipient to induce the growth of tubular tissues [58, 
59]. This technique has demonstrated high mechanical strength and good mid-term patency in 
animal models; because they are grown inside the subject’s own body, there is no tissue 
rejection. However it remains to be seen whether this approach can be repeated in humans. 
One approach to creating multilayered constructs more rapidly involves the use of rapid 
prototyping approaches, including bioprinting. Norotte and colleagues developed a rapid 
prototyping bioprinting method for scaffold-free small diameter vascular reconstruction. 
Bioprinting was used to arrange macrofilamentous, sausage-like cell aggregates and acellular 
agarose rods into tubular vessel-like constructs [60]. 
Synthetic substitutes 
Limited long term success and availability of allografts, which were the first valid vascular 
replacements, led to the development of synthetic substitutes in the 2nd half of the past century. 
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Numerous attempts were made using silver, glass, rubber, and so on as grafting materials. A 
majority of these experiments failed due to early thrombosis, foreign body reaction, or rejection 
[6]. In 1951, Voorhees and co-workers [27] found that plastic tubes were accepted by the 
organism as a blood conduit if they had a porous wall and were biocompatible. Materials such 
as polyester and polypropylene fulfilled these criteria, and artificial conduits were developed as 
woven or knitted tubes in various forms and sizes.  
Dacron and ePTFE. For more than 50 years, Dacron (polyethylene terephthalate) and PTFE 
(polytetrafluoroethylene) have been used as synthetic vascular prostheses. Both of these 
molecules are highly crystalline and hydrophobic [5]. Dacron is a thermoplastic polymer resin 
of the polyester family and is used in synthetic fibers of round cross-section (FIGURE 5b). 
These fibers are fashioned into multifilament yarns, which can be woven (over-and-under 
pattern) or knitted (looped fashion) into textile vascular graft fabrics and tubes. A crimping 
technique (an undulating surface) is sometimes used to increase distensibility and kink-
resistance [5]. ePTFE is an expanded polymer which is manufactured by a heating, stretching, 
and extruding process resulting in a nontextile porous tube composed of irregular-shaped solid 
membranes (“nodes”) (FIGURE 5c). The molecule is relatively biostable, i.e. less prone to 
deterioration in biological environments than Dacron [61, 62], and the graft surface is 
electronegative, which minimizes its reaction with blood components. It is characterized by a 
node-fibril structure, and its average porosity is described by the internodal distance, which is 
usually 30 to 90 μm. However, the actual available ingrowth spaces between fibrils are much 
smaller than the internodal distance [5]. In small diameter applications, these two synthetic 
grafts are highly susceptible to clotting and failure due to a lack of a confluent non-
thrombogenic endothelial monolayer. Upon implantation, the luminal surface of the synthetic 
graft is coated with plasma proteins, and eventually a platelet-fibrin aggregate (pseudointima). 
This is then covered with an endothelial layer, but only in a 10-15 mm zone from the 
anastomosis. The pseudointima that is not endotheliazed can be subjected to SMC migration 
and proliferation leading to intimal hyperplasia, or trigger clot formation and thrombosis. 
Fibrous hyperplasia caused by an over active physiological repair response at the anastomic 
site also often leads to failure of the grafts. 
Polyurethanes. Polyurethane (PU) is a copolymer that consists of three different monomer 
types: a diisocyanate hard domain, a chain extender, and a diol soft domain. At physiologic 
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temperatures, the soft domains provide flexibility, whereas the hard domains impart strength. 
The most common medical grade polyurethanes are based on soft domains made from 
polyester, polyether, or polycarbonate [63]. Although PU grafts possess many 
interesting features, e.g. the presence of a surface that is conducive for seeding, excellent 
healing, good surgical handling and low suture bleeding, polyurethane grafts have had variable 
clinically results with a tendency to hydrolytic biodegradation causing aneurysm formation [5]. 
The latest generation of polycarbonate-based PU is hydrolytically and oxidatively stable, and 
promoted faster luminal endothelialization and less neointimal formation as small-calibre 
vascular prostheses [64]. 
 
 
Figure 5. Vascular prostheses. (a) Tissue engineering blood vessel (non-exogenous scaffold) 
produced by L’Heureux and colleagues [55], (b) Dacron, (c) ePTFE.  
 
Reducing thrombogenicity of vascular grafts 
Attempting to produce new biocompatible materials with good performance as vascular 
conduit, many researchers improved the features of existing synthetic grafts e.g. with regard to 
surface properties like hydrophilicity and presence of chemical groups, or alternatively by 
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covalent attachment of bioactive substances, or even the incorporation of autologous vessel 
wall cells into the vascular graft, where various biological functions of the native vessel are 
mimicked. 
Surface properties modification 
This strategy aims the modification of the surface properties of commonly used materials, to 
minimize reactions at the blood-material/tissue-material interface, avoiding modification of the 
bulk characteristics. This policy is likely to facilitate introduction of the modified vascular grafts 
to the market, as less problems with regulatory agencies and acceptance by surgeons are 
expected. 
A film of plasma proteins is immediately deposited on the surface of the vascular graft after the 
contact with blood, making the foreign material attractive for either platelet adhesion and 
subsequent platelet aggregation and /or promotion of endothelial cell growth [65-67]. The 
implant surface qualities are usually described in the categories of texture (roughness), charge 
(or electrostatic potential) and chemistry. These factors all influence the sequence of protein 
adsorption and the subsequent platelet adhesion/thrombus formation. Although the 
mechanism of occlusion and disfunction of artificial prostheses is multifactorial, all the studies 
performed suggest that fibrinogen and platelet deposition play a predominant role [67, 68]. 
The surface electrical charge of vascular graft influences the adhesion of platelets to the graft.  
It is known that both the blood vessel wall and platelets have electronegative surface charge, 
which causes their mutual repulsion. Sawyer and colleagues demonstrated that injury to the 
vessel wall results in the exposition of positively charged material [69]. Although PTFE has a 
weak negative charge, after implantation a fibrinous layer is formed enhancing the presence of 
negative charges, contributing to antithrombogenicity and also to antibacterial properties, as 
those bacteria that are associated with graft infection have electronegative surface properties 
[70]. A common clinical practice is the coating of PTFE with carbon to increase its 
electronegativity [71]. 
Although electronegativity on the graft surface is a prerequisite, this alone will not ensure an 
antithrombogenic surface, additional surface properties being also critical in determining the 
platelet reaction. The surface hydrophilicity may confer thromboresistance but that is not to say 
that all hydrophilic surfaces are thromboresistant [72]. The thrombogenicity of hydrophilic 
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surfaces has been previously investigated, with variable results. Hydrophilic coatings have been 
shown to diminish the thrombogenicity of polyurethane catheters [73]. Furthermore, an in vitro 
study demonstrated that hydrophilic surfaces bound less fibrinogen and fewer platelets than 
did either nonhydrophilic or heparin-coated catheters [74]. However, other studies showed no 
correlation between hydrophilicity and thromboresistance [75, 76].  
Surface properties may be altered by plasma-treatment techniques. Chu and colleagues [77], 
modified poly( -lactic acid) (PLLA) with ammonia plasma technique to improve the adhesion of 
Human endothelial cell (HUVEC) and of rabbit microvascular endothelial cell (RbMVEC). Tseng 
and Edelman [78] applied amide and amine plasma (butylamine) to ePTFE grafts surfaces 
using radio frequency glow discharge. The Plasma modified ePTFE vascular grafts showed 
increased surface hydrophilicity and enhanced the endothelial cell lining under constant and 
pulsatile flow conditions. 
Another approach consists on surface-binding chemical groups. O-Carboxymethylchitosan 
(OCMCS) was covalently immobilized onto ePTFE vascular graft using a photosensitive hetero-
bifunctional crosslinking reagent, 4-azidobenzoic acid. The OCMCS-modified PTFE 
demonstrated good blood-compatibility with reduced fibrinogen adsorption and inhibition of 
platelet adhesion and activation [79]. Phaneuf and co-workers applied mild hydrolyzation 
treatment of Dacron with NaOH, which created carboxyl groups at the surface, without 
significantly decreasing the tensile strength and the sample weight. The introduced groups 
serve as ‘anchor sites’ for covalent attachment of plasma albumin to the surface, thus creating 
a surface with improved biocompatibility [80]. 
In some other approaches, functional groups were introduced on the surface of the material to 
immobilize specific proteins. In this way, Chandy et al. [81] modified ePTFE and Dacron with 
argon plasma and then coated the materials with collagen IV and laminin, subsequently 
immobilizing bioactive molecules like PGE1, heparin or phosphatidyl choline via the 
carbodiimide functionalities. The results showed that these biomolecules, immobilized on 
vascular prostheses, significantly reduced the fibrinogen adsorption and the deposition and 
spreading of platelets, demonstrating superior biocompatibility. Also PTFE was modified using 
ammonia plasma or alkylamine plasma to covalently bind collagen, fibronectin or a mixture of 
both proteins, which improved adhesion of endothelial cells to the surface [82, 83]. 
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Coatings 
Porous textile synthetic graft, such as Dacron, are also pervious, sealing being necessary at the 
time of implantation. Two sealing techniques are known: preclotting of the prosthesis with the 
patient's own plasma, blood, serum or fibrin glue at the time of implantation, or impregnation 
of the prosthesis with a bioresorbable substance prior to implantation. Once resorbed, the gap-
filling matrices, whether cruoric or proteinic, left in place the porous synthetic structure, which 
could then be infiltrated by the cicatricial reaction. The preclotting technique consists in 
making the textile structure of the prosthesis impervious by impregnating it with an adhesive 
thrombotic matrix. The use of preclotting is as old as textile prostheses [84, 85].  
The first sealing molecules used in 1961 were collagen [86], crosslinked or not, and heat-
denatured gelatin [87]. Albumin was introduced later on [87]. 
Collagen. Collagens are the most abundant and ubiquitous proteins in the body of the 
vertebrates, showing great similitude in all mammals. The collagen molecule is constructed of 
three helical polypeptide chains that revolve around each other to form a triple helix. Collagen 
molecules line up by the thousands in regular sequences aligned with their longitudinal axis, 
thus forming a collagen fibril and these fibrils conglomerate to form a fiber. To be used as a 
biomaterial, collagen must first be extracted and purified, generally in an acid environment and 
salt precipitation. It can be prepared in solid form by drying or as a sol (liquid colloidal solution) 
through dispersion in an acid solution. Collagen is a good choice as impregnant matrix once it 
is naturally found in connective tissues and has chemotactic properties.  [84, 88]. 
Collagen is advantageous as a sealant since it also improves cell adhesion and migration onto 
the surface of the prosthesis, thus leading to a better integration with the host tissues [89].  
Gelatins. Gelatin is derived from collagen by thermal or chemical processes, applied to 
destroy the organized structure of water insoluble colllagen, to generate a multitude of small 
hydrosoluble molecules, the gelatin. The production of gelatin requires first the extraction of 
noncollagenous compounds from the ground tissue, commonly bone or skin, then the 
transition from collagen to gelatin, and finally the conditioning of gelatin in a dried, solid form. 
Compared to collagen, the more widespread use of gelatin as an impregnation matrix can be 
accounted for by its easier production, lower cost, and low thrombogenicity. It replaces 
collagen in situations where mechanical properties are secondary [84]. 
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Several collagen and gelatin impregnated vascular grafts are nowadays available, some of 
which have shown to be clinically well tolerated for medium-diameter grafts (5–6 mm) [90]. 
However, in most of the collagen- and gelatin-coated vascular grafts, glutaraldehyde or 
formaldehyde is used to crosslink the protein matrix. These crosslinking agents, which are 
incorporated into the coating, are released during degradation and may evoke cytotoxic 
reactions [91]. Alternatively, non-toxic carbodiimide can be used to crosslink gelatin in vascular 
grafts [92]. 
Albumin. Albumin, synthesized by the liver, is the main plasma protein. Its molecular weight 
is approximately 69,000 daltons. Albumin can be coagulated and denatured by heat. It can be 
separated from other plasmatic proteins by either electrophoresis or globulin precipitation in a 
27% sodium sulfate solution. Easy production and a low thrombogenicity account for its use in 
impregnating vascular prostheses [84]. 
The impregnation has advantage over the preclotting of vascular grafts, once impregnated 
prostheses are impervious straightaway at the time of implantation, not depending upon the 
patient’s hematologic characteristics (eg. patients under general heparin therapy) and 
so wards off the risk of preclotting. A reduction in prostheses handling, thanks to 
suppression of the preclotting stage, may contribute to a decrease in the risk of intraoperative 
bacterial contamination. On the other hand, some authors have mentioned handling 
difficulties, which they ascribe to a lack of pliancy in impregnated prostheses [84].  
Since crosslinked proteins started to be used to fill the pores of vascular grafts, pre-clotting of 
the grafts became superfluous. Besides this elementary function, other biological activities 
have been added to sealants to make them even more useful. The most frequently used 
additives are anticoagulants and growth factors. More recently, incorporation of antibiotics in 
sealants has been proposed. 
 
Seeding the surface with endothelial cells 
The significant difference in patency between prosthetic and autologous vein grafts could 
partially be attributed to the presence of viable endothelial cells (ECs) on the luminal surface of 
autologous veins. These cells are known to prevent thrombosis and intimal hyperplasia actively 
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and serve as an anticoagulant surface [93]. ECs are therefore interesting as coverage of 
prosthetic grafts. This is the key rationale behind utilizing autologous ECs to make a 
hemocompatible artificial polymeric surface that will perform the major functions of an intact 
healthy endothelium that would normally be found in the blood vessel. This will then provide an 
anticoagulant and antithrombogenic surface to the circulating blood constituents. 
In humans, the natural endothelialization of prosthetic grafts is restricted to a short region 
around the anastomosis area. Experimental evidence indicated that lack of a confluent EC 
lining on the surface of prosthetic graft contributes to their failure by thrombosis formation. A 
cellular engineering approach has been used to overcome this problem by covering in vitro the 
lumen of the graft with ECs, the process known as seeding [94].  
There are two types of seeding procedure: one-stage cell seeding, where the endothelial cells 
of the patient are extracted and immediately used to cover the grafts in the timeframe of the 
surgical procedure. And the two-stage cell seeding, where after the extraction of the EC from 
the patient the cells are expanded in vitro to obtain a great number of cells to be seeded on the 
graft (a process known as sodding) before the transplantation. Sodding is needed because 
many cells are lost from the graft lumen after the pulsatile flow has been restored. The main 
disadvantage regarding clinical use is that it cannot be used in the emergency situation 
because of the prolonged cell culture time and the significant chances of failure due to 
infection of the cells and the inability of the cells to proliferate effectively. In addition, there is 
the extra cost of a cell culture technician and the need for a cell culture laboratory [94]. 
The lack of retention of cells can be partly overcome by sodding, but other techniques, 
involving engineering the lumen to improve cell attachment and retention or stimulate self-
endothelialization of the graft have been developed. 
 
Improvement of endothelial cell seeding procedures 
Numerous research groups have examined whether modifications of the lumen of the 
prosthetic graft surface can either stimulate self-endothelialization or improve the attachment 
and retention of preseeded cells when exposed to arterial flow. 
The interaction of ECs with the biomaterial surface has been improved by using different 
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techniques. One approach consist on promoting non-specific interaction of the cells with the 
material via hydrogen bonding, electrostatic, polar or ionic interactions between the cell 
membrane and functional chemical groups on the polymers (without any extracellular matrix 
proteins or their functional parts). In contrast to integrin-mediated cell adhesion, this type of 
interactions cannot ensure the transmission of adequate signals from extracellular 
environments into cells and survival of anchorage-dependent cells. If the cells are not able to 
synthesize and deposit their own ECM molecules in a relatively short time (usually in 24 to 48h 
after seeding), or they do not have some of these molecules attached on cell membrane, they 
undergo apoptosis [95]. 
Functional receptor-mediated and signal-transmitting cell adhesion on a conventional 
biomaterial is mediated by ECM molecules, such as fibronectin, vitronectin, collagen or laminin 
[95]. Fibronectin coatings have shown to be the most successful for improving endothelial cell 
retention. Increased cell attachment is typically seen when fibronectin is used in combination 
with another protein or ligand [96]. The tripeptide Arg-Gly-Asp (RGD), an amino acid sequence 
found in many adhesive plasma and extracellular matrix protein, has been used to enhance 
cell adherence [97-103] (FIGURE 6). Other peptide sequences found to enhance endothelial 
cell adhesion include YIGSR (Tyr-Ile- Gly-Ser-Arg) [104], derived from laminin and REDV (Arg-
Glu-Asp-Val), which is present in a domain of fibronectin and binds endothelial cells selectively, 
without binding fibroblast, smooth muscle cells, or platelets [105, 106]. The success of this 
approach has been limited, due to coatings being washed off with high flow rates [94, 107] 
and, in some cases, poor specificity between the ligand or protein and the cell allows for 
undesirable platelet adhesion [90]. 
 
Figure 6. Endothelial cell interact by integrin family of cell-matrix receptors with the wall bound 
RGD-sequence and adhere to the vascular graft. Adapted from Walluscheck et al., 1996 [108]. 
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Adherent cells are strongly influenced by the mechanical aspects of biomaterials and many 
studies indicate that micro- and nano-scale mechanical stresses generated by cell-matrix 
adhesion have significant effects on cellular phenotypic behaviour [109]. Thus, physical 
methods attempting to the modification of the surface topography of vascular graft have been 
developed. Gray and colleagues showed that endothelial cells preferentially accumulate on 
stiffer regions of a poly(dimethylsiloxane) (PDMS) substrate, suggesting that material stiffness 
may be used to promote preferential endothelial cell adhesion [110]. Goodman and co-workers 
created a polyurethane scaffold micro-patterned to mimic the natural sub-endothelial 
extracellular matrix topography [109]. Endothelial cells seeded on these surfaces were found to 
more closely resemble those attached to the native extracellular matrix, suggesting that 
mechanical cues from textured surfaces can alter cellular phenotype. Bettinger and co-workers 
developed a rounded surface topography that was able to promote the alignment and 
elongation of endothelial cells; this effect was speculated to be a result of the ability of filopodia 
to sense changes in surface topography [111]. Finally, Daxini and co-workers created a pattern 
of microchannels with a defined geometry in order to create regions of lowered shear stress to 
improve the retention of endothelial cells on polyurethane surfaces [112] 
Another method used to enhance endothelial cell attachment to a polymer scaffold is the 
process of flow conditioning by which cells are exposed in vitro to flow-induced shear stress 
post-seeding procedure [113-116]. Results obtained by some groups showed that this enabled 
enhanced retention of ECs with strengths adequate to withstand physiological shear stresses. 
Additionally, it has been shown that shear stress influences the phenotype of endothelial cells, 
including the ability to adhere to a surface, and may be used to control vascular cell 
differentiation [117]. The various surface modifications undertaken to promote spontaneous 
and seeded endothelialization are summarized in Table 3. 
 
Cell source 
Autologous cells are preferred for prosthetic graft seeding since problems with immunological 
rejection can be avoided. The veins used in humans are saphenous and external jugular veins. 
Forearm veins and arteries have also been used, but in less extent [118]. However, despite 
strong evidence that in vitro EC lining improves the patency of small-diameter vascular 
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prostheses, a major disadvantage of this studies is that a limited number of ECs can be 
extracted from veins. It takes a 4- to 5- week delay between cell harvest and graft implantation, 
growth and infection problems can occur, and the costs of cell culture are substantial. 
Furthermore, seeded cells have been cultured under all sorts of growth factors, inducing the 
risk of unwanted growth after implantation. To avoid these problems, a search for other cell 
types and for other EC sources has been started [93]. 
An alternative source for ECs are cells from the microvessels present in human fat tissue; this 
source provide large number of cells that can be readily available at the time of surgery. Over 
the years several sources of fat tissue have been used to obtain ECs, with subcutaneous and 
mainly the omental fat being the most studied tissues. Cells extracted from omentum have 
been characterized as mesothelial cells by some authors while others still regard these as 
endothelial cells. However, both these types of cell have similar functional properties including 
the release of anticoagulant substances [119]. One disadvantage of extract ECs from fat is that 
some contaminating cells could be also extracted during the process while cells extracted from 
vein are pure ECs [94]. 
In the recent few years, stem cell has become a major cell source for tissue engineering. The 
merit of utilizing stem cell as a seeding cell source is that those cells are able to self renew and 
differentiate into mature cells in the proper conditions. Generally there are two types of stem 
cells based on their origin, the embryonic and adult stem cells. Embryonic stem cells are able 
to produce all types of cells, while adult stem cells are normally limited to certain lineages. The 
advantage of choosing the adult instead embryotic stem cells is that the first one can be 
obtained from patients themselves, which can avoid the immuno-rejection and ethical 
problems. In addition, adult stem cells are normally limited to certain lineages, which do not 
have tumorgenic capacity [49]. 
Adult stems cells are isolated from bone marrow or circulating blood. It is expected that bone 
marrow cells can differentiate into cells such as fibroblasts, ECs, and SMCs [94]. Endothelial 
progenitors cells (EPCs) are one type of the adult stem cells that have the capacity to 
proliferate, migrate and differentiate into mature ECs. EPCs are mainly located in bone marrow 
and could be mobilized into peripheral blood by certain growth factors, such as granulocyte 
macrophage colony stimulating factor (GM-CSF) or VEGF. EPCs could be also isolated from 
umbilical cord blood [49].  
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Table 3. Summary of surface modification to enhance endothelialization (in chronological order). 
Graft  Modified Additive  Study Type  Outcome  Reference 
PTFE  P15 peptide  in vitro  ↑endothelialisation; ↓IH [120] 
PTFE   Anti-CD34 
antibodies 
animal model Rapid endothelialisation; ↑IH [121] 
PTFE  Vascular 
Endothelial, GF  
animal model  ↑endothelialisation; ↑IH [122] 
Poly(ether) 
urethane 
(Tecothane) 
Cholesterol in vitro  ↑endothelialisation and resistance 
to shear stress; ↑endothelial 
precursor cell adherence 
[123] 
PTFE  Poly(amino acid) 
urethane  
animal model  ↑endothelialisation [124] 
Fibrin   Endothelial cell GF in vitro  ↑vEC proliferation; ↓early platelet 
adhesion; ↓late thrombus; 
↑patency 
[125] 
Polyurethaneurea   YIGSRa in vitro  ↑endothelialisation; ↑transmural 
cell migration; ↑hydroxyproline 
productionb 
[126] 
PTFE   Tumorigenic human 
squamous cell line 
animal model Confluent endothelialisation by 5 
weeks 
[127] 
Dacron, PTFE, 
polypropylene, 
silicone, 
polyurethane 
Titanium in vitro  ↑vEC adhesion; no increase in 
inflammation 
[128] 
Dacron Collagen film in vitro  Confluent endothelialisation [129] 
Dacron Collagen  animal model Largely endothelialised and 
thrombus free at 3 weeks 
[130] 
Collagen  Heparin  in vitro  ↑basic fibroblast growth factor 
(bFGF) binding and release 
[131] 
Polyurethane  bFGF/Heparin  animal model  ↑endothelialisation, 
neovascularisation 
[132] 
PTFE  Nitrogen, oxygen 
(↑hydrophilicity) 
in vitro  ↑endothelialisation, ↑plasma 
protein adsorption 
[133] 
PTFE  RGD cell adhesion 
peptide  
in vitro  ↑immediate vEC adhesion; no long 
term advantage compared with 
fibronectin coating 
[134] 
Dacron   Carbon in vitro  vEC proliferation [135] 
Polyurethanes 
and silicones  
Extracellular matrix; 
fibronectin; 
gluteraldehyde 
preserved matrix 
(GPM) 
in vitro  GPM provides optimal vEC 
proliferation 
[136] 
PTFE  Fibronectin  animal model  ↑endothelialisation (both 
spontaneous and seeded) 
[137] 
a Endothelial cell adhesive peptide sequence; b Mark of collagen synthesis; GF (growth factor); 
vEC (vasculae endothelial cells); IH (intimal hyperplasia). Sarkar et al., 2006 [71]. 
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The advantage of using this source of cells is that they can be easily obtained from peripheral 
blood of adults by venopuncture rather than by an operation. A disadvantage is that ex vivo 
expansion, takes on average 2 weeks. Besides, the drawbacks of in vitro culture are risk of 
infection, change of phenotype, the need for culture facility, and limitations for emergency 
situation [93]. 
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Bacterial Cellulose: Properties, Production and 
Applications 
 
Adapted from: Andrade FK, Pertile RAN, Dourado, F, Gama FM. Bacterial Cellulose: Properties, Production and 
Applications. In: Lejeune A, Deprez T, editors. Cellulose: Structure and Properties, Derivatives and Industrial Uses: 
Nova Science Publishers, Inc., 2010. p. 427-458. 
 
 
Bacterial cellulose (BC) is produced by bacterial strains from the genera Acetobacter, 
Agrobacterium, Pseudomonas, Rhizobium and Sarcina, the last one being the only genus of 
Gram-positive bacteria in this field [138]. Interestingly, only a few bacterial species, 
taxonomically related to this genus, extracellularly secrete the synthesized cellulose as fibers.  
While the first studies on BC were geared towards elucidating the cellulose biosynthetic 
pathway, BC has quickly developed into a field of study of its own, as observed by the growing 
number of patents and publications worldwide (Figure 7). Special attention was given to strains 
from Gluconacetobacter xylinus (=Acetobacter xylinum), first described by Brown in 1886 
[139]. While the secreted cellulose is identical to the one produced by plants, regarding the 
molecular structure, it is chemically pure, i.e. not mixed with non-cellulosic polysaccharides 
[138, 140-143]. Its unique properties account for its extraordinary physico-chemical and 
mechanical behaviour, resulting in characteristics that are quite promising for modern 
medicine and biomedical research [142, 144-148]. 
 
1. Biosynthesis, Structure and Properties 
The classical medium to culture G. xylinus and maximize the growth and cellulose production 
was described by Hestrin and Schramm. The pH of the medium is 6 and the optimum growth 
temperature is 30 oC, though the bacteria grow well over a temperature range of 25 to 30oC. 
The static culture leads to the production of a cellulose pellicle holding bacterial cells floating 
on the surface medium. In a culture medium aerated by shaking, bacteria grow faster, but less 
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cellulose, presented as ball-shaped particles, is produced. When G. xylinus is cultured on solid 
medium, the colonies have a dry, wrinkled appearance [149, 150]. 
The ultrastructure of the cellulose synthesis apparatus is best understood in G. xylinus. The 
cellulose synthase is considered the most important enzyme in the bacterial cellulose 
biosynthesis.  
 
Figure 7. Publications and patents on bacterial cellulose.  
 
The cellulose synthase operon codes protein complexes aligned along the long axis of the cell. 
Cellulose synthesizing complexes are present in the surface of the bacteria, next to the cell 
membrane pores where the cellulose fibrils are extruded through, associating with other fibrils 
and making up the ribbon of crystalline cellulose [138, 143]. Each bacterium synthesizes a 
cellulosic ribbon with a width ranging from 40 to 60 nm, parallel to the longitudinal axis of the 
bacterial cell. The ribbon of cellulose is composed of microfibrils with around 1.5 nm 
thickness, secreted through extrusion sites in the outer membrane of the bacterium. Then, the 
microfibrils aggregate into 3 to 4 nm microfibrils via crystallization of adjacent glucan chains 
and finally, together, form the larger cellulosic ribbon [149]. 
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Several studies were developed to clarify the physiologic role of cellulose. As the cellulose 
matrix is less dense than water, it has been proposed to allow maintaining the bacterial cells in 
an oxygen-rich environment. Additionally, it allows protecting the bacteria from ultraviolet light, 
competing microorganisms and heavy-metal ions, while retaining the moisture and allowing 
nutrient supply by diffusion [142, 148, 150, 151]. 
As Gluconacetobacter microorganisms are mandatory aerobes, under static conditions, BC is 
synthesized at the air/liquid interface of the culture medium [138, 142]. Other relevant 
aspects for the BC production are the carbon and nitrogen sources and concentration, the pH 
and temperature, and the surface area of the fermentation system. All these aspects affect the 
cellulose production as well as the membrane properties, in static or agitated cell culture. Also, 
differences in the bacterial strains play an important role in the microstructure and production 
rate. Figure 8 shows a membrane produced by ATCC 10245 G. xylinus strain [138, 142, 152-
156]. 
Besides macroscopic morphological differences, BC produced in static and agitated cultures 
differs also at various structural levels. While the fibril network remains the same, there are 
some differences in the structure of the crystals and molecular chains. The crystallinity and 
cellulose I alpha content, as well as the degree of polymerization, is lower in agitated than in 
static culture [157]. 
As referred above, the bacterial and vegetable celluloses have the same molecular structure, 
both being built up of β(1→4)–linked D-glucose units. The degree of polymerization is however 
rather different, about 13000-14000 for plants and 2000-6000 for bacterial cellulose. Both 
celluloses are highly crystalline; differing in the arrangement of glucosyl units within the unit 
cells of the crystallites, and several studies suggests that these celluloses are synthesized by 
enzymatic complexes that differ at the molecular level. Also, this bacterial polysaccharide is 
secreted free of lignin, pectin, hemicelluloses and other biogenic compounds, which are 
associated with plant cellulose [138, 142, 158]. 
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Figure 8. Bacterial cellulose pellicle produced by ATCC 10245 G. xylinus strain in static culture. 
 
Morphology. The gelatinous BC membrane formed in static culture is characterized by a 3D 
ultrafine fibrous network structure, containing about 99% water. The randomly assembled 
ribbon-shaped fibrils are less than 100nm wide and composed of elementary nanofibrils, 
aggregated in bundles with lateral size of 7-8nm. The crystallinity degree of BC is in the range 
of 60-90% [159-163]. Crystallographically, BC is a Cellulose I, with 60% Iα /40% Iβ [148, 163]. 
The crystallographic molecular arrangement may influence the physical properties, as the 
allomorphs have different crystal packing, molecular conformation, and hydrogen bonding 
[159, 163]. In 2006, Sanchavanakit characterized BC pellicles obtained after 48 hours culture: 
the surface area of the air-dried BC films was 12.6 m2/g, with a pore size distribution ranging 
from 45 to 600 Å. The pore diameter of the air-dried film was inferior to 0.1 µm; however, 
when the air-dried pellicle was swollen with water, at 30 oC, the apparent pore diameter raised 
to 0.2-1.0µm [164]. Due to its high crystallinity and small fiber diameter, BC possess excellent 
mechanical strength and high surface area when compared to plant derived cellulose [165] 
and the application and biological function of celluloses are based on its distinct fiber 
morphology [159].  
Mechanical properties. Both the micro and macrostructure of BC are influenced by the 
growing culture environment and the treatment after synthesis. According to Iguchi, a BC 
pellicle obtained after 7 days of culture and air-dried at 20 oC and low pressure, presents a 
Young’s modulus of 16.9 GPa, tensile strength of 256 MPa and elongation of 1.7% [148]. 
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However, when a pellicle was dried through the heat-press method described by Iguchi [166] 
and an excess of pressure (490 – 1960 kPa) was applied, the tensile strength as well as 
elongation tend to decrease, while the Young modulus remains constant. According to 
Sanchavanakit (2006), a BC dried film (from a 48h grown culture) with a thickness of 0.12 
mm presents a tensile strength and break strain of 5.21 MPa and 3.75%, whereas for the wet 
films the values are 1.56 MPa and 8.0%, respectively [164]. The high Young’s modulus and 
tensile strength of BC films seems to result from its high crystallinity, high planar orientation of 
ribbons pressed into a sheet, ultrafine structure, and the complex network of the ribbons 
[167]. 
Water holding capacity. BC is highly hydrophilic, holding over 100 times its weight in 
water. Klemm and colleagues showed that the “never dried” BC has water retention values 
(WR) in the range of 1000%, drastically decreasing after air-drying to values that can be 
compared with those of plant cellulose, 106% and 60%, respectively. The method of drying has 
been shown to affect the BC porosity, freeze-drying (WR of 629%) being reported as the most 
effective method to preserve the porous structure [142]. 
 
Medical Applications 
The biocompatible nature of cellulose-based materials, such as oxidized cellulose, regenerated 
cellulose hydrogels, sponge cellulose and bacterial cellulose, has allowed comprehensive 
research targeted at medical applications [168-172]. Representative examples BC-based 
scaffolds for tissue engineering include vascular grafts, cartilage, neural regeneration and 
wound dressings. Table 4 describes the biomedical application of BC and some results 
obtained. 
The interaction between cells and BC has been investigated by several research groups. In 
1993, BC was described as a substrate for mammalian cell culture by Watanabe and 
colleagues [146]. Adhesion to BC was observed using anchorage-dependent cell lines (L929 
mouse fibroblasts, Detroit 551, HEL, mouse 3T3 Swiss, SV40/Balb 3T3, CHO, Human J-111 
and Human epidermal Keratinocytes). Modification of the BC surface, to improve the 
interaction with cells, involved the introduction of electrical charge and adhesive proteins, such 
as collagen type I, collagen type IV, fibrin, fibronectin or laminin [146]. 
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Table 4. Summary of biomedical applications of bacterial cellulose. 
Biomedical 
Applications 
Study Outcome  References 
Cartilage repair  1. In vitro study – BC as scaffolds for 
chondrocytes culture; 
2. Reconstruction and rehabilitation 
of the nasal framework in rabbits. 
1. Growth, cell migration and ingrowth; 
expression of collagen by the cells; 
2. Good integration. 
[147, 173, 
174] 
Vascular grafts  1. In vitro studies were developed to 
improve BC as scaffold to tissue 
engeneering of vascular grafts; 
2. In vivo studies with stents coated 
with BC (rabbit model); 
3. In vivo studies of BC as 
microvessel endoprosthesis (rats 
and pig models) 
 
1.Many of the strategies used (e.g. 
increasing the porosity, improving the 
mechanical properties, 
functionalization with adhesion 
peptides, etc.) improved the adhesion, 
migration and proliferation of smooth 
muscle cells or endothelial cell to BC; 
2. BC accelerated re-endotelialization 
of the area covered by the stent, acting 
as a barrier to the migration of muscle 
cells; 
3. good incorporation in the host tissue 
without any rejection reaction. 
 
[142, 152, 
162, 163, 
175-178] 
Wound 
dressing 
1. Corneal healing (rabbits); 
2. Skin healing (swine); 
3. Dural substitute exposed to intact 
and damaged brain of dogs; 
4. Human patients with chronic 
venous insufficiency and lower-leg 
ulceration; 
5. Repair of chronic lower extremity 
ulcers in humans; 
6. Rabbit’s laryngotracheal region. 
1. Improved healing; 
2. Good performance in healing and 
adhesion to the wound; 
3.Good acceptance of the graft;  
4. BC dressings create a protective, 
hypoxic, moist environment and 
improved healing. ↓patients pain; 
5. ↓of time for epithelization and the 
time for wound closure over standard 
care; 
6. No inflammatory signs. 
[179-189] 
Dental implants 1. Periondontal disease treatment, 
dental implants and guided bone 
regeneration; 
2. Biocompatibility evaluation with 
implantation of BC (Gengiflex®) in rat 
subcutaneous connective tissue; 
3. BC (Gengiflex®) was used for 
guided tissue regeneration of bone 
defects in rabbits. 
1. Provide a good alternative for guided 
tissue regeneration; ↑regeneration of 
the lesions; 
2. BC behaved as a stranger material 
to the host tissue in comparision to 
Milipore and Teflon membranes; 
3. PTFE presented better results than 
Gengiflex®. 
[190-196] 
Nerve 
regeneration  
1. Micronerve reconstruction of rat 
sciatic nerve using BC tubes 
(BASYC®); 
2. BC tubes (BASYC®) were used as 
drug depot of neuroregenerative 
substances; 
3. BC sheets to envelop peripheral 
nerve lesions (dogs); 
4. Facial nerves repair (rats) with BC 
sheets (Biofill®). 
1. ↑regeneration of the functional 
nerve; the reappearance of 
acetylcholine as the transmitter of 
nerve impulses to the executive organ 
was observed; 
2. Improved healing; 
3. A moderate fibrous reaction and 
realignment and axonal growth through 
the injury were observed. 
4. Improve guidance of the nerve 
fibers, allowing the concentration of 
neurotrophic factors, which 
consequently promoted the nerve 
regeneration. 
[142, 197, 
198] 
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The interaction of BC films with human transformed skin keratinocytes and human normal skin 
fibroblasts was evaluated [164]. The results demonstrated that BC supports the proliferation of 
both cell types, with no signs of toxicity; the keratinocytes exhibited normal cell proliferation, 
spreading and also maintained the normal phenotype, while for the fibroblast culture the 
pattern of cell distribution and stability on BC film was poorer. Moreover, the migration of 
keratinocytes on a BC film was comparable to that of a polystyrene plate. Pértile and 
colleagues, in 2007, found a similar behavior when studying the interaction between BC 
pellicles and skin fibroblasts. Figure 9 shows a detail of the BC network with fibroblast cells 
adhered on BC membranes [199]. 
 
 
Figure 9. Scanning eletron microscopy of bacterial cellulose. Fibroblasts adhered on bacterial 
cellulose membranes after 24h in culture (Left, 1000x); detail of BC membranes surface (Right, 
10.000x). 
 
In an in vivo biocompatibility study, BC was subcutaneously implanted in mice, for a period of 
up to 12 weeks [140]. BC was shown to integrate well into the host tissue, with cells infiltrating 
the BC network and no signs of chronic inflammatory reaction or capsule formation. The 
formation of new blood vessels around and inside the implants was also observed, evidencing 
the good biocompatibility of the biomaterial.   
BC as vascular grafts. In 2006, Backdhal and colleagues evaluated BC as a novel 
biomaterial for the tissue engineered blood vessels [162]. The BC was compared to similar 
structures of porcine carotid artery (PCA) and expanded-polytetraflourethylene (ePTFE). The 
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mechanical properties of the BC rings were comparable to those of PCA, although PCA 
significantly exceeded BC in both stress and strain at break and Young’s modulus. The authors 
also studied the interaction between BC and smooth muscle cells (SMCs), the compact and 
porous side of the BC pellicle being separately analyzed. The results showed that, although the 
attachment and proliferation of SMCs cultured on the compact and porous sides were similar, 
differences in the morphology were observed. Furthermore, a maximum ingrowth distance on 
the porous side of 20µm and 40µm was observed after 1 and 2 weeks, respectively, the more 
compact side allowing an ingrowth of up to 1-5µm depth. The results revealed that the cells 
could push the nanofibrils aside, while migrating into the cellulose nanofibril network. In 2008, 
the same research group developed a novel method to prepare three dimensional nanofibril 
network tubes from BC with controlled microporosity, by placing paraffin wax and starch 
particles of various sizes in a growing culture of G. xylinus [175]. SMCs migrate into this more 
porous cellulose to a greater depth than in the native BC pellicle. The SMCs produced collagen 
fibers both in the surface cell layer and further into the scaffolds made with paraffin. However, 
a mechanical evaluation of the SMC-seeded scaffold was not performed. 
The effectiveness of angioplasty using conventional stents was compared to bacterial cellulose 
coated stents, in a rabbit model, by Negrão et al. [176]. The authors showed that BC coated 
stents do not present adverse events in the angioplastic procedures. Indeed, BC accelerated 
re-endotelialization of the area covered by the stent, acting as a barrier to the migration of 
muscle cells, thus representing a promising strategy for the prevention and treatment of 
restenosis in endovascular procedures. 
Bodin et al. analyzed the growth of endothelial cells (ECs) in the lumen of BC tubes obtained 
by culturing the bacteria under different concentrations of oxygen [152]. All tubes had a denser 
inner side and a more porous outer side. The cross section observation revealed layered tube 
walls, the number of layers and the yield of cellulose increasing with the oxygen pressure. The 
cells were able to growth in the tubes, forming a confluent layer after 7 days. The same group 
developed a novel method to graft the RGD cell adhesion peptide on the cellulose, to enhance 
cell adhesion [163]. The cellulose was modified with xyloglucan and xyloglucan bearing the 
GRGDS (Gly-Arg-Gly-Asp-Ser) peptide. The results revealed that the nanocellulose material was 
homogeneously modified; also, cell adhesion studies confirmed a faster adhesion of 
endothelial cells on the xyloglucan-GRGDS-modified cellulose. 
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Klemm et al. investigated the application of patented BC tubes (BASYC® - BActerialSYnthesized 
Cellulose) as microvessel endoprosthesis for end-to-end anastomosis procedure, using the 
carotid artery of a white rat [142]. In this study, four weeks after implantation, the carotid 
artery-BASYC complex was wrapped up with connective tissue and the BC tube was completely 
incorporated in the body without any rejection reaction. Putra et al. described a simple 
technique that allows to obtaining a tubular – BC gel with desired length, inner diameter and 
thickness, along with an oriented fibril structure [177]. This technique requires a shorter 
cultivation time, as compared to the methodology described by Klemm et al.[142]. Over a 
period of 12 weeks, implanted BC grafts in the carotid artery of pigs showed good in situ tissue 
regeneration without signs of thrombosis, inflammation or fibrotic capsule formation around 
the implants. The luminal wall of the newly formed tissue showed complete endothelialisation, 
with a confluent endothelial layer [178]. 
 
Improving the Bacterial Cellulose Properties for Biomedical Applications 
Biocompatibility is one of the main requirements for any biomedical material. It can be defined 
as the ability to remain in contact with living tissue without causing any toxic or allergic side 
effects, simultaneously performing its function [145]. In this context, BC has been modified to 
further enhance its’ biocompatibility. Depending on the envisaged biomedical application, 
improved cellulose integration with the host tissue, increased degradation in vivo or modified 
mechanical properties, to mimic the tissue to be replaced, are required. Chemical surface 
modifications, incorporation of bioactive molecules, modification of the porosity and 
crystallinity, design of 3D structures and nanocomposites, are examples of viable methods to 
make BC an ideal material for reparative tissue engineering. 
The attachment of cells to biomedical materials can be improved by using adhesion molecules, 
present in the extracellular matrix substances, such as fibronectin, vitronectin, or laminin. The 
amino acid sequence Arg-Gly-Asp (RGD) has long been recognized for its cellular adhesion 
function. Bodin et al. described a novel method to activate the bacterial cellulose surface with 
the RGD peptide, to enhance cell adhesion [163]. The adsorption of modified xyloglucan 
(GRGDS-xyloglucan) increased the BC wettability, which might explain the decreased or even 
negligible amount of adsorbed protein. Modification with xyloglucan (XG) did not alter the BC 
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morphology. The water contact angle was lower on BC modified with XG (29 ± 4.8) and XG-
GRGDS (32 ± 5.8), when compared to unmodified material (44 ± 5.3). Whitney et al. also used 
xyloglucan to modify BC, in this case incorporating the polyssaccharide in the G. xylinus culture 
medium. These authors verified that XG binds to cellulose, altering its cristallinitty [200].  
In order to improve cell adhesion to BC, Watanabe and co-workers developed several methods 
of chemical modification, aiming the introduction of electrical charge to the BC membrane 
[146]. In this context, membranes of trimethyl ammonium betahydroxypropyl-BC (TMAHP – 
BC), diethyl aminoethyl-BC (DEAE – BC), aminoethyl-BC (AE – BC) and carboxymethyl-BC (CM 
– BC) were produced. Also, the TMAHP – BC was covered with adhesive proteins (collagen 
type I, collagen type IV, fibrin, fibronectin or laminin). The new bacterial cellulose substrates 
favored the adhesion of cells, as compared to the unmodified BC. 
Phosphorylation and sulfation of BC matrices were explored by Svensson et al. as a means to 
add surface charges, mimicking the glucosaminoglycans of cartilage tissue in vivo [147]. The 
materials were analyzed for mechanical properties, microstructure and cell–material 
interactions, in order to assess the potential of this matrix as a scaffold for cartilage tissue 
engineering. The compressive modulus of the phosphorylated samples increased with the 
reaction time and was higher than the compressive modulus of native BC. This result was 
probably due to the more compact structure of the 3D network in the phosphorylated BC. An 
even more compact network structure was found in sulfated BC, which showed an higher 
resistance to compressive forces when compared to phosphorylated and native BC. Sulfated – 
BC had significantly lower Young’s modulus than the unmodified BC, resulting in a reduction of 
the mechanical integrity. The lower strength of sulfated-BC may be due to the prevention of 
hydrogen bonding between the cellulose chains by the covalently bonded sulfate groups, chain 
scission by acid hydrolysis, or a combination of both.  
It is known that BC properties such as the mechanical strength and permeability can be 
changed by post production (ex situ) treatments [201]. As an example, treatment with sodium 
hydroxide is widely used to clean the cellulose membranes, after fermentation, for biomedical 
applications. George et al. analyzed the effect of various alkali treatment methods for BC 
cleaning, such as potassium hydroxide, sodium carbonate and potassium carbonate. 
According to these authors, any of these chemicals is milder than the sodium hydroxide, better 
preserving the BC integrity, and improving the tensile strength of the membranes [202]. 
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Backdhal et al. developed a method to produce a highly porous BC [175]. The authors added 
paraffin wax and starch particles of various sizes to the growing culture of G. xylinus. Bacterial 
cellulose scaffolds with different porosities and interconnectivity were prepared through this 
approach. The partially fused paraffin particles were incorporated throughout the scaffold, 
while starch particles were found only in the outermost area of the resulting scaffold. This 
methodology allows the modulation of the porosity, thickness and interconnectivity of tubular 
BC scaffolds, by varying the porogen size and fermentation conditions. In addition, the 
porogens can be successfully removed from the BC network. 
As G. xylinus has been reported to move along cellulose rails while secreting BC, Urakiet al. 
attempted to expand the utilization of BC and developed novel functional biomaterials, through 
the transformation of BC into a honeycomb-patterned material [203]. Fabrication of such 
patterned BC structure was possible by controlling the bacterial movement using an agarose 
film scaffold with honeycomb-patterned grooves, in a humid CO2 atmosphere. The results 
suggest that the obtained honeycomb-patterned network is a continuous porous film, built up 
with highly oriented and Iα cellulose microfibrils. 
Aiming at the production of a in vivo degradable polysaccharide, while exhibiting both chitin- 
and cellulose-like properties, attempts were made to incorporate N-acetylglucosamine (GlcNac) 
residues into bacterial cellulose. Ogawa characterized the enzymatic susceptibility of BC 
containing N-acetylglucosamine (N-AcGBC) residues for cellulase, lysozyme and chitinase 
hydrolysis [204]. The results showed that N-AcGBC posses high susceptibility for lysozyme 
(proportional to the GlcNac content) and cellulase but only slight susceptibility for chitinase. 
The random distribution of GlcNAc residues on N-AcGBC is responsible for the higher lysozyme 
reactivity. This approach was also studied by Shirai, who described a G. xylinus strain adapted 
to a medium containing GlcNAc, that was used to prepare a novel cellulosic polysaccharide 
containing residual GlcNAc[205]. The resulting polysaccharide was lysozyme-susceptible. The 
amino sugar content in the pellicles was measured after cultivation of the bacteria in the 
presence of various ammonium salts. Ammonium chloride seems to be the best additive to 
enhance GlcNAc incorporation, under rotatory and aerobic conditions. The acceleration of 
GlcNAc incorporation in the presence of ammonium salts seems to be due to the shift of the 
aminotransferase equilibrium in the presence of a high concentration of ammonium ion. The 
production of similar polysaccharides was obtained by incubation of G. xylinus in a modified 
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Hestrin – Schramm medium containing lysozyme-susceptible phosphoryl chitin (P-chitin) and 
D-glucose [206]. Analysis of the culture medium by HPLC showed that the P-chitin is 
depolymerized to monomeric and oligomeric residues, during the incubation, and these were 
utilized as a carbon source by the bacteria. Furthermore, monomeric GlcNAc 6-phosphate was 
also found to enhance the incorporation of GlcNAc residues into the polysaccharide. Also, 
Ciechanska obtained a modified bacterial cellulose by adding chitosan to the culture medium 
during the bacterial growth [207]. By FTIR analysis, glucosamine and N-acetylglucosamine 
units were shown to have been incorporated into the cellulose chain, providing a material with 
good mechanical properties in the wet state, high moisture-keeping properties, release of 
oligosaccharides under lysozyme action, and bacteriostatic activity. 
Lee and colleagues investigated the flexibility of the BC synthesis apparatus of a G. xylinus 
strain in incorporating different monomers present in culture medium [208]. The bacteria 
incorporated 2-amino-2-deoxy-D-glucose (glucosamine) and 2-acetamido-2-deoxy-D-glucose (N-
acetylglucosamine), but not 3-O-methyl-D-glucose or 2-deoxy-D-glucose into the exopolymer. 
The average molar percentage of glucosamine and N-acetylglucosamine in the exopolymers 
amounted to about 18%. The authors suggested that the cellulose synthase and other enzymes 
involved in the cellulose synthesis have broad specificity. Preliminary analysis of the fibers 
(cellulose and the new copolymers) by environmental scanning electron microscopy suggested 
similar gross morphology (e.g. diameter and surface smoothness). 
Kobayashi et al. produced a cellulose-chitin hybrid polysaccharide by enzymatic 
polymerization, using a chitinase and a cellulase from Trichoderma viride [209]. The molecular 
weight values of the cellulose-chitin hybrid polysaccharides reached 4030 and 2840, which 
correspond to 22 and 16 saccharide units, respectively. These MW are rather low compared 
with naturally occurring chitin and cellulose. The produced cellulose-chitin hybrid 
polysaccharide did not exhibit a crystalline structure and was hydrolyzed in vitro by lysozyme. 
Also, Phisalaphong and Jatupaiboon obtained a nanostructured BC-chitosan composite, by 
supplementing the BC culture medium with low-molecular-weight chitosan [210]. Films with a 
denser fibril structure, smaller pore diameter and higher surface area than the native BC were 
obtained; however no significant influence in the crystallinity and anti-microbial activity were 
observed. 
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Another type of BC modification was described in 2008 by Berti et al. [211]. This group 
produced membranes of BC-PHA by mixing BC olygomers with polyhydroxyalkanoates 
produced by Ralstonia eutropha and Chromobacterium violacium, obtaining membranes with 
different surface properties and porosities. 
 
BC Nanocomposites used in Medicine. According to Ajayanet al., nanocomposites can be 
described as solid structures with nanometer-scale dimensional repeat distances between the 
different structural phases [212]. These materials typically consist of two or more 
inorganic/organic phases in some combinatorial form. At least one of the phases or features 
must be in the nanosize scale. In general, nanocomposite materials demonstrate new and/or 
improved mechanical, electrical, optical, electrochemical, catalytic or structural properties. 
Polyvinyl alcohol (PVA) is a hydrophilic biocompatible polymer with characteristics suitable for 
biomedical applications. Combined with BC fibres, it has been used to develop biocompatible 
nanocomposites [213-215]. The PVA–BC nanocomposite is highly anisotropic and its 
properties make it comparable to heart valve tissue. According to the authors, PVA–BC 
nanocomposite with specific composition and processing parameters can be obtained to create 
a custom-designed biomaterial mimetizing the mechanical properties of the tissue to be 
replaced. 
A composite named CollagenBC was developed by Wiegand, by adding collagen type I to the 
culture medium of BC fermentation, for the treatment of chronic wounds [216]. This 
composite induces an in vitro reduction of protease activity, interleukin concentration and 
reactive oxygen species, relevant features to support the healing process in chronic wounds. 
This composite combines the ability of collagen to alter the milieu parameters in chronic 
wounds, with the excellent BC physical properties. Following the same approach, Zhou and 
colleagues used a culture medium containing sodium alginate (NaAlg) for the production of 
BC, obtaining a cellulose with lower cristallinity and a smaller crystallite size [217]. Also, 
Phisalophong developed a BC-alginate blend exhibiting improved water absorption capacity and 
water vapor transmission rate combined with a smaller pore size, although the tensile strength 
and elongation at break of the film decreased [218]. 
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BC is composed of dense microfibrils forming a material with relatively small pore sizes, the 
pure BC lacking a suitable pore structure essential for tissue engineering scaffolds. In contrast, 
the hydroxyapatite/BC (Hap/BC) nanocomposite scaffolds combine good mechanical 
properties with an open pore structure, suitable candidates for tissue engineering applications. 
With the purpose of evaluating the potential of porous Hap/BC nanocomposite as a bone 
tissue engineering scaffold, Fang et al. performed in vitro assays [219, 220] were the 
proliferation and osteoblastic differentiation of stromal cells derived from human bone marrow 
(hBMSC) on Hap/BC nanocomposite was investigated. The results showed that the 
nanocomposites performed better than pure BC, regarding cell adhesion, due to the improved 
pore sizes and presence of the inorganic component. In addition, the authors demonstrated 
that the nanocomposites stimulate cell proliferation while enhancing osteoblastic differentiation 
of hBMSC, without osteogenic reagents. Other authors have also synthesized and 
characterized BC-hydroxyapatite scaffolds, for bone regeneration [221-223]. Shi and 
colleagues used an alkaline treatment to optimize the biomimetic mineralization of BC pellicles 
[172]. Calcium-deficient carbonate hydroxyapatite/BC (CaDHCAp/BC) nanocomposites were 
synthesized in a 3D network of BC nanofibers. The alkaline treatment improved the 
mineralization efficiency, making the CaDHCAp/BC a potential biomaterial for bone tissue 
engineering. 
BC is a very attractive material for wound dressings, providing a moist environment for wound 
regeneration, resulting in a better healing. However, bacterial cellulose itself has no 
antimicrobial activity to prevent wound infection. To achieve antimicrobial activity, Maneerung 
et al. impregnated BC with silver nanoparticles, by immersing the BC pellicles in a silver nitrate 
solution [224]. Sodium borohydride was then used to reduce the absorbed silver ion (Ag+), 
inside the BC network, to metallic silver nanoparticles. The size and size distribution of the 
nanoparticles were effectively controlled by adjusting the molar ratio of NaBH4:AgNO3. Under 
optimal conditions, well dispersed and regular spherical silver nanoparticles were obtained. 
The freeze-dried silver nanoparticle-impregnated bacterial cellulose exhibited a strong 
antimicrobial activity against Escherichia coli (Gram-negative) and Staphylococcus aureus 
(Gram-positive), bacteria commonly found on contaminated wounds. 
Another composite material was recently reported by Charpentier and colleagues: polyester 
modified with UV/ozone and plasma treatments, bearing improved hydrophilic character, was 
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coated with BC to produce a new hybrid material that presents potential use in vascular 
prosthetic devices [225]. 
Haigler et al. added carboxymethylated cellulose (CMC) to the G. xylinus culture medium and 
analyzed the properties of the altered BC produced [226]. The results revealed that an 
alteration of the ribbon assembly occurs in the presence of CMC, often inducing synthesis of 
separate, intertwining bundles of microfibrils. Similarly, Tajima incorporated water-soluble 
polymers such as CMC and methyl cellulose in BC, by incubating G. xylinus in a medium 
containing these polymers [227]. Increased BC production and composites with controllable 
degradability and mechanical strength were obtained. Also Sakairiet al. produced CMC-BC 
composites by adding CMC to the culture medium [228]. The obtained material had ion 
exchange ability, with enhanced specific adsorption affinity for lead and uranyl ions, as 
compared to the original CMC and BC. Using the same approach, Whitney and colleagues 
[229] added mannan-based polysaccharides to the culture medium, and observed the 
formation of networks with distinct architecture and modification of other molecular features, 
such as reduction of crystallinity. A range of different cellulose-associated networks could be 
formed, depending of the levels of glucomannan and galactomannans added.  
Many other studies enlarge the repertoire of different bacterial cellulose composites with 
potential biomedical application. Different processes were developed to produce BC 
nanocomposites filled with silica particles, yielding improved elastic modulus and strength, as 
compared to native BC [230]. Serafica et al. produced BC in a rotating disk bioreactor. Several 
kinds of solid particles (silica gel, iron, aluminum, glass beads, etc) were added to the 
medium, during gel formation, being trapped to form new classes of composite materials 
[231]. Other works report the production of BC – nanocomposites, for example BC/starch 
[232], BC reinforced with cellulose acetate butyrate [233], BC/glucoronoxylan blends [234], 
BC/poly dimethylacrilamide and BC/gelatin [235, 236]. 
 
Carbohydrate – Binding Module (CBM) 
Carbohydrates are the most abundant biomolecules on Earth and are implicated in 
intercellular recognition, bacterial and virus infection, metabolism, structural support, energy 
storage, targeting, attachment, etc. To perform such roles, several carbohydrate-active 
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(CAZymes) proteins have acquired noncatalytic modules that interact very specifically with 
mono, oligo, and polysaccharides. In general, these carbohydrate-binding modules (CBM) are 
autonomous folding without enzymatic activity that brings the catalytic domain in close 
proximity to the substrate, insuring a prolonged contact and increasing the effective 
concentration of the enzyme on the target [237, 238]. 
CAZy (CarbohydrateActive enZyme, http://www.cazy.org/) is a database of glycoside 
hydrolases (GHs), glycosyltransferases (GTs), polysaccharide lyases (PLs), carbohydrate 
esterases (CEs) and CBMs. These protein groups are further subdivided into a number of 
families within the groups. In the CAZy database, a CBM is currently defined as a contiguous 
amino acid sequence within a carbohydrate-active enzyme with a discrete fold having 
carbohydrate-binding activity. Few works described the occurrence of isolated CBMs, as a 
single protein [239-241] and CBMs that integrate the cellulosomal scaffoldin proteins [242-
244]. The requirement of CBMs existing as modules within larger enzymes sets this class of 
carbohydrate-binding protein apart from other non-catalytic sugar binding proteins such as 
lectins and sugar transport proteins. 
CBMs may be found in any domain of life and are present in a large variety of enzymes, with 
different functions and substrate affinities that recognize polysaccharides such as crystalline 
cellulose, non-crystalline cellulose, chitin, β-1,3-glucans and β-1,3-1,4-mixed linkage glucans, 
xylan, mannan, galactan and starch [238]. They have been classified based on amino acid 
similarity into 59 primary structure-based families in the CAZy database. Structures for 44 of 
the 59 families have been reported and, from its analysis, it is clear that while CBMs vary 
widely in their carbohydrate specificities, common folds are observed in proteins with different 
specificities and belonging to different taxonomic groups. CBMs contain from 30 to about 200 
amino acids and exist as a single, double, or triple domain and are located at C- or N-terminal, 
and in a less extent, centrally positioned within the polypeptide chain of proteins. The primary 
functions of CBMs in CAZyme [237, 238, 245] are described in table 5. 
Once the CBMs are independent folding units (allowing it to be expressed in chimeric proteins) 
and its binding specificities can be controlled using Genetic Engineering technology and in 
general the attachment matrices for these domains are abundant and inexpensive [245],  
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Table 5. Functions of CBMs in CAZyme 
Proximity effect  CBMs promote the association of the enzyme with the substrate, insuring a 
prolonged contact, and thereby increasing their effective concentration. 
Targeting effect Fine specificity for polysaccharide substructures. 
Nonhydrolytic substrate disruption Leading to an increase in substrate access and more susceptibility to 
enzymatic hydrolysis. 
Avidity effect  Increases the avidity of the CAZyme for the substrate. 
 
different applications of CBMs have been described: the improvement of fibers in textile and 
paper industry [246-250];  surface-exposed CBMs can be an efficient means of whole-cell 
immobilization [251-254]; the recombinant DNA technology allows the production of chimeric 
proteins containing foreign CBM. Many protein have been expressed fused to CBMs, 
establishing CBMs as high-capacity purification tags for the isolation of biologically active target 
from biotechnological products at relatively low cost [250]; Several studies have shown the 
potential of CBMs for modifying the characteristics of several enzymes through the addition or 
substitution of a CBM in order to improve the enzyme stability or hydrolytic activity [255]; 
Other studies involved actual modification of the CBM moiety to match a set of defined 
reaction conditions, for example, replacing some amino acid in different positions, its possible 
to obtain a definite pH dependency [256]; Another field for CBM application is bioremediation 
where, for example, an enzyme capable to degrade or chelate harmful substances to the 
environment could be expressed with a CBM that enable the anchorage of the enzyme in a 
support, such as reactors with immobilized enzyme for the detoxification of hazardous 
organophosphates, heavy metals, etc [257-259]; Finally, CBMs have been used as analytical 
tools in research and diagnostics, such as probes for protein-carbohydrate interaction and 
microarrays [238, 245]. 
Cellulose-binding module from the Clostridium thermocellum. The initial event in the 
cellulose degradation process is the binding of the cellulolytic enzyme(s) or the entire 
microorganism to the cellulose substrate. This binding is mediated by a separate module that 
binds to cellulose, a cellulose-binding module (CBM). CBMs appear to play a multiple role in 
cellulolysis. They often comprise a distinct domain of a free enzyme, linked to one or more 
catalytic domains (not necessarily cellulases). In some cases, they occur in a discrete subunit, 
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together with additional non-catalytic domains, which serve to integrate the catalytic subunits 
into a multifunctional enzyme complex, the cellulosome [260, 261]. Besides targeting cells to 
cellulose substrate, CBM mediate the non-hydrolytic disruption of cellulose fibers [262]. 
A cellulose-binding module family-III from the cellulosomal-scaffolding protein A of the bacteria 
Clostridium thermocellum (an anaerobic thermophilic bacterium that excretes large amounts of 
cellulolytic enzymes of particularly high specific activity) [263] was used to modified structures 
based on bacterial cellulose in the works developed in this thesis. The enzymatic degradation 
of cellulose by C. thermocellum is mediated by a cellulosome, that consist of discrete multi-
functional, multi-enzyme complexe, wherein all the enzymic factors leading to cellulose 
degradation are physically attached to a central scaffold component (CipA – Cellulosome 
integrating protein) [242]. The CipA contains cohesin modules, normally in multiple copies, for 
incorporation of the catalytic domains, including β-(1→4)-endoglucanases, cellobiohydrolases, 
hemicellulases and other cellulosomal components. The scaffolding also frequently includes a 
carbohydrate-binding module (i.e., a cellulose-binding module), through which the complex 
usually recognizes and binds to the substrate [264, 265]. Family-Ill CBMs comprise -150 
amino acid residues. Currently have 285 members, one with chitin binding ability; the 
structure of six of these CBM3 is known. They have been identified in many different bacterial 
enzymes, and in the non-hydrolytic proteins CbpA [243], CipA [266], CipB [267] and CipC 
[244] which are responsible for the structural organization of the cellulosomes present in 
Clostridium cellulovorans (CbpA), Clostridium thermocellum (CipAand CipB from strains ATCC 
27405 and YS, respectively), and Clostridium cellulolyticum (CipC), respectively. 
The crystal structure of a family-III cellulose-binding module (CBM3) from the cellulosomal 
scaffoldin subunit of Clostridium thermocellum was determined by Tormo and collegues[268]. 
According to this work the proteic structure forms a nine-stranded β-sandwich with a jelly roll 
topology and contains a Ca2+ binding site. Conserved, surface-exposed residues map into two 
defined surfaces located on opposite sides of the molecule. On the face that is proposed to 
bind to crystalline cellulose there is a planar linear strip of aromatic residues (His57, Tyr67 
and Trp118) and two polar side chains of aspartic acid (Asp56) and arginine (Arg112). The 
other conserved residues are contained in a shallow groove, the function of which is currently 
unknown, and which has not been observed previously in other families of CBMs [268]. 
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Improving the affinity of fibroblasts for bacterial 
cellulose using carbohydrate – binding modules 
fused to RGD 
 
  
Adapted from: Journal of Biomedical Materials Research: Part A 2010; 92A (1): 9-17. 
 
Abstract 
The attachment of cells to biomedical materials can be improved by using adhesion 
sequences, such as Arg-Gly-Asp (RGD), found in several extracellular matrix proteins. In this 
work, bifunctional recombinant proteins, with a Cellulose-Binding Module – CBM, from the 
cellulosome of Clostridium thermocellum - and cell binding sequences - RGD, GRGDY - were 
cloned and expressed in E. coli. These RGD-containing cellulose binding proteins were purified 
and used to coat bacterial cellulose fibres. Its effect on the cell adhesion/biocompatibility 
properties was tested using a mouse embryo fibroblasts culture. 
Bacterial cellulose (BC) secreted by Gluconacetobacter xylinus (=Acetobacter xylinum) is a 
material with unique properties and promising biomedical applications. CBMs adsorbs 
specifically and tightly on cellulose. Thus, they are a useful tool to address the fused RGD 
sequence (or other bioactive peptides) to the cellulose surface, in a specific and simple way. 
Indeed, fibroblasts exhibit improved ability to interact with bacterial cellulose sheets coated 
with RGD – CBM proteins, as compared with cellulose treated with the CBM, i.e., without the 
adhesion peptide. The effect of the several fusion proteins produced was analysed. 
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Introduction 
The fundamental premise of tissue engineering is to develop tissue substitutes to restore or 
improve the function of diseased or damaged human tissues. Many biomaterials have been 
studied as scaffolds, in which the cells can be seeded, cultured and then, implanted to induce 
and direct the growth of new, healthy tissue. 
The primary function of a scaffold is tissue conduction and, therefore, it must allow cell 
attachment, migration onto or within the scaffold, cell proliferation and cell differentiation. It 
must also provide an environment where the cells conserve their phenotype [1]. The 
successful development of tissue engineering scaffolds requires proper substrates for cell 
survival and differentiation. The attachment of cells to the biomedical materials can be 
improved by using adhesion molecules. These molecules, present in the extracellular matrix 
proteins, regulate the adhesion, migration and growth of cells, by binding to integrin receptors 
located on the outer cellular membranes [2, 3]. The tripeptide motif RGD was identified 23 
years ago by Pierschbacher and Rouslahti as the minimal essential cell adhesion peptide 
sequence in fibronectin [4]. Since than, cell adhesive RGD sites were identified in many other 
extracellular matrix (ECM) proteins, including vitronectin, fibrinogen, von Willebrand factor, 
collagen, laminin, osteopontin, tenascin and bone sialoprotein as well as in membrane 
proteins, in viral and bacterial proteins, and in snake venoms (neurotoxins and disintegrins) 
[5]. The RGD sequence is by far the most effective and most often employed peptide sequence 
used to stimulate cell adhesion on synthetic surfaces, due to its widespread distribution and 
use throughout the organism, its ability to address more than one cell adhesion receptor, and 
its biological impact on cell anchoring, behaviour and survival [6]. Incorporation of biomimetic 
adhesion sites can be used to promote cell adhesion and migration on or within bioactive 
materials. The selection of which type of cells adhere to a material and their spatial distribution 
can also be controlled through the selection of the adhesion sites that are incorporated into the 
bioactive material [7]. 
In the present study, we analyzed the adhesion of mouse embryo fibroblasts on bacterial 
cellulose (BC). BC is secreted by Gluconacetobacter xylinus (=Acetobacter xylinum). It is a 
material with unique properties, including high water holding capacity, high crystallinity, a 
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ultrafine fiber network, and high tensile strength [8]. Although chemically identical to plant 
cellulose, it has a unique fibrillar nanostructure, which determines its extraordinary physical 
and mechanical properties, characteristics which are quite promising for modern medicine and 
biomedical research [9]. For example, membranes of bacterial cellulose were used as an 
artificial skin for temporary covering of wounds and bacterial cellulose tubes were produced as 
substitution material for blood vessels. BC was also successfully used in periodontal 
treatments and applied as replacement for dura mater (a membrane that surrounds brain 
tissue) [8, 9]. 
A method for producing chimeric proteins, RGD-CBM containing a cellulose-binding module 
(CBM), was developed. CBMs are discrete protein modules found in a large number of 
carbohydrolases and a few nonhydrolytic proteins [10]. A cellulose–binding domain family III 
from the cellulosomal-scaffolding protein A of the bacteria Clostridium thermocellum, was used 
in the present work [11]. The main goal was the functionalization of bacterial cellulose aiming 
its utilization as scaffold in tissue engineering. There are several methodologies to bind 
adhesion molecules to the biomaterials. However, the use of a CBM, as proposed in this work, 
is a simple way to direct bioactive peptides to the cellulose surface, avoiding the use of 
complex peptide chemical grafting. Furthermore, the adsorption of this CBM to BC is specific 
and very stable. Indeed, the removal of CBM from cellulose can be achieved only using 
denaturant agents [10]. Thus, the coating of BC with recombinant proteins is stable enough for 
its practical application in the designed of biomaterials. 
The genes encoding these CBM-containing chimeric proteins were cloned, and the proteins 
expressed and purified. Polystyrene surfaces and bacterial cellulose sheets where “coated” 
with these RGD-containing proteins, and then used in adhesion/biocompatibility tests, using a 
mouse embryo fibroblasts culture. Fibroblasts were selected as model animal cells to test our 
strategy of bacterial cellulose modification, while the polystyrene plate was used as a model 
surface to test the recognition of the RGDs sequences by the integrins on cells membrane. 
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Materials and methods 
Production of bacterial cellulose 
Gluconacetobacter xylinus (ATCC 53582) purchased from the American Type Culture 
Collection was grown in Hestrin-Schramm medium, pH 5.0. The medium was inoculated with 
the culture, added to the 24-well polystyrene plate (1 mL/per well) and incubated statically at 
30 oC, for 7 days. BC pellicles were purified by 4% SDS treatment at 70 oC, for 12 h followed by 
4% NaOH at 70 oC, for 90 min. Samples were autoclaved and stored in PBS pH 7.4, at 4ºC, 
prior to use (FIGURE 1). 
 
 
Figure 1. Gluconacetobacter xylinus (ATCC 53582) cultured on liquid Hestrin-Schramm medium 
after 7 days. The medium was inoculated with the culture and added to the 24-well polystyrene 
plate (1 mL/per well) and incubated statically at 30 oC. 
 
Construction of a gene fusion encoding the adhesion peptide and a CBM 
The pET21a vector (Novagen) with the CBM from C. thermocellum and a N-terminal linker 
cloned in the NheI and XhoI restriction sites was used as template for amplification of the 
fused genes. The nucleotide sequence of each peptide was determined and the sequences 
optimized for E. coli expression. Peptides were then amplified by PCR with the enzyme Vent 
DNA polymerase (New England Biolabs) using primers presented in Table 1. Primers included 
NheI and XhoI restriction sites, which are shown in bold. PCRs were performed as follows: 
preheating at 95 ºC for 2 min, 40 cycles at 95 ºC for 45 s, 53 ºC for 45 s and 72 ºC for 45s, 
followed by an elongation at 72 ºC for 10 min. The DNA recombinant coding sequences were 
cloned in pET21a using E. coli XL1 Blue (Strategene) as cloning strain. Clones containing the 
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recombinant genes were identified by restriction enzyme analysis. Amplified fragments were 
sequenced to ensure that no mutations had occurred in the PCRs.  
The recombinant derivates were then digested with NheI and XhoI and the excised products 
were cloned into the expression vector pET21a (Novagen), previously digested with the same  
Table 1. PCR primers with the restriction sites NheI (GCTAGC) and XhoI (CTCGAG) used for 
cloning the gene fusions encoding the adhesion peptide with CBM. 
Recombinant protein name Primers 
RGD/CBM Fwd: 5´- CTA GCT AGC AGA GGT GAT ACA CCG ACC AAG GGA G - 3´ 
Rev: 5´- CAC CTC GAG TTC TTT ACC CCA TAC AAG AAC - 3´ 
GRGDY/CBM Fwd: 5´- CTA GCT AGC GGT AGA GGT GAT TAT ACA CCG ACC AAG GGA G - 3´ 
Rev: 5´- CAC CTC GAG TTC TTT ACC CCA TAC AAG AAC - 3´ 
RGD/CBM/RGD Fwd: 5´- CTA GCT AGC AGA GGT GAT ACA CCG ACC AAG GGA G - 3´ 
Rev: 5´- CAC CTC GAG ATC ACC TCT CGG TTC TTC AGG TTC TGT ACC GCC CGG 
CGG CGT TCC TTC TTT ACC CCA TAC AAG AAC - 3´ 
GRGDY/CBM/GRGDY Fwd: 5´- CTA GCT AGC GGT AGA GGT GAT TAT ACA CCG ACC AAG GGA G - 3´ 
Rev: 5´- CAC CTC GAG ATA ATC ACC TCT ACC CGG TTC TTC AGG TTC TGT ACC GCC 
CGG CGG CGT TCC TTC TTT ACC CCA TAC AAG AAC - 3´ 
 
restriction enzymes. This vector carries a T7lac promoter and includes a C-terminal His6-tag in 
the recombinant proteins to facilitate purification. The sequence encoding the adhesion peptide 
(RGD or GRGDY) was annealed with the CBM at the N- terminal, through the N-terminal linker 
from the CBM containing 40 amino acids. In order to introduce another adhesion sequence at 
the C-terminal of the CBM, a linker containing 12 amino acids was inserted between the C-
terminal of the CBM and the new adhesion sequence (TABLE 1, FIGURE 2).  
 
 
Figure 2. Construction of the gene fusion encoding adhesion peptide and the Linker-CBM. (A) 
Construction containing one copy of the adhesion peptide at the N-terminal of the CBM; (B) 
Construction containing two copies of the adhesion peptide. 
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Production and purification of recombinant proteins 
High-level expression studies and protein production were carried out in E. coli BL21 (DE3) 
cells grown at 37 oC in LB medium supplemented with ampicillin at 100µg/ml. Cultures were 
induced at OD595 = 0.5 with IPTG (1mM). Five hours after induction the cells were separated 
from the culture medium by centrifugation at 13,000g. Then, cell pellet was ressuspended 
with buffer A (20mM Tris, 20mM NaCl 5mM CaCl2 pH 7.4 and phenylmethylsulfonylfluoride 
(PMSF) 0.1mM) and lysed by sonication. Imidazole was added to a final concentration of 
40mM and the pH was adjusted to 7.4. The cell free extract (soluble fraction) was then, 
collected by centrifugation at 15,000g for 30 minutes, at 4 ºC and the His6 – tagged 
recombinant proteins purified by immobilized metal ion affinity chromatography, using a 5mL 
nickel His–Trap column (GE Healthcare). Following purification, the proteins were dialyzed 
against buffer A and stored at -20 ºC, prior to use. Samples from purification’s different steps 
and pure protein were analysed by SDS – PAGE using a 12% (W/V) acrylamide gel, Coomassie 
stained. 
 
Interaction of recombinant proteins with the cells 
In order to demonstrate the interaction of the recombinant RGD with cell membrane, the 
recombinant proteins were chemically conjugated with isothiocyanate (FITC). The fluorescent 
proteins were added to the wells of 96-well polystyrene plates and the fibroblasts were added 
in 200µl of DMEM medium with/without serum. The plates were incubated for 1 hour at 37 
oC, in atmosphere of 5% CO2 and 95% humidified air. The cells were observed through 
fluorescence microscopy. 
 
Effect of the recombinant proteins on the adhesion and spreading of fibroblasts 
The mitochondrial activity of the cultured cells was determined using a colorimetric assay, 
which is related to cell viability. The MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] assay was performed as follows: the 
purified recombinant proteins were added to the wells of the 96-well polystyrene plates 
(0.05mg of protein/per well), and left adsorbing to the plate at 4ºC, overnight. Unbound 
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protein was washed out with PBS. In a second test, the adhesion proteins were added to the 
wells of 24-well polystyrene plates (0.25mg of protein/per well), coated with bacterial cellulose 
sheets. As referred above, the BC sheets were produced in similar 24-well polystyrene plates, 
such that they tightly fit in the wells, completely covering the bottom surface. The plates were 
incubated overnight at 4 ºC. Unbound protein was removed and analyzed by SDS – PAGE, 
then the bacterial cellulose sheets were washed with PBS. The fibroblasts 3T3 were seeded on 
the polystyrene plate at a density of 4 x 104 cells/per well, in DMEM medium without serum. 
One hour after the addition of the cells, the wells were washed with PBS and DMEM with 
serum (10%) was added. The MTS assay and microscope observations of the attached and 
spreading 3T3 fibroblasts was carried out at 1h, 5h, 24h and 48h after the addition of the 
cells. In the assay with BC, the fibroblasts 3T3 were seeded at a density of 12 x 104 cells/per 
well, in DMEM medium without serum. The plates were incubated at 37 oC, in atmosphere of 
5% CO2 and 95% humidified air. Two hours after the addition of the cells, the wells were 
washed with PBS and DMEM with serum (10%) was added. The MTS assay and microscope 
observations of the attachment and spreading of 3T3 fibroblasts were carried out at 2h, 24h 
and 48h after the addition of the cells. The results were obtained from at least 3 different 
assays, each one with samples in triplicates. 
 
Results 
Production and purification of recombinant proteins 
The gene fragment encoding RGD–CBM was subcloned into the high-expression vector pET 
21a, a plasmid vector containing the T7 promoter and a histidine tag sequence. Four different 
constructs were made, through the fusion of different peptides with a family 3 CBM from the 
Clostridium thermocellum cellulosome. It has been found, by other authors, that the 
aminoacids flanking the RGD sequence may affect the affinity of the integrin binding. This 
interaction may also depend on the peptide exposure, and therefore different constructs were 
analyzed in this work. Two constructs were made by fusing the RGD or GRGDY sequences at 
the N – terminal of the linker – CBM. In the other two recombinant constructs a C – terminal 
linker was designed and an additional RGD or GRGDY sequence was inserted (FIGURE 2). As 
shown in Figure 3, all the four recombinant fusion proteins (CBM, RGD–CBM, RGD–CBM–
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RGD, GRGDY–CBM and GRGDY–CBM–GRGDY) were expressed by E. Coli in the soluble 
fraction. It can also be observed from Figure 3 that the recombinant proteins were isolated to 
high purity and concentration.  
 
 
Figure 3. Analysis by SDS-PAGE of recombinant protein expression and nickel column protein 
purification. 1-Molecular weight marker (250 kD, 150 kD, 100 kD, 75 kD, 50 kD, 37 kD, 25 kD, 
20 kD); 2-Insoluble fraction; 3-Soluble fraction; 4- Column filtrate; 5 to 9-Eluted fraction with 300 
mM of Imidazole. (A) CBM; (B) RGD–CBM; (C) RGD–CBM–RGD; (D) GRGDY–CBM; (E) GRGDY–
CBM–GRGDY. 
 
The interaction of RGD and GRGDY with the cells, in medium with or without 
serum 
The fibroblasts, incubated with the recombinant proteins conjugated with FITC, were observed 
by fluorescence microscopy. This study was performed to evaluate whether the recombinant 
proteins are able to interact with the cells through the RGD/GRGDY peptides. When the assays 
were performed with serum free medium, only the cells treated with RGD–CBM and GRGDY–
CBM became fluorescent, as displayed in Figure 4. When medium containing serum was used, 
no fluorescent cells were observed, due to competition of the serum proteins with RGD/GRGDY 
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for the integrins on the cell membranes. These results demonstrate the interaction of the 
RGD/GRGDY with the cells, and furthermore that the CBM does not interact with the cells. 
 
 
 
Figure 4. Fluorescent microscopy showing the binding of recombinant proteins to cell membranes. 
The arrows point with respect to some of the fluorescent cells. (A) RGD/CBM; (B) GRGDY/CBM; 
(C) CBM.  
Attachment of fibroblasts to the polystyrene plate coated with recombinant 
proteins  
In order to test the effect of the recombinant proteins in improving the adhesion and 
proliferation of fibroblasts, the cell culture polystyrene plates – with non-specifically bound 
proteins - were used. The polystyrene plates allow the observation of the cells morphology, 
unlike the bacterial cellulose. In these assays we aimed at observing whether the RGD 
containing proteins improve the adhesion of fibroblasts and also their effect on the cell 
differentiation.  
The MTS results and microscopic observations showed that the proteins containing the RGD 
sequence (RGD–CBM and RGD–CBM–RGD) were able to improve the adhesion of fibroblast on 
polystyrene plates, when compared to the controls (CBM or buffer). Furthermore, the RGD 
sequence was more effective than GRGDY. The results also showed that, while the protein 
containing one copy of the GRGDY sequence was able to improve the adhesion of fibroblasts to 
the polystyrene surface, the protein containing two copies of the GRGDY showed no effect. The 
fibroblast cells adhered to the wells treated with RGD–CBM and RGD–CBM–RGD showed an 
elongated morphology one hour after seeding, while the cells on the wells treated with the 
GRGDY–CBM and GRGDY–CBM–GRGDY and also on the control assays exhibit more spherical 
morphology (FIGURE 5 and FIGURE 6).  
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Figure 5. Photographs showing the effect of the recombinant proteins on cell (fibroblasts 3T3) 
attachment to polystyrene plate. (A) RGD–CBM, (B) RGD–CBM–RGD, (C) GRGDY–CBM, (D) 
GRGDY–CBM–GRGDY, (E) CBM, (F) Buffer, and (G) Control. The photographs were taken at 1, 5, 
24, and 48 h after addition of cells. 
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Figure 6. MTS assays of fibroblast culture on polystyrene plates treated with the recombinant 
proteins (CBM, RGD–CBM, RGD–CBM–RGD, GRGDY–CBM, and GRGDY–CBM–GRGDY). The MTS 
test was developed at 1, 5, 24, and 48 h after addition of cells. 
 
It is quite clear from the results that the presence of the RGD–CBM, RGD–CBM–RGD and, to 
lower extent, GRGDY–CBM proteins, adsorbed on the polystyrene cell culture wells, improves 
the adhesion of fibroblasts. 
 
Attachment of fibroblasts on BC surfaces  
The recombinant proteins were added to the bacterial cellulose sheets and left adsorbing 
overnight. Then, the non–adsorbed protein was removed and analysed by SDS-PAGE 
electrophoresis. As may be seen in Figure 7, most of the protein adsorbed on the BC fibers. 
Thus, not only a functional RGD is present in the recombinant proteins, but also the CBM 
module fully conserves its functionality and ability to bind cellulose. 
The adhesion of fibroblasts to BC was improved by the presence of the adsorbed recombinant 
proteins. Indeed, the results of the MTS test demonstrated that the proteins containing the 
RGD sequence were able to significantly increase the adhesion of fibroblast to BC surfaces, 
while the proteins containing the GRGDY sequence had no effect, taking as reference the 
cellulose treated with the CBM or with buffer. The results also demonstrated that the protein 
containing one RGD sequence have a stronger effect than the protein containing two RGD 
sequences (FIGURE 8). 
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Figure 7. Analysis by SDS-PAGE of the interaction between the recombinant proteins with the 
cellulose sheets. Line 1, 10, and 11 - Molecular weight marker (250 kD, 150 kD, 100 kD, 75 kD, 
50 kD, 37 kD, 25 kD, 20 kD); line 2, 3 - RGD–CBM; line 4, 5 - RGD–CBM–RGD; line 6, 7 - GRGDY–
CBM; line 8, 9 - GRGDY–CBM–GRGDY; line 12, 13 - CBM. Lines 3, 5, 7, 9, and 13 represent the 
proteins after the interaction with BC sheets. 
 
 
 
Figure 8. MTS assays of fibroblast culture treated with the recombinant proteins (CBM, RGD–
CBM, RGD–CBM–RGD, GRGDY–CBM, and GRGDY–CBM–GRGDY) at the bacterial cellulose 
pellicles. The MTS test was developed at 2, 24, and 48 h after addition of cells. 
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Discussion 
It is known that the amino acids flanking the RGD sequence can influence (positive or 
negatively), the interaction of the RGD with the integrins on the cell membrane. Many 
sequences exhibiting different activities have been described: RGDS, GRGDG, GRGDS, GRGDF, 
YRGDS, CGRGDSPK, etc[6]. Different cell lines recognize the RGD sequences in a distinct way. 
In this work, the sequences RGD and GRGDY were fused to a CBM, and the interaction of the 
recombinant proteins with fibroblasts was analyzed. 
The observation of fibroblasts, incubated with the soluble recombinant proteins conjugated 
with FITC, by fluorescence microscopy, revealed that the integrins interact with the RGD and 
GRGDY sequences. Different effects are observed in serum and serum–free medium. These 
differences are probably due to competition of fibronectin and other serum proteins with the 
RGD/GRGDY – CBM for the integrins on the cell membrane. 
The recombinant proteins containing the RGD or GRGDY sequences were able to improve the 
adhesion of fibroblasts to the polystyrene plate, the CBM alone having no effect. Early cell 
spreading was also triggered by RGD-CBM and RGD-CBM-RGD proteins, as revealed by the 
more elongated morphology of the cells one hour after seeding on the polystyrene plates. 
Similar results have been previously obtained by other authors. Wierzba et al. (1995) produced 
a recombinant protein containing a RGD sequence at the C-terminus of a CBM from the 
Cellulomonas fimi endoglucanase A (CenA) [12]. This CBM/RGD promoted the attachment of 
green monkey Vero cell to polystyrene and cellulose acetate. Wang et al. (2006) studied the 
effect of a protein containing two GRGDS sequences at the N- and C- terminal of a CBM from 
Trichoderma koningii; this recombinant protein improved the adhesion of keratinocytes and 
dermal fibroblasts when grafted on the petri dish [13]. 
The proteins containing the RGD sequence significantly increased the adhesion of the fibroblast 
on the cellulose sheet, as compared to the cellulose treated only with CBM or buffer, while the 
GRGDY had no effect. The protein containing a single RGD had, surprisingly, a stronger effect 
on the adhesion of fibroblasts than the protein containing two RGDs. Thus, the effects of RGD 
vs GRGDY and 1xRGD vs 2xRGD are distinct, depending on whether the proteins are adsorbed 
on polystyrene or in bacterial cellulose. The affinity of the cells is expected to increase with the 
concentration of RGD copies. This was the motivation for the production of fusion proteins with 
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two RGD copies. However, the results demonstrate that there is not a simple and 
straightforward relation between the RGD surface concentration and the cells adhesiveness 
and proliferation. Besides concentration, also the exposure, conformation and steric effects 
may play a role to the RGD-integrin interaction. In fact, it seems that the second RGD or 
GRGDY brings no further functionality to the proteins. It must be remarked that the presence of 
a RGD sequence, in a protein, does not guarantee cell attachment activity. Indeed, several 
hundred proteins contain the RGD tripeptide, but most of these do not have cell attachment 
activity. To be functional, the RGD sequence must be appropriately exposed, in a conformation 
that can be recognized by a cell surface receptor [12]. The results obtained in this work 
consistently showed that, in the assays with BC, the protein containing two RGD sequences 
had lower activity. The CBM used in this work, from the bacteria Clostridium thermocellum, 
has N- and C- terminals close to each other [11]. Probably, the second linker - containing 
twelve amino acids, followed by the second adhesion peptide and the hexahistidine tag - at the 
protein C-terminal interferes with the interaction between the N-terminal RGD or GRGDY with 
the integrins on the cell membrane. Also, it may be that the presence of a hexahistidine tag, 
following the RGD, interferes with the exposure of this sequence and its interaction with the 
integrins. This effect is more relevant with cellulose – where the CBM adsorbs with a specific 
conformation and orientation - than with the polystyrene plate – where the non-specific 
adsorption probably leads to random orientation of the molecules. Wierzba et al. (1995) 
observed that different cell lines exhibited different patterns of attachment to CBM–RGD, 
depending on whether it was immobilized on polystyrene plate or cellulose acetate. Vero, COS, 
HFF, 3T3, 293, and U373 cells attached well to CBM–RGD immobilized on polystyrene or 
cellulose acetate. CHO, MRC-5, and HEp-2 cells attached to CBM–RGD immobilized on 
polystyrene, but not to CBM–RGD immobilized on cellulose acetate. BHK and L cells failed to 
attach to CBM–RGD immobilized on both surfaces. The authors conclude that the adsorption 
of CBM–RGD to polystyrene plate is nonspecific and presents the RGD in a different 
configuration or environment, and this may account for differences in the observed cell-binding 
properties, as observed in this work [14]. 
  
 
 
Chapter 2 
 
  86 
Conclusion 
Bacterial cellulose is a material with excellent biocompatibility and mechanical properties, thus 
holding great potential for biomedical applications. In this work, a new approach was 
developed to functionalise the bacterial cellulose, through recombinant proteins containing 
adhesion peptides conjugated with a cellulose binding-module. The use of recombinant 
proteins containing a CBM domain, exhibiting high affinity and specificity for cellulose surfaces, 
allows the control on the interaction of this material with cells. The CBM may virtually be 
combined to any biologically active protein for the modification of cellulose-based materials, for 
in vitro or in vivo applications.  The recombinant proteins containing the RGD or GRGDY 
sequences were cloned and successfully expressed in fusion with a family 3 CBM of 
Clostridium thermocellum in E. coli expression system. The recombinant proteins containing 
the adhesion peptide were able to promote adhesion and spreading of the cells. Furthermore, 
the proteins containing the sequence RGD showed a stronger effect than GRGDY on fibroblast 
cells. The effect of different adhesive sequences seems to depend on the material where they 
are adsorbed, probably due to conformation effects. Protein models – not in the scope of this 
work - would probably be useful on helping the design of more effective recombinant proteins. 
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Improving bacterial cellulose for blood vessel 
replacement: functionalization with a chimeric 
protein containing a cellulose-binding module and 
an adhesion peptide 
 
Adapted from: Acta Biomaterialia 2010; 12;6:4034–4041. 
 
Abstract 
Chimeric proteins containing a cellulose-binding module (CBM) and an adhesion peptide (RGD 
or GRGDY) were produced and used to improve the adhesion of human microvascular 
endothelial cells (HMEC) to Bacterial Cellulose (BC). The effect of these proteins on the HMEC-
BC interaction was studied. The results obtained demonstrated that the recombinant proteins 
containing adhesion sequences were able to significantly increase the attachment of HMEC to 
BC surfaces, specially the RGD sequence. The images obtained by SEM microscopy showed 
that the cells on the RGD-treated BC present a more elongated morphology, 48h after cell 
seeding. The results also showed that the RGD decreased the in-growth of the HMEC cells 
through the BC and stimulated the early formation of cordlike structures by these endothelial 
cells. Thus, the use of recombinant proteins containing a CBM domain, with high affinity and 
specificity for cellulose surfaces, allows the control on the interaction of this material with cells. 
CBM may be combined virtually to any biologically active protein for the modification of 
cellulose-based materials, for in vitro or in vivo applications. 
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Introduction 
Cardiovascular disease is the leading cause of mortality in Western countries. Surgical bypass 
with autologous grafts remains the most used treatment, saphenous veins and mammary 
arteries being preferably used. However, many patients do not have suitable vessels, due to 
preexisting vascular disease, amputation or previous harvest for prior vascular procedures. 
Moreover, a second surgical procedure is needed to obtain the vessel [1, 2]. For the 
reconstruction of arteries with large caliber, currently available synthetic grafts (e.g.: Dacron, 
and ePTFE) offer a reasonable solution and proven clinical efficacy. However, for small size (<6 
mm) grafts, these materials generally present poor performance, due the anastomotic intimal 
hyperplasia and surface thrombogenicity [3-5]. This scenario prompts the search for new 
materials, suitable for the effective replacement of small blood vessels. 
Bacterial cellulose (BC) produced by Acetobacter organisms is a biomaterial that has gained 
interest in the field of tissue engineering, due to its unique properties. BC has been studied by 
several research groups as a scaffold for cartilage [6-8], wound dressing [9, 10], dental 
implants [11-17], nerve regeneration [18, 19] and vascular grafts [18, 20-23]. The in vivo 
biocompatibility of BC was also evaluated in a study conducted by Helenius and colleagues 
[24]. 
Many strategies have been pursued to improve the compatibility and effectiveness of vascular 
grafts, through the production of unreactive surfaces, the surface modification of existing 
synthetic grafts (e.g. modifying surface properties, the incorporation of biologically active 
substances) and coating with autologous cells [4]. Seeding the graft surface with endothelial 
cells [25] is a quite promising approach; the native vessel is this way mimicked, thereby 
decreasing thrombosis. However, the high loss of ECs by the restored blood flow after 
implantation presents a major challenge [4, 26, 27]. The rate and quality of endothelialization 
of a synthetic vascular graft depends on interaction of EC with these cardiovascular materials. 
Several approaches have been attempted to increase the EC adhesion on typically non-
adhesive polymeric biomaterials used for synthetic vascular grafts [28]. One such approach 
involves pre-coating with EC specific adhesive glues. The tripeptide Arg-Gly-Asp (RGD), an 
amino acid sequence found in many adhesive plasma and extracellular matrix protein, has 
been used to enhance cell adherence. Binding of cells to the RGD-sequence occurs via integrin 
receptors on the cell membranes. The improvement of the biocompatibility and performance of 
bacterial cellulose – envisaging its use as small-diameter vascular grafts – by enhancing the 
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adhesion of human microvascular endothelial cells (HMEC-1), was attempted in this work by 
coating BC with adhesion peptides. 
Many strategies developed to modify the materials used as synthetic grafts (e.g., Dacron, 
ePTFE, polyurethane) with the adsorption of active substances, like heparin, RGD, albumin-
heparin conjugates, dipyridamole, have little or no effect due to the coatings being washed 
away [27]. In a previous work (presented in chapter 2), we described the production of 
recombinant proteins containing the adhesion sequences fused to a CBM (cellulose-binding 
module) [29]. For artificial grafts based on cellulose, the use of a CBM (exhibiting high affinity 
and specificity for cellulose surfaces) that can virtually be combined to any biologically active 
protein is an important strategy to avoid loosing the biological agents coating the graft. 
 
Materials and methods 
Cell culture assays 
Human Microvascular Endothelial Cells (HMECs) (kindly provided by Dr João Nuno Moreira, 
Coimbra University) were used between passages 13 and 22. HMECs were cultured in RPMI 
1640 medium (Invitrogen Life Technologies, UK) supplemented with 10% FBS (Invitrogen Life 
Technologies, UK), 1% penicillin/streptomycin (Invitrogen Life technologies, UK), 1.176 g/L of 
sodium bicarbonate, 4.76 g/L of Hepes, 1mL/L of EGF and 1 mg/L of hydrocortisone > 98% 
(Sigma, Portugal), and maintained at 37ºC in a humidified 5% CO2 atmosphere. 
 
Cell attachment, proliferation and viability 
Production and purification of recombinant proteins: The recombinant proteins (RGD–CBM, 
RGD–CBM–RGD, GRGDY–CBM, GRGDY–CBM–GRGDY) have been formerly cloned in 
Escherichia coli and its production and purification was conducted as previously described [29] 
in chapter 2.  
Production of bacterial cellulose and coating with the recombinant peptides: Gluconacetobacter 
xylinus (ATCC 53582 and DSMZ 46604) purchased from the American Type Culture Collection 
and from the German Collection of Microorganisms and Cell Cultures were grown in Hestrin-
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Schramm medium, pH 5.0. The medium was inoculated with the culture, added to the 24-well 
or 96-well polystyrene plate (1 mL or 0.2mL per well, respectively) and incubated statically at 
30 oC, for 5 days (ATCC 53582) or 10 days (DSMZ 46604). BC pellicles were purified by 2% 
SDS treatment at 60 oC, for 12 h followed by 4% NaOH at 60 oC, for 90 min. Samples were 
autoclaved and stored in PBS pH 7.4, at 4ºC, prior to use. The pellicles produced by the DSMZ 
46604 strain (BC – L) presented a thickness of about 0.5mm, while the pellicles produced by 
the ATCC 53582 strain (BC – H) are approximately 3mm thick. The recombinant proteins were 
added (0.25mg of protein/per membrane) and left adsorbing to BC for 12 hours, 4 oC. Then, 
the membranes were washed with phosphate buffered saline (PBS). 
HMEC-1 Adhesion and proliferation: The mitochondrial activity of the cultured cells was 
determined using a colorimetric assay, which is related to cell viability. The MTS [3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] assay was 
performed as follows: BC – H or BC – L membranes treated with the recombinant proteins 
were added to the wells of 24-well polystyrene plates. As referred above, the BC sheets were 
produced in similar 24-well polystyrene plates, such that they tightly fit in the wells, completely 
covering the bottom surface. The HMEC-1 cells were seeded on the BC at a density of 12 x 104 
cells/well, in RPMI medium without serum. The plates were incubated at 37 oC, in atmosphere 
of 5% CO2 and 95% humidified air. Two hours after the addition of the cells, the wells were 
washed with PBS and RPMI with 10% Foetal Bovine Serum (FBS) was added. The MTS assay 
of the adsorbed HMEC-1 cells was carried out to evaluate the adhesion of cells after 2h and 
proliferation 24h, 48h and 7 days after cell seeding. The results were obtained from at least 3 
different assays, each one with samples in triplicates. 
In order to evaluate the effect of the RGD on the rate of cell adhesion, a similar assay was 
performed at 15, 30, 60, 90 and 120 minutes after cell seeding, the non-adherent cells being 
washed out before running the MTS assay. 
Live and dead assay: The viability of the cells coating the cellulose (BC – L), treated or not with 
the recombinant proteins, was also analyzed with the LIVE/DEAD® Viability/Cytotoxicity Kit for 
mammalian cells (Invitrogen, UK). This kit provides two-color fluorescence cell viability assay, 
based on the simultaneous determination of live and dead cells with two probes that measure 
the intracellular esterase activity and the plasma membrane integrity. This assay employs 
calcein, a polyanionic dye, which is retained within the living cells, producing green 
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fluorescence. It also employs the ethidium bromide homodimer dye (red fluorescence), which 
can enter the cells through damaged membranes, binding to nucleic acids and being excluded 
by the intact plasma membrane of the living cells. The experiment was developed as described 
for the MTS assay. The fluorescence microscopy observations of the cells were carried out 
after 24 hours of incubation. Cells seeded on polystyrene were used as positive control (living 
cells), and cells further treated with methanol 70% for 30 min were taken as negative control 
(dead cells). Live and dead assay was also used to analyze the apoptosis event (qualitatively) in 
combination with the TUNEL assay (quantitatively). Samples were visualized and imaged using 
a Fluorescent microscope Olympus BX51 (Olympus Portugal SA, Porto, Portugal). 
 
Morphological analysis by fluorescent and SEM microscopy 
The BC – L membrane treated with recombinant proteins were seeded with cells as previously 
described. For fluorescent microscopy, 14 days after cells seeding on BC, the membranes 
were washed with prewarmed PBS; then, the cells were fixed in 4% formaldehyde (Pierce, 
Rockford, IL, USA) in PBS, permeabilized with acetone (Sigma) at –20ºC, and stained with 
Alexa Fluor 546-phalloidin (Molecular Probes). Nuclei were visualized by staining with DAPI. 
Microscopy observations were performed using an Olympus BX51 (Olympus Portugal SA, 
Porto, Portugal) fluorescence microscope. Fluorescence microscopic observations were carried 
out only with the BC – L membranes, which allow a proper visualization of the cells due to 
their thinness. For SEM microscopy, 48 hours after cell seeding the medium was removed and 
the BC pellicles washed twice with PBS. Next, 1ml of 2.5% glutaraldehyde in PBS was poured 
into each well, and the materials were maintained at room temperature for 1h, in order to fix 
the cells on the membrane. Afterwards, the membranes were rinsed with distilled water, and 
finally dehydrated by successive immersion in a series of ethanol-water solutions (55, 70, 80, 
90, 95, 100% v/v), for 30 min each, and allowed to evaporate at room temperature. The 
surface of the membranes with the adherent cells was observed with scanning electron 
microscopy (LEICA S 360), after gold-sputtering treatment. 
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Cell apoptosis 
Tunel Assay: HMEC-1 cells (12 × 104 cel/well) were seeded on the BC – L as described for the 
MTS assay and after 24h of incubation the TUNEL assay (Terminal deoxynucleotidyl 
transferasemediated deoxyuridine triphosphate nick-end labeling), which examines DNA strand 
breaks during apoptosis, was performed using the In Situ Cell Death Detection kit (Roche 
Diagnostics, Basel, Switzerland), according to the manufacturing instructions and as previously 
described [30]. To facilitate the counting of the total nucleus, the cells were also stained with 
DAPI. 
 
Cell invasion 
To evaluate the RGD effect on the migration of the endothelial cells through the BC a migration 
chamber and an attractant were used to stimulate the cells migration into the BC. The 
migration chamber consisted of cell culture inserts with a membrane pore size of 8.0 µm in a 
24 well plate (BD Biocoat TM Matrigel TM Invasion Chamber, BD, NJ, USA). Initially, HMEC-1 cells 
were seeded onto BC – L (treated with the recombinant proteins) at a density of 2.5x 104 
cell/well in Medium RPMI without serum. After four hours, 10% FBS serum was added to the 
wells. The plates were incubated at 37 oC in atmosphere of 5% CO2 and 95% humidified air for 
24 hours. In the next day, cell-coated BC pellicles were transferred to the invasion chamber 
containing medium with 2% FBS. To attract the cells to migrate into the cellulose, 20% FBS 
were added to the cell culture medium in the wells. Cell cultures were incubated for 72 hours. 
After conclusion of the experiments, the Matrigel membranes were removed from the inserts 
with a scalpel. The cellulose and Matrigel membranes were fixed and stained with a methanol 
– DAPI solution and photographed through fluorescence microscopy. The cells that migrated 
from the cellulose to matrigel were counted. 
 
Angiogenesis 
BC – L pellicles produced in a 24-well polystyrene plate were treated with the recombinant 
proteins and coated with HMEC cells (4 x 104 cel/well), in serum-free medium for two hours. 
Then, 10% FBS was added to the wells. The pellicles were incubated for 24 hours at 37 oC in 
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atmosphere of 5% CO2 and 95% humidified air. Afterwards, the medium was removed and 
fresh medium with serum (10%) was added. The plates were incubated for four days. To 
evaluate the effect of the recombinant protein on the morphology and assembly of EC into 
capillary-like structures when cultured on BC pellicles, the cordlike structures were observed 
qualitatively in a Leica DM IL inverted microscope (Leica Microsystems, Wetzlar, Germany). 
 
Immunocytochemistry 
The cells were grown on BC treated with the recombinant proteins (RGD-CBM or CBM) or 
buffer for 14 days, then fixed with methanol at -20 ºC. To avoid unspecific interactions the 
cellulose membranes were blocked with BSA 4% in PBS. The Primary antibody was vWF (von 
Willebrand factor) (1:100) (Chemicon, Hofheim, Germany) and the secondary antibody was an 
anti-rabbit FITC-conjugated (1:1000) (Santa Cruz Biotechnology, santa Barbara, USA). The 
Nuclei were counterstained with DAPI (Sigma Aldrich, Portugal). Cells were observed through 
fluorescent microscopy (Nikon Eclipse 50i, Japan). The endothelial specificity of the cells was 
also verified by the uptake of DiL-labelled acetylated low-density lipoprotein (Biomedical 
Techologies Inc., USA) another specific marker for these cells. 
 
Statistical analyses 
All experiments were performed in triplicate. Quantifications are expressed as mean (± SD) of 
3 independent experiments. Statistical significance of difference between various groups was 
evaluated by one-way analysis of variance (ANOVA test) followed by the Bonferroni test. 
 
Results 
The results of the MTS assay demonstrated that the recombinant proteins containing adhesion 
sequences were able to increase significantly the attachment of HMEC to BC – H surfaces 
(FIGURE 1). Two hours after cell seeding, approximately 140-150% and 60-80% more cells 
adhered to BC treated with the proteins containing the RGD and GRGDY peptides, respectively, 
when compared to non-treated BC – H.  
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Figure 1: MTS assays of HMEC-1 culture on BC – H pellicles treated with the recombinant proteins 
(CBM, RGD-CBM, RGD-CBM-RGD, GRGDY-CBM and GRGDY-CBM-GRGDY) and buffer. The MTS 
assay was developed at 2, 24, 48 hours and 7 days after cells addition. Results are expressed in 
absorbance values at 490nm. 
 
The results demonstrated that the proteins containing RGD sequence have a stronger effect 
than the protein containing GRGDY sequences. Moreover, it seems that the presence of a 
second adhesion sequence at the C-terminal of the protein did not significantly enhance the 
effect of the recombinant protein when compared with the protein containing only one copy of 
the peptide. Moreover, the results indicated that the adsorption of the CBM protein to BC – H 
slightly decreases cell adhesion (FIGURE 1) by 14%. When the assay was developed with BC – 
L membranes, coated with proteins containing one or two RGD copies, around 108 and 77% 
more cells adhered to the material than to non-treated BC – L. The proteins containing the 
GRGDY peptide promoted an increase of only 22-40% of cell adhesion (FIGURE 2). Figure 3 
shows that the improvement of cell attachment is significant already 15 minutes after cell 
seeding. From figures 1 and 2, after 24 and 48 hours following the cell seeding no proliferation 
is detected, irrespective of the BC membrane or treatment used. However, after 7 days, 
proliferation is noticeable on BC – H treated with the RGD and GRGDY containing proteins (in 
contrast with CBM and buffer treated BC-H), while no proliferation is visible when cells were 
cultured on BC – L. 
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Figure 2: MTS assays of HMEC-1 culture on BC – L pellicles treated with the recombinant proteins 
(CBM, RGD-CBM, RGD-CBM-RGD, GRGDY-CBM and GRGDY-CBM-GRGDY) and buffer. The MTS 
assay was developed at 2, 24, 48 hours and 7 days after cells addition. Results are expressed in 
absorbance values at 490nm. 
 
 
Figure 3: MTS assays of HMEC-1 culture on BC- H pellicles treated with CBM, RGD-CBM and 
buffer. The MTS test was developed at 15, 30, 60, 90 and 120 minutes after addition of cells. 
Results are expressed in absorbance values at 490nm. 
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To estimate the viability of the cells on the protein coated BC, the LIVE/DEAD assay was 
performed 24 hours after cell adhesion. The fluorescence images obtained show that, 
irrespective of the treatment, the cells remain viable on the BC pellicle (FIGURE 4). TUNEL 
assay results corroborated the LIVE/DEAD assay, showing no significant differences between 
BC pellicles treated with the recombinant proteins (RGD-CBM and CBM) when compared with 
control (buffer) (FIGURE 5). 
 
 
Figure 4: Fluorescence photographs of endothelial cells stained with LIVE/DEAD® 
Viability/Cytotoxicity Kit for mammalian cells. Live cells are stained in green and dead cells are 
stained in red. BC-L treated with RGD-CBM (a), CBM (b) and buffer (c). Controls with cells on 
polystyrene, live (d) and dead (e). Images were acquired using objectives 40x (scale 50µm). 
 
We next investigated whether the RGD affects HMEC invasion capacity using a double-chamber 
assay. The cells were seeded on the BC – L pellicle treated with the RGD, CBM or buffer. The 
number of migrating cells was then quantified through the double-chamber assay, using serum 
at 20% as chemoattractant. In comparison to the controls, the RGD decreased the ingrowth of  
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Figure 5: Apoptosis was quantitatively evaluated by the TUNEL assay. The HMEC cells were 
seeded on the BC – L and after 24h of incubation the TUNEL assay was performed. Bars represent 
the percentage of apoptotic cells evaluated by the ratio between TUNEL-stained cells and DAPI-
stained nuclei in every culture. Experiments were repeated three times with identical results.  
the HMEC cells through the BC. A 4- and 2.4-fold increase of the number of cells migrating 
through the membrane was obtained, respectively for the BC treated with buffer and CBM, 
taking as reference the BC treated with RGD (FIGURE 6). 
Optical Microscopy observation indicated that the RGD stimulated the formation of cellular 
cordlike structures, at an earlier stage as compared with the other groups. These findings 
showed that 24 hours after seeding, most of the cells present a round shape in all groups 
(data no shown). However, after 96 hours, the cells of the RGD treated - BC are more 
elongated than those on the buffer control, starting to form cordlike structures, while the cell of 
the CBM group remain round shaped (FIGURE 7). In fact, the structure showed in image (d) 
from figure 7, obtained by fluorescent microscopy, was found only in the BC surfaces treated 
with RGD. Details on the morphology of the cells 48 hours after cell seeding were obtained by 
SEM. The cells on the RGD treated BC presented an elongated shape; in fact, as can be seen 
in image (a), most of the cells are so elongated that become hardly noticeable on SEM, unlike 
cells observed on the untreated or CBM treated – BC where most remain rounded (FIGURE 8). 
The von Willebrand factor expression is a widely used criterion for defining endothelial cell type 
[31-33], thus to determine whether HMECs cells maintain the endothelial phenotype  
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Figure 6: Effect of RGD on the HMEC cell invasion through bacterial cellulose pellicles. Invasion 
was quantified in a double-chamber assay using medium complemented with 20% FBS as a 
chemoattractant. Bars represent the number of invasive cells. 
 
Figure 7: Images (a), (b) and (c) - optical microscopy photographs showing the effect of the RGD 
on the assembly of endothelial cells into capillary-like structures. BC – L treated with RGD-CBM 
(a), CBM (b) and buffer (c). Image was acquired using objective 20x (scale 200µm). Image (d) - 
Fluorescent microscopy image showing HMECs cells cultured at 14 days on BC – L pellicle treated 
with RGD – CBM recombinant protein. Nuclei were visualized by staining with DAPI (blue) and f- 
actin with Alexa Fluor 546-phalloidin (red). Image was acquired using objective 20x (scale 
100µm). 
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characteristic after 14 days cultured on BC, the vWF expression was evaluated. 
Immunocytochemistry results showed that cells grown on BC treated with the recombinant 
proteins or buffer maintained their positive staining for vWF (FIGURE 9). 
 
 
Figure 8: SEM micrographs of bacterial cellulose. BC treated with RGD–CBM (a, b); CBM (c, d) 
and buffer (e, f). The arrows remark cells with elongated morphology. (a), (c) and (e) scale 50µm; 
(b), (d) and (f) scale 5µm. 
 
 
Figure 9: Immunocytochemical analyses using anti-vWF antibody. The results showed that HMEC 
cells cultured after 14 days on BC–L treated with recombinant proteins or buffer stained positively 
for vWF. (a) RGD-CBM, (b) CBM and (c) buffer. Image was acquired using objective 20x (scale 
100µm). 
 
Discussion 
Gluconacetobacter xylinus constructs a BC pellicle that presents a denser and flatter surface 
side and a gelatinous layer on the opposite side [18]. In this study, all the experiments were 
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conducted on the denser side of both the BC-H and BC-L, because a smooth surface, being 
similar to the basal membrane of the luminal side of blood vessels, is preferable for the 
attachment of endothelial cells [20]. Analysis by SEM showed that G. xylinus ATCC 53582 
produce a thicker and more compact cellulose pellicle than the DSMZ 46604 strain (data not 
shown). Therefore, the BC-H pellicle presents a smoother surface than the BC-L. This may lead 
to differences between BC-H and BC-L in the adhesion and proliferation of the cells in the MTS 
test. The results from the attachment assay were similar to those obtained in our previous 
work (chapter 2), when fibroblasts were seeded on BC produced by ATCC 53582 strain coated 
with adhesion peptides [29]. In that previous work, the RGD improved the adhesion of 
fibroblast onto cellulose and the presence of a second RGD did not enhance the effect of the 
recombinant protein, probably because the RGD at the C-terminal of the protein was not 
properly exposed to be recognized by integrins. However, unlike the results with endothelial 
cells, the GRGDY sequence was not effective on the adhesion of fibroblasts. Apparently, the 
microvascular endothelial cells adhere stronger than fibroblasts to the recombinant protein 
containing RGD sequences. Indeed, endothelial cells may have substantially more αvβ3 integrin 
than fibroblasts [34]. The results also demonstrated that pre-coating BC with the RGD-
containing protein decreased the incubation time required for adsorption. A short incubation 
period is particularly important in single-stage seeding as the incubation time is kept to a 
minimum to fit into the time frame of the surgical procedure [26]. 
Several works have been developed to improve the interaction of cells to bacterial cellulose 
[21, 29, 35, 36]. However, only a few studied the migration and ingrowth of cells on BC [20, 
21, 37, 38]. The migration of the cells is mediated mainly by integrins, a diverse family of 
glycoproteins that form heterodimeric receptors for ECM molecules. During migration, cells 
project lamellipodia that attach to the ECM, and simultaneously break existing ECM contacts at 
their trailing edge. This allows the cell to pull itself forward. Integrins are essential for cell 
migration and invasion, not only because they directly mediate adhesion to the extracellular 
matrix, but also because they regulate intracellular signaling pathways that control cytoskeleton 
organization, force generation, gene transcription, and survival [39]. 
Endothelialization may either be developed ex vivo or post-implantation, stimulating the ECs 
(from tissues adjacent to anastomosis or from circulation) to adhere and proliferate on the 
graft. The rate and quality of a vascular graft endothelialization depends on the cell-material 
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interaction, leading to functions such as adhesion and migration. Several studies have shown 
that cell adhesiveness to substratum modulates cell migration on surfaces coated with ECM 
proteins [25, 40-42]. Our results showed that a small number of cells migrated through the 
cellulose when compared with the rather large number of cells added (2.5x 104 cel/well). 
During invasion, cells release proteases that degrade and remodel the ECM, promoting cell 
passage through to the stroma and entrance into the new tissue [39]. However, cellulose could 
not be degraded by animal cells [24] and in order to migrate in a fibrous hydrogel as BC the 
cells must push the nanofibrils aside when migrating into the cellulose nanofibril network [20]. 
Probably, the time used in the experiment (72h) was too short to enable cells to migrate 
through the BC pellicle with around 0.5mm of thickness. Nevertheless, the results obtained 
allowed the observation that the migration of endothelial cells on BC was decreased by the 
presence of the RGD. Since adhesion involves receptor/ligand binding, cell migration can be 
regulated by controlling cell integrin expression level, integrin-ECM binding affinity or 
substratum ECM surface density. However, if other stimuli are added, such as growth factors 
that affect signaling processes of the cell, the migration/adhesion relationship can be 
dramatically altered [43, 44]. The migration rates of cells are influenced by the chemical and 
physical interaction with the surface of the material. Studies described that cell migration 
capacity presents a biphasic behavior depending on the attachment strength. Optimal 
migration speed can be achieved with intermediate strengths of adhesiveness, since when the 
adhesion to the substratum is weak no traction occurs, so that the locomotion is not possible 
and the cell spreads poorly. On the other hand, with strong adhesion, cell is well-spread and 
immobilized, so dynamic disruption of cell-substratum attachments is difficult and locomotion 
again does not occur [28, 40, 41, 45, 46]. The CBM used in this work presents a great affinity 
to cellulose and adsorbs in a specific and very stable way. Probably, the amount of protein 
used in the experiments was great enough as to saturate the surface of the cellulose pellicle 
with the RGD-containing proteins, promoting an intense affinity of the cells to the substratum 
and affecting negatively the locomotion through BC. The saturation of the surface of the 
cellulose pellicle with the RGD-containg proteins is corroborated by the results shown in our 
previous work (chapter 2) [29]. In order to enhance endothelialization of BC vascular grafts it is 
important to promote not only the adhesion of endothelial cells, but also to allow migration 
through the material. The treatment used in this work greatly improved the adhesion, however 
the migration was negatively affected by the presence of the RGD, because the affinity of 
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HMEC cells to the material surface became to strong. However, it is probably possible to 
improve migration of the cells on BC by optimizing the concentration of RGD containing 
protein, attempting to reach a compromise between adsorption and migration. However, longer 
experiments are needed to better assess the effect of RGD on cell migration through BC. 
The effect of the RGD on HMECs morphology was observed by SEM. The cells on the RGD – 
coated BC exhibits a more elongated, flattened morphology, while the ones on “bare” BC were 
round (Fig. 8a and b). The more extended morphology of the HMECs upon interaction with the 
adhesive peptides is likely driven by the larger number of focal contacts between integrins and 
RGDs peptides linked to the BC surface. It is well known that a critical RGD density is essential 
for the establishment of mature and stable integrin adhesions, which, in turn, induce efficient 
cell migration, spreading and formation of focal adhesions [47-50]. 
During angiogenesis events, cells must adhere to one another and to extracellular matrix 
(ECM) to construct and extend new microvessels [51]. Angiogenesis depends not only on 
growth factors and their receptors, being also influenced by receptors for ECM proteins. Our 
results showed that the RGD-containing recombinant protein (RGD-CBM protein) stimulated the 
early formation of cellular cordlike structures by on bacterial cellulose when compared to BC 
treated with the recombinant protein without the adhesion peptide (CBM protein) or buffer. 
HMEC-1 cells express αVβ3 and αVβ5 integrins [52] that can bind an array of ligands such as 
vitronectin, fibronectin, von Willebrand factor, fibrinogen, osteopontin, thrombospondin, and 
RGD-containing peptides [51, 53]. Moreover these two complexes also have been identified as 
having an especially interesting expression pattern among vascular cells during angiogenesis 
and vascular remodeling. 
Immunocytochemistry results showed that cells grown on BC maintained their positive staining 
for von Willebrand factor (vWF). This glycoprotein is one of the various secretory and 
membrane-bound molecules produced by the endothelium. The vWF mediates the interaction 
of platelets with damaged endothelial surfaces at sites of vascular injury and has been long 
favored as an endothelial-cell marker, once the expression of this factor is highly restricted to 
endothelial cells, platelets, and megakaryocytes [33].  
In the current scenario of regenerative medicine there is a great demand for production of new 
materials appropriate for small-diameter blood vessel replacements. In this work, bacterial 
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cellulose, a promising cardiovascular biomaterial, was successfully functionalized. The strategy 
used aims the improvement of microvascular cell adhesion to BC, through recombinant 
proteins containing adhesion peptides and a cellulose-binding module. For artificial grafts 
based on cellulose, the use of a CBM (exhibiting high affinity and specificity for cellulose 
surfaces) is an excellent feature, once CBM can virtually be combined to any biologically active 
protein and used to modify the cellulose-based materials. The chimeric proteins were able to 
enhance endothelial cells adhesion to BC and stimulate angiogenesis. However, the ingrowth 
of the cell through cellulose was decreased. We believe that an improved migration of the cells 
on BC will be achieved with intermediary concentration of protein used in this work. 
Chapter 3 
 
  107 
References 
1. Isenberg BC, Williams C, Tranquillo RT. Small-diameter artificial arteries engineered in 
vitro. Circ Res 2006 Jan 6;98(1):25-35. 
2. Wang X, Lin P, Yao Q, Chen C. Development of small-diameter vascular grafts. World J 
Surg 2007 Apr;31(4):682-689. 
3. Conte MS. The ideal small arterial substitute: a search for the Holy Grail? FASEB J 
1998 Jan;12(1):43-45. 
4. Bos GW, Poot AA, Beugeling T, van Aken WG, Feijen J. Small-diameter vascular graft 
prostheses: current status. Arch Physiol Biochem 1998 Apr;106(2):100-115. 
5. Zilla P, Bezuidenhout D, Human P. Prosthetic vascular grafts: wrong models, wrong 
questions and no healing. Biomaterials 2007 Dec;28(34):5009-5027. 
6. Svensson A, Nicklasson E, Harrah T, Panilaitis B, Kaplan DL, Brittberg M, et al. 
Bacterial cellulose as a potential scaffold for tissue engineering of cartilage. Biomaterials 2005 
Feb;26(4):419-431. 
7. Oliveira RCB, Souza FC, Castro M. Avaliação da resposta tecidual quando da 
substituição da cartilagem do septo nasal de coelhos por manta de celulose bacteriana. 
Estudo experimental. ACTA ORL/Técnicas em Otorrinolaringologia 2007;25(4):267-277. 
8. Bodin A, Concaro S, Brittberg M, Gatenholm P. Bacterial cellulose as a potential 
meniscus implant. J Tissue Eng Regen Med 2007 Sep-Oct;1(5):406-408. 
9. Fontana JD, de Souza AM, Fontana CK, Torriani IL, Moreschi JC, Gallotti BJ, et al. 
Acetobacter cellulose pellicle as a temporary skin substitute. Appl Biochem Biotechnol 1990 
Spring-Summer;24-25:253-264. 
10. Pippi NL, Sampaio AJSA. Estudos preliminares sobre o comportamento do Biofill na 
ceratoplastia lamelar em coelhos. Revista do Centro de Ciências Rurais 1990;20(3-4):297-
302. 
11. dos Anjos B, Novaes AB, Jr., Meffert R, Barboza EP. Clinical comparison of cellulose 
and expanded polytetrafluoroethylene membranes in the treatment of class II furcations in 
mandibular molars with 6-month re-entry. J Periodontol 1998 Apr;69(4):454-459. 
12. Novaes AB, Jr., Novaes AB, Grissi MFM, Soares UN, Gabarra F. Gengiflex, an Alkali-
Cellulose membrane for GTR: Histologic observations. Brazilian Dental Jornal 1993;4(2):65-
71. 
13. Novaes AB, Jr., Novaes AB. Immediate implants placed into infected sites: a clinical 
report. Int J Oral Maxillofac Implants 1995 Sep-Oct;10(5):609-613. 
14. Novaes AB, Jr., Novaes AB. Bone formation over a TiAl6V4 (IMZ) implant placed into 
an extraction socket in association with membrane therapy (Gengiflex). Clin Oral Implants Res 
1993 Jun;4(2):106-110. 
Chapter 3 
 
  108 
15. Novaes AB, Jr., Novaes AB. Soft tissue management for primary closure in guided 
bone regeneration: surgical technique and case report. Int J Oral Maxillofac Implants 1997 
Jan-Feb;12(1):84-87. 
16. Salata LA, Craig GT, Brook IM. In-Vivo Evaluation of a New Membrane (Gengiflex(R)) 
for Guided Bone Regeneration (Gbr). Journal of Dental Research 1995;74(3):825-825. 
17. Sonohara MK, Greghi SLA. Avaliação da resposta biológica a diferentes barreiras 
mecânicas, utilizadas na técnica de regeneração tecidual guiada (RTG). . Revista da Faculdade 
de Odontologia de Bauru 1994;2(4):96-102. 
18. Klemm D, Schumann D, Udhardt U, Marsch S. Bacterial synthesized cellulose - 
artificial blood vessels for microsurgery. Progress in Polymer Science 2001 Nov;26(9):1561-
1603. 
19. Brancher JA, Torres MF. Reparação microcirúrgica de nervo facial de ratos Wistar por 
meio de sutura - Parte II. Revista Sul-Brasileira de Odontologia 2005;2(2):34-38. 
20. Backdahl H, Helenius G, Bodin A, Nannmark U, Johansson BR, Risberg B, et al. 
Mechanical properties of bacterial cellulose and interactions with smooth muscle cells. 
Biomaterials 2006 Mar;27(9):2141-2149. 
21. Backdahl H, Esguerra M, Delbro D, Risberg B, Gatenholm P. Engineering 
microporosity in bacterial cellulose scaffolds. J Tissue Eng Regen Med 2008 Aug;2(6):320-
330. 
22. Negrão SW, Bueno RRL, Guérios EE, Ultramari FT, Faidiga AM, de Andrade PMP, et al. 
A eficácia do stent recoberto com celulose biosintética comparado ao stent convencional em 
angioplastia em coelhos. Revista Brasileira de Cardiologia Invasiva 2006;14(1):10-19. 
23. Wippermann J, Schumann D, Klemm D, Kosmehl H, Salehi-Gelani S, Wahlers T. 
Preliminary results of small arterial substitute performed with a new cylindrical biomaterial 
composed of bacterial cellulose. Eur J Vasc Endovasc Surg 2009 May;37(5):592-596. 
24. Helenius G, Backdahl H, Bodin A, Nannmark U, Gatenholm P, Risberg B. In vivo 
biocompatibility of bacterial cellulose. J Biomed Mater Res A 2006 Feb;76(2):431-438. 
25. Palecek SP, Loftus JC, Ginsberg MH, Lauffenburger DA, Horwitz AF. Integrin-ligand 
binding properties govern cell migration speed through cell-substratum adhesiveness. Nature 
1997 Feb 6;385(6616):537-540. 
26. Salacinski HJ, Tiwari A, Hamilton G, Seifalian AM. Cellular engineering of vascular 
bypass grafts: role of chemical coatings for enhancing endothelial cell attachment. Med Biol 
Eng Comput 2001 Nov;39(6):609-618. 
27. Hoenig MR, Campbell GR, Campbell JH. Vascular grafts and the endothelium. 
Endothelium 2006 Nov-Dec;13(6):385-401. 
28. Kouvroukoglou S, Dee KC, Bizios R, McIntire LV, Zygourakis K. Endothelial cell 
migration on surfaces modified with immobilized adhesive peptides. Biomaterials 2000 
Sep;21(17):1725-1733. 
Chapter 3 
 
  109 
29. Andrade FK, Moreira SM, Domingues L, Gama FM. Improving the affinity of fibroblasts 
for bacterial cellulose using carbohydrate-binding modules fused to RGD. J Biomed Mater Res 
A 2010 Jan;92A(1):9-17. 
30. Costa R, Carneiro A, A. R, Piarraco A, Falcão M, Vasques L, et al. Bevacizumab and 
ranibizumab on microvascular endothelial cells. A comparative study. J Cell Biochem in press. 
31. Jaffe EA, Hoyer LW, Nachman RL. Synthesis of von Willebrand factor by cultured 
human endothelial cells. Proc Natl Acad Sci U S A 1974 May;71(5):1906-1909. 
32. Monteiro R, Calhau C, Silva AO, Pinheiro-Silva S, Guerreiro S, Gartner F, et al. 
Xanthohumol inhibits inflammatory factor production and angiogenesis in breast cancer 
xenografts. J Cell Biochem 2008 Aug 1;104(5):1699-1707. 
33. Jahroudi N, Lynch DC. Endothelial-cell-specific regulation of von Willebrand factor gene 
expression. Mol Cell Biol 1994 Feb;14(2):999-1008. 
34. Joshi P, Chung CY, Aukhil I, Erickson HP. Endothelial cells adhere to the RGD domain 
and the fibrinogen-like terminal knob of tenascin. J Cell Sci 1993 Sep;106 ( Pt 1):389-400. 
35. Watanabe K, Eto Y, Takano S, Nakamori S, Shibai H, Yamanaka S. A new bacterial 
cellulose substrate for mammalian cell culture. A new bacterial cellulose substrate. 
Cytotechnology 1993;13(2):107-114. 
36. Bodin A, Ahrenstedt L, Fink H, Brumer H, Risberg B, Gatenholm P. Modification of 
nanocellulose with a xyloglucan-RGD conjugate enhances adhesion and proliferation of 
endothelial cells: implications for tissue engineering. Biomacromolecules 2007 
Dec;8(12):3697-3704. 
37. Svensson A, Nicklasson E, Harrah T, Panilaitis B, Kaplan DL, Brittberg M, et al. 
Bacterial cellulose as a potential scaffold for tissue engineering of cartilage. Biomaterials 2005 
Feb;26(4):419-431. 
38. Sanchavanakit N, Sangrungraungroj W, Kaomongkolgit R, Banaprasert T, Pavasant P, 
Phisalaphong M. Growth of human keratinocytes and fibroblasts on bacterial cellulose film. 
Biotechnol Prog 2006 Jul-Aug;22(4):1194-1199. 
39. Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nat Rev Cancer 
2002 Feb;2(2):91-100. 
40. DiMilla PA, Barbee K, Lauffenburger DA. Mathematical model for the effects of 
adhesion and mechanics on cell migration speed. Biophys J 1991 Jul;60(1):15-37. 
41. DiMilla PA, Stone JA, Quinn JA, Albelda SM, Lauffenburger DA. Maximal migration of 
human smooth muscle cells on fibronectin and type IV collagen occurs at an intermediate 
attachment strength. J Cell Biol 1993 Aug;122(3):729-737. 
42. Lauffenburger DA, Horwitz AF. Cell migration: a physically integrated molecular 
process. Cell 1996 Feb 9;84(3):359-369. 
43. Maheshwari G, Brown G, Lauffenburger DA, Wells A, Griffith LG. Cell adhesion and 
motility depend on nanoscale RGD clustering. J Cell Sci 2000 May;113 ( Pt 10):1677-1686. 
Chapter 3 
 
  110 
44. Maheshwari G, Wells A, Griffith LG, Lauffenburger DA. Biophysical integration of effects 
of epidermal growth factor and fibronectin on fibroblast migration. Biophys J 1999 
May;76(5):2814-2823. 
45. Wacker BK, Alford SK, Scott EA, Das Thakur M, Longmore GD, Elbert DL. Endothelial 
cell migration on RGD-peptide-containing PEG hydrogels in the presence of sphingosine 1-
phosphate. Biophys J 2008 Jan 1;94(1):273-285. 
46. Cox EA, Huttenlocher A. Regulation of integrin-mediated adhesion during cell 
migration. Microsc Res Tech 1998 Dec 1;43(5):412-419. 
47. Heilshorn SC, Liu JC, Tirrell DA. Cell-binding domain context affects cell behavior on 
engineered proteins. Biomacromolecules 2005 Jan-Feb;6(1):318-323. 
48. Kurihara H, Nagamune T. Cell adhesion ability of artificial extracellular matrix proteins 
containing a long repetitive Arg-Gly-Asp sequence. J Biosci Bioeng 2005 Jul;100(1):82-87. 
49. Cavalcanti-Adam EA, Volberg T, Micoulet A, Kessler H, Geiger B, Spatz JP. Cell 
spreading and focal adhesion dynamics are regulated by spacing of integrin ligands. Biophys J 
2007 Apr 15;92(8):2964-2974. 
50. Singer, II, Kazazis DM, Scott S. Scanning electron microscopy of focal contacts on the 
substratum attachment surface of fibroblasts adherent to fibronectin. J Cell Sci 1989 May;93 ( 
Pt 1):147-154. 
51. Bischoff J. Cell Adhesion and Angiogenesis.  Cell adhesion in vascular Biology: J. Clin. 
Invest., February 1997. p. 373-376. 
52. Xu Y, Swerlick RA, Sepp N, Bosse D, Ades EW, Lawley TJ. Characterization of 
expression and modulation of cell adhesion molecules on an immortalized human dermal 
microvascular endothelial cell line (HMEC-1). J Invest Dermatol 1994 Jun;102(6):833-837. 
53. Eliceiri BP, Cheresh DA. The role of alphav integrins during angiogenesis: insights into 
potential mechanisms of action and clinical development. J Clin Invest 1999 
May;103(9):1227-1230. 
 
 
Chapter 4 
 
  111 
Chapter 4 
 
 
Studies on the hemocompatibility of bacterial 
cellulose 
  
  
Abstract 
Vascular grafts must gather a complex and vast number of attributes, namely good mechanical 
properties and an appropriate post implantation healing response. Among the strategies 
developed over the years to modify materials for vascular devices, pre-coating with the 
tripeptide Arg-Gly-Asp (RGD) improves endothelialization thus lowering thrombogenicity. In the 
present work, the blood compatibility of native and RGD-modified bacterial cellulose (BC) was 
studied. Although this is a rather promising material for vascular replacements, to our 
knowledge only very recently a first publication was dedicated to this subject.  
The clotting times (aPTT, PT, FT and PRT) and whole blood clotting results results demonstrate 
the good hemocompatibility of BC. A significant amount of plasma protein adsorbed to BC 
fibres, albumin presenting a higher BC affinity than γ-globulin or fibrinogen. According to 
analysis carried out by intrinsic tryptophan fluorescence, the BC adsorbed albumin, fibrinogen 
and γ-globulin do not undergo major conformational modifications. Although the presence of 
the adhesion peptide on bare-BC surface increases the platelet adhesion, when the material 
was cultured with human microvascular endothelial cells a confluent cell layer was readily 
formed, inhibiting the adhesion of platelets. As a general conclusion, both native and RGD-
modified BCs may be classified as hemocompatible materials, since they showed to be non-
hemolytic and the whole blood coagulation studies shows that the results are comparable to 
those produced by currently available materials for blood replacements. 
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Introduction 
Biocompatibility refers to the ability of a biomaterial to perform with an appropriate host 
response in a specific situation [1]. It is well known that blood-contacting surfaces may activate 
the coagulation and complement systems, as well as trigger cellular responses [2, 3]. Thus, 
blood-contacting biomaterials and artificial organs, such as artificial blood vessels, pumps and 
artificial hearts, require improved blood compatibility for clinical uses. In addition, vascular 
grafts must bear both good mechanical attributes and post implantation healing responses. 
However, vascular substitutes currently available (e.g. Polyurethane, Dacron and ePTFE) still 
do not fully achieve these ideals, trombogenicity hampering their use as small-diameter (<6 
mm) arterial substitutes. Vascular graft failure is mainly caused by 
thrombosis/thromboembolism, infections, intimal fibrous hyperplasia and poor mechanical 
performance [4]. These problems arise from the fact that, after half a century of research and 
implant of cardiovascular devices, no material has been found to be truly blood-compatible [5]. 
While developing materials for blood-contacting devices, researchers have primarily focused 
their attention on hydrophobic polymers, such as Teflon, silicones and polyethylene, which 
have good mechanical properties and optimal surface lubricity for applications as catheters 
and shunts [6]. However, these materials have strong affinity for proteins, like fibrinogen, that 
adsorb on the surface, forming a monolayer that promotes platelets adhesion. These events 
are associated with coagulation factors activation and thrombus formation [7, 8]. Also, highly 
hydrophobic materials generally retard wound healing due to very slow tissue ingrowth [9]. 
Bacterial Cellulose (BC) is a highly hydrophilic material and according to several research 
groups a promising arterial substitute [10-14]. This biomaterial, produced by Acetobacter 
microorganisms, is a glucose polymer with unique properties, including high water holding 
capacity, high crystallinity, ultrafine fiber network, and high tensile strength [13]. Several 
authors addressed the potential use of BC as scaffold, for tissue engineering applications, 
given its harmless interaction with mammalian cells [15-18], and in vivo good integration with 
host tissues, showing no signs of chronic inflammatory or foreign body reactions [19]. 
The biomedical devices conceived to perform in contact with blood are often surface modified 
using active substances like heparin, to reduce thrombogenicity. However, the limited success 
of surface treatments for improved blood compatibility has encouraged researchers to pursue 
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other strategies. Instead of designing materials that avoid indiscriminately the problematic 
interaction with blood proteins and platelets, the incorporation of molecules that can stimulate 
the adhesion and colonization of endothelial cell (EC) has been investigated [20]. It is known 
that ECs covering the lumen of vessels actively inhibit thrombosis and intimal hyperplasia, also 
serving as anticoagulant surface [21, 22]. Therefore, the formation of an EC layer on the 
luminal surface of prosthetic grafts is highly desirable. The endothelialization of the graft may 
either be developed ex vivo, or post-implantation, stimulating the ECs (from tissues adjacent to 
anastomosis or from circulation) to adhere and proliferate on the graft. The rate and quality of 
a vascular graft endothelialization depends, of course, on the cell-material interaction. Several 
approaches have been used, attempting to increase the EC adhesion on typically non-adhesive 
polymeric biomaterials used for synthetic vascular grafts [23]. One such approach, that 
involves pre-coating the material with the tripeptide Arg-Gly-Asp (RGD), an amino acid 
sequence found in many adhesive plasma and extracellular matrix proteins, has been used to 
enhance cell adherence. Binding of cells to the RGD-sequence occurs via integrin receptors on 
the cell membranes. In a previous work, we described the production of recombinant proteins 
containing the adhesion sequences fused to a CBM (cellulose-binding module) [18] (chapter 
2). For artificial grafts based on cellulose, the use of a CBM (a protein exhibiting specific high 
affinity for cellulose surfaces) may be a facile and smart strategy to avoid loosing the biological 
agents coating the graft when the blood flow is restored, after implantation. In the same lines, 
we have also shown [24] that the presence of RGD sequences significantly increases the 
adhesion of human microvascular cells (HMECs) on BC (chapter 3). Thus, RGD sequence 
could be used to improve the endothelialization of vascular substitutes based on bacterial 
cellulose. However, although envisaging the graft coverage with ECs, the blood compatibility of 
both the bare native and RGD-modified bacterial cellulose must be also characterized. 
To our knowledge, only one study conducted by Fink et al. [25] evaluated the thrombogenic 
properties of vascular graft tubes based on BC and compared with commercial vascular grafts 
of poly(ethylene terephtalate) (PET) and expanded poly(tetrafluoroethylene) (ePTFE). The 
results showed that the BC material did not induce plasma coagulation to any great extent and 
in comparison with PET and ePTFE, the BC material performed very well and was found to 
induce the least and slowest activation of the coagulation cascade. Further characterization is 
necessary, not only to confirm the promising hemocompatibility of BC, but also to better 
understand the BC-blood interaction, through more comprehensive characterization. 
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Materials and Methods 
Production of bacterial cellulose 
Gluconacetobacter xylinus (ATCC 53582) purchased from the American Type Culture 
Collection was grown in Hestrin-Schramm medium, pH 5.0. The medium was inoculated with 
the culture, added to the 24-well polystyrene plate (1 ml per well) and incubated statically at 
30 oC, for 5 days. BC pellicles were purified by 2% sodium dodecyl sulfate (SDS) treatment at 
60 oC, for 12 h, followed by 4% NaOH at 60 oC, for 90 min. Samples were autoclaved and 
stored in phosphate buffered solution (PBS) pH 7.4, at 4ºC, prior to use. The pellicle produced 
in a 24-well polystyrene plate presented a diameter of 15.5mm. 
 
Production and purification of recombinant proteins 
The recombinant proteins RGD – CBM and CBM have been formerly cloned in Escherichia coli 
and its production and purification was conducted as described in our previous work [18] 
(chapter 2). 
 
Surface modification with CBM and RGD-CBM proteins 
The surface modification of BC was developed as previously described [18] (chapter 2). The 
purified recombinant proteins were added to the wells of 24-well polystyrene plates (0.25mg of 
protein/per well), coated with bacterial cellulose sheets produced in similar 24-well polystyrene 
plates. The plates were incubated overnight at 4 ºC. Unbound protein was removed and the BC 
pellicles were washed with PBS and used in the in vitro blood compatibility assays. 
 
Preparation of blood samples 
Whole blood was collected from healthy donors with vacuum blood-collection tubes of 1.8ml, 
containing sodium citrate buffer solution 3.2% (0,109 mol/l). The citrated whole blood was 
immediately centrifuged for 15 min (300g, 4 ºC) and the citrated platelet-rich plasma (PRP) 
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was collected. Citrated platelet poor plasma (PPP) was also prepared from the whole blood, by 
centrifugation for 15 min at 2000g, 4 ºC. 
 
Determination of the amount of adsorbed plasma proteins 
Plasma protein adsorption on the membrane surface was evaluated as follows. Disk-shaped 
BC pellicles (1.88 cm2, ∼ 2.4mg), previously incubated with the recombinant proteins (RGD-
CBM and CBM) or buffer, were immersed in PPP (0.5ml per pellicle) diluted (1:2) with a 
phosphate-buffered solution (PBS, pH 7.4), at 37 ºC for 3 hours. Expanded tetrafluoroethylene 
(MAXIFLOTM ePTFE Vascular Prosthesis, Vascutek Ltda, Scotland) samples  (1.4 cm2, ∼ 114 
mg) were used as a control. The unbound fraction (supernatant) of plasma proteins was then 
collected. The total protein in the PPP and supernatants were quantified using the micro-BCA 
method (Pierce); the protein concentration was calibrated with bovine serum albumin solution 
(Applichem Biochemica, Darmstadt, Germany).  
 
Albumin, fibrinogen and Human γ- globulin adsorption on BC 
Disk-shaped BC pellicles – untreated or previously treated with the recombinant proteins and 
also the control materials (ePTFE – 1.4 cm2  and polystyrene plate – 1.88 cm2) – were 
immersed in phosphate buffered solution (PBS, 0.02M, pH 7.4) of (1) 5mg/ml human serum 
albumin (HSA), (2) 1mg/ml Human γ-globulin (IG) or (3) 0.3mg/ml human fibrinogen (HFG), 
for 120 min at 37oC [26, 27]. The concentrations of the tested proteins were chosen to reflect 
a 10-fold dilution of their levels in blood.  
In another study, to evaluate the affinity of HSA, HFG and IG for bacterial cellulose, adsorption 
isotherms of these proteins on BC were developed as follows: untreated BC membranes were 
immersed (0.5ml) in two-fold dilution series of protein solutions (with concentrations ranging 
from 10mg/ml to 0.078125 mg/ml) and shaken for 60 min, 37oC. After the removal of the 
supernatant and rinsing the membranes five times with PBS, 0.5ml of 1wt% aqueous solution 
of SDS was added; the samples were then shaken for 60min at room temperature, to remove 
the proteins adsorbed on the membranes. Both the concentration in the supernatant and the 
desorbed protein recovered after washing were quantified using the micro-BCA method 
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(Pierce). The protein concentration was calibrated with bovine serum albumin solution 
(Applichem Biochemica, Darmstadt, Germany). The amount of adsorbed protein on the BC 
membrane was calculated through the difference between the initial protein and the protein 
from supernatant. 
 
Determination of conformational changes of adsorbed proteins 
Intrinsic tryptophan fluorescence was used to evaluate the conformational changes of albumin, 
fibrinogen and γ-globulin adsorbed on bacterial cellulose. BC pellicles were immersed in 
phosphate buffered solution (PBS, 0.02M, pH 7.4) of (1) 1mg/ml human serum albumin 
(HSA), (2) 1mg/ml Human γ-globulin (IG) or 1mg/ml human fibrinogen (HFG), for 60 min at 
37oC, then the pellicles were washed five times with PBS to removed unbound proteins. 
Fluorescence measurements were performed using a Fluorolog 3 spectrofluorimeter®, 
equipped with double monochromators in both excitation and emission. Fluorescence spectra 
were corrected for the instrumental response of the system. Emission spectra were measured 
by exciting the sample at 295 nm or 270 nm and collecting the emitted fluorescence from 305 
to 400 nm. Protein solutions of HSA, IG and HFG were used as controls. 
 
Coagulation Times 
BC membranes, treated either with the recombinant protein (RGD-CBM) or buffer, were 
incubated with 0.5ml of PPP, at 37 ºC for 1h. The activated Partial Thromboplastin Time 
(aPTT), Prothrombin Time (PT) and Fibrinogen Time (FT) of the PPP were determined, as 
described below, using an automated coagulation analyser (STA-R Evolution®, Diagnostica 
STAGO, France). The polystyrene plate, ePTFE, glass coverslips and glass microspheres (with 
0.10mm of diameter) were used as controls. The coagulation times of PPP non-contacted with 
the materials were also analysed, as a control. The comparison of coagulation times (aPTT, PT 
and FT) of endothelialized polymers were also tested. For the description of the methods used 
in cell culture, please see item “Platelet adhesion to BC covered with human microvascular 
endothelial cells” from materials and methods. 
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Activated partial thromboplastin time: The aPTT is a simple and highly reliable measurement of 
the capacity of blood to coagulate through the intrinsic coagulation pathway and the effect of 
the biomaterial on possible delay of the process. After contacting the materials, 50µl of the 
PPP was removed and then activated by addition of 50µl of Pathromtin SL® (Siemens 
Healthcare Diagnostics, Marburg, Germany). This reagent contains silicon dioxide particles, 
plant phospholipids, sodium chloride and Hepes, pH 7.6. Then, immediately after adding 
calcium chloride 0.025M (50µl, 37oC), the time for initiation of clot formation was measured 
by using an automated coagulation analyser (STA-R Evolution®, Diagnostica STAGO, France). 
Prothrombin time: Prothrombin time was measured to assess BC-induced deferment, 
interdiction or activation of the extrinsic coagulation pathway. After contact with the materials, 
50µl of the PPP was removed and then 100µl of Thromborel® S (Siemens Healthcare 
Diagnostics, Marburg, Germany) – a reagent containing human placental thromboplastin with 
calcium chloride – was added. Immediately, the time for initiation of clot formation was 
detected by using an automated coagulation analyser (STA-R Evolution®, Diagnostica STAGO, 
France). 
Fibrinogen time: In the presence of excess thrombin, the coagulation time of a plasma sample 
is inversely proportional to the fibrinogen concentration. Thus, to assess the effect of BC 
interaction with the fibrinogen plasma, FT was developed. After contact with the materials, 
100µl of the PPP was removed and then human thrombin (STA Fibrinogen, Diagnostica 
Stago/Roche Diagnostics, Mannhein, Germany) was added. Immediately afterwards the time 
for initiation of clot formation was detected by using an automated coagulation analyser (STA-R 
Evolution®, Diagnostica STAGO, France). 
 
Measurement of plasma recalcification profiles 
The measurement of plasma recalcification time was analyzed through the adapted method 
described by Motlagh et al. [28]. Blood was drawn from healthy adult volunteers into citrated 
tubes (as described above) and centrifuged at 2000g in order to obtain the PPP. BC samples 
were incubated with 0.5ml of PPP, at 37 ºC for 1h. Then 100µl of citrated PPP were 
transferred to the wells of a 96-well plate. Controls consisted of polystyrene plate (exposed to 
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PPP with and without CaCl2), ePTFE and glass microspheres. Following the addition of PPP, 
100ml of 0.025M CaCl2 was added to each well (except the negative control with no Ca+2). The 
plate was then immediately placed in a 96-well plate reader, where the kinetics of the clotting 
process due to recalicification were monitored by measuring the absorbance at 405nm (every 
30 s for 30 min) at 37 ºC. In calculating the mean absorbance at each time point, tested 
samples treated with PPP from 5 different donors were averaged per sample. The clotting time 
to reach half maximal absorbance was calculated and analyzed. 
 
Quantification of whole blood clotting time 
The thrombogenicity of BC was evaluated using a whole blood kinetic clotting time method, as 
previously described [28].  Samples of the tested materials were used per time point. Briefly, 
the clotting reaction was activated with the addition of 850 µl CaCl2 (0.1M) to the 8.5 ml 
sample of citrated blood. A 100µl volume of the activated blood was carefully added to BC 
lyophilized samples, which were placed in the wells of a 12-well plate. Glass microspheres, 
ePTFE and polystyrene were used as controls. All samples were incubated at room 
temperature for 0, 5, 15, 25 and 35. At the end of each time point, the samples were 
incubated with 2.5ml of distilled water for 5 min. Each well was sampled in triplicate (200 ml 
each) and transferred to a 96-well plate. The red blood cells that were not trapped in a 
thrombus were lysed with the addition of distilled water, thereby releasing hemoglobin into the 
water for subsequent measurement. The concentration of hemoglobin in solution was 
assessed by measuring the absorbance at 540nm using a 96 well plate reader. The size of the 
clot is inversely proportional to the absorbance value. 
 
Evaluation of Platelet Adhesion 
Bare-BC membranes, treated with the recombinant proteins or buffer, were placed in contact 
with 0.5ml of human PRP and incubated for 2h. Then, the supernatant was removed and the 
BC pellicles washed twice with PBS. Next, 0.7ml of 2.5% glutaraldehyde in PBS was poured 
into each well, and the materials were maintained at room temperature for 1h, in order to fix 
the blood components on the membrane. Afterwards, the membranes were rinsed with 
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distilled water, and finally dehydrated by successive immersion in a series of ethanol-water 
solutions (55, 70, 80, 90, 95, 100% v/v), for 30 min each, and allowed to evaporate at room 
temperature. The surface of the membranes with adsorbed platelets was observed with 
scanning electron microscopy (LEICA S 360), after gold-sputtering treatment. 
In a parallel assay, the number of platelets adhered on the bare-BC membranes was 
determined by the lactic acid dehydrogenase (LDH) activity method [29]. The PRP (0.4 ml) was 
placed in contact with BC membranes, in the 24-wells, and allowed to stand for 90 min at 37 
ºC. The samples were washed twice. In order to release the intracellular LDH, adhered 
platelets were lysed with 0.3ml of Triton X-100 (0.1%) for 45min, at 37 ºC. Then, the 
supernatant was used to determine the LDH activity as follows: The supernatant (0.050ml) 
was added to a tube containing 1.5 ml of solution I (50mM phosphate, 0.63 mM piruvate 
(Sigma), pH 7.5) and 0.025ml of solution II (11.3mM β-NADH (Sigma), 119 mM sodium 
bicarbonate), and homogenised. Recording of the enzymatic reaction kinetics started promptly, 
reading the absorbance at 340nm (Jasco V-550) for 120s, at 25 ºC. The initial reaction rate 
was determined as the slope of the graph obtained plotting the optical density vs reaction time, 
at time zero. The LDH calibration curve was obtained by measuring the enzymatic activity of a 
set of samples with a known concentration of platelets, under the same conditions as above. 
The ePTFE was used as a reference material. 
 
Platelet adhesion to BC covered with human microvascular endothelial cells 
Cell culture: Human Microvascular Endothelial Cells (HMECs) were cultured in RPMI 1640 
medium (Invitrogen Life Technologies, UK) supplemented with 10% FBS (Invitrogen Life 
Technologies, UK), 1% penicillin/streptomycin (Invitrogen Life technologies, UK), 1.176 g/L of 
sodium bicarbonate, 4.76 g/L of Hepes, 1mL/L of EGF and 1 mg/L of hydrocortisone > 98% 
(Sigma, Portugal), and maintained at 37 ºC in a humidified 5% CO2 atmosphere. 
As previously described [24] (chapter 3), the HMEC-1 cells were seeded on the BC and ePTFE 
(control) at a density of 12 x 104 cells/well, in RPMI medium without serum. The plates were 
incubated at 37 oC, in atmosphere of 5% CO2 and 95% humidified air. Two hours after the 
addition of the cells, the wells were washed with PBS and RPMI with 10% Foetal Bovine Serum 
(FBS) was added. The cells were allowed to grow on BC for 14 days. 
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Platelet adhesion: 0.5ml of human PRP was loaded on the HMECs proliferated on BC and 
ePTFE, and incubated for 2h at 37 ºC in a humidified 5% CO2 atmosphere. Then, the 
supernatant was removed and the BC pellicles washed twice with PBS. Next, 0.7ml of 2.5% 
glutaraldehyde in PBS was poured into each well, and the materials were maintained at room 
temperature for 1h, in order to fix the blood components on the membrane. Afterwards, the 
membranes were rinsed with distilled water, and finally dehydrated at 30 ºC. The surface of 
the membranes with adsorbed platelets was observed with scanning electron microscopy 
(Nova NanoSEM 200, The Netherlands), after gold-sputtering treatment. By counting the 
number of adhered platelets on the sample surfaces, the platelet adhesion densities were 
determined for each kind of sample. On each sample, five different areas (19x103 µm2) were 
selected [30]. The bare polymers (BC and ePTFE) that were incubated with RPMI with 10% 
Foetal Bovine Serum for 14 days were used as controls. 
 
Hemolysis 
Hemolysis studies were conducted according to the procedures described in American Society 
for Testing and Materials (ASTM F756-00, 2000). BC samples with 1.88 cm2 were equilibrated 
in PBS (Ca and Mg free), and then transferred to a tube containing 7 ml of PBS (Ca and Mg 
free). Then, 1 ml of diluted blood (hemoglobin concentration of 10mg/ml) was added. The 
material was maintained in contact with the blood for 3h, at 37 ºC, in a water bath. The tubes 
were gently inverted twice every 30 min to promote the BC-blood contact. Afterwards, the 
membranes were removed and the diluted blood centrifuged at 750g, 15 min. The hemoglobin 
was determined adding 1 ml of the supernatant to 1 ml of Drabkin´s reagent (Sigma); after 15 
min, the absorbance at a wavelength of 540nm was read (Jasco V-550). The hemoglobin 
concentration (HC) was determined using a calibration curve prepared with human hemoglobin 
(Sigma) and was calculated by the equation: HC = AxFxd (A, Absorbance; F, Slope of the 
hemoglobin curve; d, dilution). The hemolytic index (HI) was obtained by the equation 
HI = 100 × (concentration of hemoglobin released in supernatant) / (total hemoglobin 
concentration in tube). As reference materials, ePTFE and PBS (negative control) and ultra 
pure water (positive control) were used. 
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Results and Discussion 
Protein adsorption 
It is well known that protein adsorption and denaturation are responsible for triggering 
hemostasis and specifically the contact pathway, upon blood-biomaterial contact. While 
albumin is considered non-thrombogenic, other plasma proteins are. Hence, in this section, 
the BC affinity and surface denaturation of the three more abundant plasma proteins was 
analysed. The total plasma protein adsorption was measured after incubation of the BC 
pellicles in diluted plasma for 3 hours. The results obtained showed that the amount of protein 
adsorbed on BC surface is not influenced by the treatment with recombinant proteins (CBM or 
RGD-CBM) and also that BC membranes adsorbed approximately 1.7 – 1.8 mg of protein per 
mg of BC, while only 0.01 mg of protein adsorbed per mg of ePTFE, the reference material 
(FIGURE 1a). It is well known that the protein adsorption is significantly influenced by surface 
characteristics, such as hydrophilicity, topography, charge, or chemistry [8]. The gelatinous BC 
membrane formed in static culture is characterized by a 3D ultrafine fibrous network structure, 
containing about 99% water [13]; it is, thus, a highly hydrophilic material. Proteins adsorb 
preferentially on hydrophobic than hydrophilic surfaces, once more energy is necessary to 
remove the water molecules from hydrophilic than from hydrophobic surfaces. The adhesion 
forces on hydrophobic substrates have been shown to be dependent on the structural rigidity 
of the protein, while on the hydrophilic substrates both the protein and surface charge are 
more important [31]. Therefore, it has been reported that polymers with a hydrophilic surface 
adsorb low amounts of serum proteins, having low thrombogenic potential [8, 32]; however, 
the large surface area of the nanofibrous network of BC allows the binding of a large quantity 
of protein. However, the amount of plasma protein adsorbed on a surface is by itself not 
enough to draw conclusions regarding the blood compatibility, its identity and conformation 
(which may change over time following adsorption) being also important [33]. When a material 
comes in contact with blood, immediately proteins adsorbs to the material surface. These 
initially adsorbed proteins may be displaced by a series of others, all within a few minutes. At 
least two or three of these proteins, namely fibrinogen, fibronectin and immunoglobulins, plays 
an important role when adsorbed, since platelets or leukocytes will adhere to these proteins 
through specific receptors [34]. 
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Figure 1: Plasma protein adsorption onto the bacterial cellulose membrane untreated or treated 
with the recombinant proteins (RGD-CBM or CBM) and controls (ePTFE and polystyrene). (a) 
Platelet-poor plasma; (b) human serum albumin; (c) human γ-globulin and (d) human fibrinogen. 
 
Platelets adhesion follows, mediated by the proteins initially adsorbed on the surface. 
Therefore, in the present work, the BC affinity for plasma proteins human albumin, fibrinogen 
and immunoglobulin, corresponding respectively to 60, 4% and 20% of the total plasma protein 
was analysed, attempting to better understand the nature of the platelet adhesion on BC 
surfaces, since it is known that plasma protein adsorption is a key phenomenon in determining 
the thrombogenicity of the materials. In a first experiment BC membranes were immersed in 
pure solutions of HSA, HFG or IG - the concentrations of the tested proteins were chosen to 
reflect a 10-fold dilution of their levels in blood. The results obtained show that the presence of 
recombinant proteins (CBM and RGD-CBM) decreased the adsorption of fibrinogen on BC, an 
effect not observed in the case of albumin and immunoglobulin (FIGURE 1b-d). We believe that 
the recombinant proteins on the BC surface interfere more significantly in the case of 
fibrinogen because its concentration (0.3mg/ml) was lower than that of albumin (5mg/ml) and 
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γ-globulin (1mg/ml). The lower concentration explains also why a different amount of adsorbed 
protein is not observed when using the PPP (FIGURE 1a). 
The adsorption isotherms (FIGURE 2) shows that, for the same concentration, the amount of 
adsorbed HSA, HFG and IG on BC-untreated are similar; however, when the membranes were 
treated with 1wt% aqueous solution of SDS, a higher amount of fibrinogen desorbed from the 
BC than albumin or immunoglobulin was observed (FIGURE 3). This result showed that the BC 
affinity of the tested proteins follows the order albumin > γ-globulin > fibrinogen. These are 
interestingly results since, fibrinogen, fibronectin and γ-globulin pre-coating, even at low levels, 
causes an increase of platelet adhesion. The opposite effect has been described for surfaces 
coated with albumin [34, 35]. 
 
Determination of conformational changes of adsorbed proteins 
Conformational changes always occur, following unfolding, to different extent depending on the 
protein, exposing previously hidden amino acid sequences. This remodeling of the protein 
surface can trigger the activation of processes such as the blood coagulation cascade. 
The intrinsic fluorescence of tryptophan, tyrosine and to a lesser extent phenylalanine is a 
sensitive probe of conformational changes because the intensity and Stockes’ shift of the 
fluorescence depends on local environment of the fluorophore [36]. The unfolding of human 
serum proteins albumin, fibrinogen and γ - globulin were studied by measuring the intrinsic 
fluorescence intensity at a wavelength of excitation corresponding to tryptophan’s or tyrosine’s 
fluorescence. For an excitation of 295 nm tryptophan is the only aromatic amino acid to 
absorb light. For an excitation of 274 nm there is a transfer of energy from the excited tyrosine 
to tryptophan, which also corresponds to a single emission peak [37, 38]. 
Figure 4 shows the fluorescence spectra at excitation wavelengths of 295 and 270 nm. 
Irrespective of the protein analyzed or the excitation wavelength used, the proteins adsorbed 
on BC exhibit no conformational changes, taking as reference the protein in solution. These 
results are a promising prospect regarding BC as vascular implants. Once proteins cover the 
surface of implants, host cells no longer contact the underlying foreign-body material but only 
the protein-coated surface.  
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Figure 2: Comparison of the adsorption isotherms for the binding human serum albumin (HSA), 
human fibrinogen (HFG) and human γ-globulin (IG) on BC. 
 
 
Figure 3: Percentage of desorbed proteins on BC at each concentration tested after treatment 
with 1wt% aqueous solution of SDS. Human serum albumin (HSA), human fibrinogen (HFG) and 
human γ-globulin (IG). 
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Figure 4: Steady-state fluorescence emission spectra of (a, b) human serum albumin, (c, d) human 
fibrinogen and (e, f) human γ-globulin adsorbed on BC and in solution. (a, c, e) and (b, d, f)  
excitation wavelength of 295 nm and 270, respectively, collected from 305 to 400 nm. 
 
The adsorbed protein layers rather than the foreign material itself may stimulate or inhibit 
further biochemical processes. Platelet adhesion and activation is strongly influenced not only 
by the adhesion but especially by the conformation change, namely of the adsorbed fibrinogen. 
The dissolved, native fibrinogen, does not bind to the adhesion receptors of platelets unless 
these are appropriately stimulated. When the fibrinogen adsorbed to a surface and a 
conformational change occur some amino acids previously hidden inside the molecule 
becomes exposed and able to interact with the platelet receptors [31, 36, 39, 40]. Also, it is 
well known that platelet adhesion and spreading do not occur on an albumin-coated surface, 
and that with increasing degree of albumin denaturation, platelet adhesion and activation are 
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enhanced [40]. Although a highly hydrophilic material, BC adsorbs a large amount of plasma 
protein due to the large surface area; however, these proteins remain their native conformation 
once adsorbed, hence are not expected to become a factor of adhesion and activation of 
platelets. 
 
Blood coagulation 
The coagulation cascade consists of three pathways: contact activation (intrinsic), tissue factor 
(extrinsic), and the final common pathway of factor X, thrombin and fibrin. Although they are 
initiated by distinct mechanisms, the two converge on a common pathway that leads to clot 
formation. The formation of a thrombus or a clot in response to an abnormal vessel wall in the 
absence of tissue injury is the result of the intrinsic pathway. Fibrin clot formation in response 
to tissue injury is the result of the extrinsic pathway [41]. When biomaterials are in contact with 
blood, plasma proteins are instantaneously adsorbed onto the surface and coagulation factors 
or platelets will then be activated, starting a series of cascade reactions and leading to blood 
coagulation [42]. Interference with the coagulation cascade can be indicated by alterations of a 
series of plasma coagulation assays: aPTT, PT and FT. APTT and PT are used to examine 
mainly the intrinsic and extrinsic pathway, respectively. FT measures how much fibrinogen 
converts into fibrin clot, by action of thrombin [43]. The results showed that the BC polymer, 
irrespective of the presence of RGD peptide covering the surface, presented similar plasma 
clotting times (FT, aPTT and PT) comparable to the ones obtained for the negative controls 
(plasma incubated in the absence of tested materials or with polystyrene) (FIGURE 5). In fact, 
none of the tested materials were able to alter the fibrinogen or extrinsic factors content (or 
even activate the extrinsic factors) present in PPP, as no differences were detected in FT and 
PT, respectively. 
To study the blood compatibility of a material, important information can be obtained through 
the evaluation of its effect on the intrinsic (contact) coagulation pathway. In the intrinsic 
pathway, activation of factor XII occurs when blood comes into contact with a surface 
containing negative charges (eg, the wall of a glass tube). This process is called "contact 
activation" and still requires the presence of other plasma components: pre-kallikrein (a serine 
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Figure 5: Comparison of anticoagulation time (aPTT, PT and FT) of BC membranes untreated or 
treated with the recombinant protein (RGD-CBM) and the controls (ePTFE, polystyrene and glass 
microspheres). The coagulation times of PPP non-contacted with the materials (pre-incubation 
control) were also analysed. 
protease) and high molecular weight kininogen (a non-enzymatic cofactor) [44]. Several 
authors used the aPTT test to evaluate the blood compatibility of materials [45-48]. In this test 
an aliquot of platelet-poor plasma is incubated with a factor XII activator (i.e., silica, celite, 
kaolin, micronized silica, ellagic acid, etc.), a reagent containing phospholipid (partial 
thromboplastin) and CaCl2. Although aPTT is appropriated to detect antithrombogenic activity 
such as in materials with heparinised surfaces [48, 49], this method should not be used when 
aiming to detect the activation of the contact pathway (as often shown in the literature). 
Indeed, the effect of the material can be masked by the reagent used for the test, which 
already contains an activating substance, as described above. This effect explains the similar 
aPTT results for the all tested materials described in the present work. 
The coagulation assays (FT, PT and aPTT) were also carried out using the endothelialized 
materials and no significant differences in the coagulation time values were observed between 
the tested materials (data not shown). Similar results were obtained by Liu et al. [46], when 
comparing the bare and endothelialized poly(D,L-lactide-co-beta-malic acid) (PLMA) polymer 
modified with the GRGDS sequence. Also, this may indicate that the cells seeded on polymers 
showed a balance of procoagulant and anticoagulant activities, which would not be displaced 
to either side without certain stimuli, as is the case for ECs in their normal state [46]. 
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For the evaluation of the BC blood compatibility, specifically to ascertain whether the activation 
of the contact pathway occurs, the plasma recalcification time (PRT) and whole blood clotting 
time tests were carried out. Plasma recalcification profiles serve as a measure of the intrinsic 
coagulation system [28, 34]. The absorbance increases as the plasma becomes more turbid, 
correlating with the formation of a clot. A rightward shift of the curve indicates a slower clotting 
time; whereas, a leftward shift of the curve indicates a faster one. Citrated platelet poor plasma 
(without the addition of CaCl2) serves as a negative control, as it should not form a clot. In the 
kinetic profiles the plasma incubated with glass microspheres produced the more leftward 
curve while the ePTFE produced the more rightward curve, and the others materials tested 
presented kinetics profiles between these two controls (FIGURE 6a). The plasma incubated 
with BC treated with RGD-CBM and untreated BC presented similar curves (data not showed). 
The clotting time to reach half-maximal absorbance (half-max time) was measured for each 
surface (FIGURE 6b). The half-max time for glass microsphere (2.826 ± 0.13 min) was 
significantly lower than that for BC (3.92 ± 0.161 min) or BC treated with RGD-CBM (3.725 ± 
0.202 min, data not showed), followed by polystyrene (5.896 ± 0.154 min), lyophilized BC 
(5.908 ± 0.141 min) and ePTFE (6.725 ± 0.117 min). Taken together, the shift of the kinetic 
profile (Fig. 6a) and the half-maximal absorbance clotting time (Fig. 6b) results, the order of 
the lower to higher coagulative materials is glass microspheres < untreated and RGD-CBM 
treated BC < polystyrene and lyophilized BC < ePTFE. We believe that the difference between 
the hydrated BC and the lyophilized BC is due to reduction of the porosity, and consequently of 
the surface area, of the cellulose after the lyophilization process [13].  
Whole blood was used to assess clotting times. In this assay, higher absorbance values 
correlate with improved thromboresistance of the material. The results showed that, after 15 
min of calcium addition, the percentage of blood coagulation was 87, 57, 9.3 and 8.6% for 
glass microspheres, lyophilized BC, ePTFE and polystyrene, respectively. At each time point 
measured, blood incubated with glass had a significantly higher coagulation percentage, while 
the polystyrene presented the lower values. In general, the BC presented a clotting time higher 
than the glass microsphere and lower than the ePTFE and polystyrene (FIGURE 7). Although 
lyophilized BC induces a faster blood coagulation than ePTFE, this may be the result of the 
larger surface area, a parameter quite difficult to control in these experiments, which directly 
influence the blood-material interaction. 
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Figure 6: Clotting kinetic profiles of the absorbance at 405nm as a function of time for PPP 
incubated with polystyrene, BC (hydrated and lyophilized), glass microspheres and ePTFE (a). 
Citrated PPP (without the addition of calcium) serves as a negative control. The data was 
averaged over five independent experiments. The half-max time of each profile (b) was calculated 
as a measure of the clotting time. 
 
 
 
Figure 7: The effect of BC, ePTFE, polystyrene and glass microspheres on thrombus formation in 
whole blood at 0, 5, 15, 25 and 35 min. 
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Platelet adhesion 
When blood contacts a foreign material, such as artificial vessel, catheter or a hemodialyzer, 
plasma proteins readily adsorb onto the material surfaces. Stimulation of adhesion of platelets, 
white blood cells and some red blood cells onto the plasma protein layer may follow. After 
adhesion and aggregation, platelets release materials such as ADP and ATP, thereby inducing 
more platelet aggregation on the surface. Finally, a non-soluble fibrin network or thrombus is 
formed [47]. Thus, platelet adhesion on BC is an important test for the evaluation of blood 
compatibility. Figure 8 shows the relative number of platelet adhered to the ePTFE and BC 
surfaces. The lactic acid dehydrogenase (LDH) activity method [29] was used for platelet 
quantification. The untreated and the CBM-treated BC adsorbed approximately 15% and 16%, 
respectively, of the platelets added to the pellicle during the assay, while the reference material 
(ePTFE) adsorbed only 6%. However, when BC was pre-treated with RGD-CBM, the amount of 
platelets adhered increased to 34%.  
The adhesion of platelets to BC may be driven by the adsorption of plasma protein and clearly, 
the RGD peptide increases the platelets adhesion by two-fold. Thus, the results demonstrate 
that the RGD was able to recognize the platelet integrin αIIbβ3, leading to platelet adhesion, 
which is in agreement with results previously reported by Hansson et al. [50]. 
 
Figure 8: Relative number of platelets adhered on ePTFE and BC membrane untreated or treated 
with the recombinant proteins (RGD-CBM or CBM).  
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Figure 9 shows SEM images of the platelets adhered to the materials tested. As can be seen, 
these results are in agreement with the LDH assay (FIGURE 8). The platelets adhered to ePTFE 
present pseudopodia, indicating that they might have been activated. In the case of BC, it is 
difficult to identify elongations of the adhered platelets, due to the fibrous structure of the 
material.  
The platelet adhesion on endothelialized polymer was also studied. As demonstrated in our 
previous work [24] (chapter 3) after 14 days, only the BC treated with RGD-CBM was able to 
form a confluent endothelial cell layer when compared with the untreated or CBM-treated BC. 
The SEM images from figure 10 shows that the presence of an endothelial layer on the RGD-
treated BC significantly decreases the platelet adhesion, when compared with bare-BC. Once 
HMECs were not able to form a confluent layer on untreated or CBM-treated BC, platelets were 
still able to adhere to the gaps between the cells. Few platelets adhered to ePTFE, and also 
HMEC cells attached and proliferated poorly on this material. The densities of adhered 
platelets on endothelialized polymers are shown in figure 11 and as can be seen the number 
of platelets on RGD-treated BC reached similar values to the reference material. Although the 
presence of RGD increased the platelet adhesion on bare-BC, it may be used to cover the BC 
grafts with ECs before implantation. This strategy has been successfully reached by other 
authors [30, 46] that observed fewer platelets adhering to surfaces covered with endothelial 
cells. ECs are antithrombogenic, the glycocalyx preventing platelets from adhering; production 
of nitric oxide and prostacyclin also inhibit platelet adhesion, aggregation and cause blood 
vessel dilatation. In addition, endothelium also displays ectonucleotidases at its luminal 
surface. These enzymes hydrolyze ATP and ADP, both potent platelet aggregating agents, into 
AMP and adenosine [51, 52]. 
Hemolysis 
The results of hemolysis quantification over incubation of blood with BC membranes and 
ePTFE are shown in table 1. As negative and positive controls, blood was incubated in an 
isotonic solution (PBS buffer) and ultra pure water, respectively. It may be observed that 
hemolysis occur in less than 2% of the red cells, thus BC is classified as a nonhemolytic 
material, since, according to the American Society for Testing and Materials (ASTM F756-00, 
2000), a material may be classified as nonhemolytic (0-2% of hemolysis), slightly haemolytic 
(2-5% of hemolysis) and haemolytic (>5% of hemolysis). However, the evaluation of the 
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haemolytic character for materials are subject to consideration of the nature of tissue contact, 
duration of contact, and surface area to body ratios, and the nature of device. 
 
Figure 9: SEM images of BC membrane and ePTFE surface after contact with PRP for 2 hours. 
Column II (scale bar 5µm) is the magnified images of Column I (scale bar 20µm). 
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Figure 10: SEM images of the adhered platelets on endothelialized BC untreated or treated with 
recombinant proteins and ePTFE. The bare BC and ePTFE were used as controls. The captions 
without “bare” indicate the cultured HMEC surface. Column II and IV (scale bar 10µm) is the 
magnified images of Column I and II (scale bar 30µm), respectively. 
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Figure 11: Densities of adhered platelets on endothelialized BC untreated or treated with 
recombinant proteins and ePTFE. The bare BC and ePTFE were used as controls. 
 
 
 
Table 1: Hemolysis of blood after contact with BC surfaces and ePTFE. 
Sample Hemolytic index 
(%) 
Ultra pure water 99.3 
PBS buffer 1.43 
BC + RGD-CBM 1.63 
BC + CBM 1.42 
BC 1.43 
ePTFE 1.85 
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Conclusions 
The blood compatibility of BC has not been systematically investigated. In this report, the 
adhesion of plasma protein and platelets and blood coagulation on bare and endothelialized 
BC surfaces was studied. The results showed that BC presents good hemocompatibility, the 
blood coagulation studies shows that the results are comparable to those produced by 
currently available materials for blood replacements and that the adsorption of total plasma 
protein was not influenced by the presence of recombinant proteins bearing the peptide RGD, 
although decreasing the adhesion of fibrinogen on pure solutions. Besides adsorption isotherm 
studies showed that BC presented a higher affinity for albumin than immunoglobulin or 
fibrinogen. Results also showed that the presence of RGD on BC polymer increased platelet 
adhesion, however when endothelial cells were cultured on RGD-treated BC, a confluent cell 
layer was formed and almost no platelets adhered to the material, thus the improvement of BC 
blood-compatibility through modification with adhesion peptides seems to be an interesting 
strategy in cases where cellulose grafts were previous covered with endothelial cells. 
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Chapter 5 
 
 
Studies on the biocompatibility of bacterial 
cellulose 
 
 
Abstract 
The production of functional blood vessels by tissue engineering techniques being already 
possible, it must be acknowledged that, due to the associated costs and lengthy production, 
the development of new materials appropriated for small diameter blood vessel replacements 
is still required. Bacterial cellulose is a promising material for this application, given its 
excellent biocompatibility and mechanical properties. In the present work, BC tubes with small 
diameter (3mm ID) were produced and its mechanical properties evaluated. The 
functionalization of BC membranes using a chimeric protein containing a cellulose – binding 
module (CBM) and the adhesion peptide Arg-Gly-Asp (RGD) improves interaction with cells – 
work previously developed in our lab; Since the recombinant protein contains a bacterial CBM, 
the biocompatibility of native and RGD-CBM treated BC – to analyse whether the presence of 
the recombinant protein gives rise to any immunologic reaction – was now investigated 
through in vitro and in vivo studies. BC was implanted subcutaneously in the sheep for 1, 2, 4, 
8, 16 and 32 weeks. Implants were evaluated regarding the inflammatory reaction, cell in-
growth and angiogenesis. Histological results showed that BC trigger a biological response 
typically observed for high surface-to-volume implants (e.g., fabrics medical devices). After 1 
week the presence of an inflammatory infiltrate suggests an acute/subacute inflammatory 
reaction that advances to a chronic inflammation confined to the implantation site and 
associated to the proliferation of small blood vessels. The presence of giant cells was observed 
at latter periods (16 and 32 weeks) and a narrow fibrous capsule was present surrounding the 
implant. There were no significant differences on the inflammation degree between the BC 
coated with the recombinant protein RGD-CBM and the native BC. 
The CryoSEM analysis showed that the BC tubes present a denser luminal side and a porous 
outer side; no orientation of the fibrils network was observed. Fluorescence microscopy reveals 
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that apart from increasing cell adhesion, the presence of RGD stimulates an even cell 
distribution, while cells coating the untreated BC seem to form aggregates. Furthermore, cells 
observed on the RGD treated – BC present a more elongated morphology. Mechanical test 
results showed that small-diameter BC tube produced by our group possess an elasticity 
higher than that of human arteries and veins. 
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Introduction 
Tissue engineering and regenerative medicine aim at promoting the regeneration of diseased 
or damaged human tissues. Biomaterials are used as scaffolds in which cells and/or growth 
factors are seeded, cultured, and implanted to induce and direct the growth of new, healthy 
tissue [1]. Among the biomaterials used, natural polymers represent one of the most attractive 
options, since being similar to biological macromolecules, may avoid the stimulation of chronic 
inflammation or immunological reactions and toxicity, often detected with synthetic polymers. 
Although several groups described the successful production of tissue engineered blood 
vessels [2-7], it must be recognized the cost and long time required for its production. 
Furthermore, the long culture time required brings about the question of the safety, due to 
possible cell differentiation. Therefore, using a material with good mechanical properties, 
allowing cell colonization, may provide a “mixed” tissue engineered/artificial prosthesis 
approach, allowing a prompt utilization and good tissue integration. 
Bacterial cellulose (BC) is a pure form of cellulose secreted by bacteria such as 
Gluconacetobacter xylinus. It is a material with unique properties, including high water holding 
capacity, high crystallinity, ultrafine fiber network, high tensile strength and the possibility to be 
shaped into three-dimensional (3D) structures during synthesis [8]. This set of features makes 
BC a promising material for the production of scaffolds in tissue engineering. In fact, several 
research groups studied the use of BC as a scaffold for cartilage [9, 10], wound dressing [11, 
12], dental implants [13-19], nerve regeneration [20, 21] and vascular grafts [22, 24-28]. 
Inflammation, wound healing, and foreign body response are generally considered as parts of 
the tissue or cellular host responses to injury and implantation of a biomaterial in the body. 
This involves injection, insertion, or surgical implantation, all of which injure the tissues or 
organs involved. The sequence of local events following implantation is: injury, acute 
inflammation, chronic inflammation, granulation tissue, foreign body reaction and 
fibrosis/fibrous capsule development [22]. The degrees to which the homeostatic mechanisms 
are perturbed and pathophysiologic conditions created and resolved are a measure of the host 
reaction to the biomaterial and may ultimately determine its biocompatibility. 
Biocompatibility is one main requirement for any biomedical material. It can be defined as the 
ability to remain in contact with living tissue without causing any toxic or allergic side effects, 
simultaneously performing its function [23]. In this context, BC has been modified to further 
enhance biocompatibility. Depending on the envisaged biomedical application, improved 
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cellulose integration with the host tissue, increased degradation in vivo or modified mechanical 
properties, to mimic the tissue to be replaced, are required. Many BC modification studies, 
such as chemical surface modifications [24-26], incorporation of bioactive molecules [27], 
modification of porosity and crystallinity [28], design of 3D structures [29], modification of BC 
composition [30-32] and production of nanocomposites [33-36], enlarge the repertoire of 
bacterial cellulose as a potential material for biomedical application. 
The functionalization of BC tubes using bioactive peptides was previously successfully 
developed in our research group, envisaging its application for vascular replacements. The 
attachment of cells to biomedical materials can be improved by using adhesion molecules, 
such as fibronectin, vitronectin, or laminin. These molecules, present in the extracellular matrix 
proteins, regulate the adhesion, migration and growth of cells, by binding to integrin receptors 
located on the outer cellular membranes. The amino acid sequence Arg-Gly-Asp (RGD) has 
been recognized as the minimal essential cell adhesion peptide sequence present in these 
proteins. In a previous work we described the production of recombinant proteins containing 
RGD sequences fused to a CBM (cellulose-binding module) [37] (chapter 2).  The use of a 
CBM (a protein exhibiting high adsorption affinity and specificity for cellulose surfaces) fused 
with biologically active peptides, allow a simple and effective approach to decorate the BC 
surface. This concept was further demonstrated using human microvascular endothelial cells 
[38] (chapter 3). The chimeric proteins were able to enhance endothelial cell adhesion to BC 
and stimulate angiogenesis. 
Very few studies on the in vivo biocompatibility of BC have been published. Helenius and 
colleagues [39] reported the histological analysis of subcutaneously implanted BC, in mice, for 
a period of up to 12 weeks. BC was shown to integrate well into the host tissue, with cells 
infiltrating the BC network and no signs of chronic inflammatory reaction or capsule formation. 
The formation of new blood vessels around and inside the implants was also observed, 
evidencing the good biocompatibility of the biomaterial. In another study, Klemm et al. [20] 
investigated the application of patented BC tubes (BASYC® - BActerialSYnthesized Cellulose) as 
microvessel endoprosthesis, using the carotid artery of a white rat. In this study, four weeks 
after implantation, the carotid artery-BASIC complex was wrapped up with connective tissue 
and the BC tube was completely incorporated in the body without rejection. Following the same 
approach, but this time in the carotid artery of pigs over a period of 12 weeks, BC grafts 
showed good in situ tissue regeneration, without signs of thrombosis, inflammation or fibrotic 
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capsule formation around the implants. The luminal wall of the newly formed tissue showed 
complete endothelialisation, with a confluent endothelial layer [40].  
To further explore the potential of BC for tissue engineering blood vessels, in this work we 
investigate the mechanical properties of BC tubes and the in vivo and in vitro biocompatibility 
of BC membranes. The fate of long term subcutaneous implants in sheep - 32 weeks - was 
analysed. Implants were evaluated in aspects of chronic inflammation, foreign body reaction 
responses, cell in-growth and angiogenesis. Once the chimeric protein used in this work 
contain a bacterial CBM – a cellulose-binding domain family III from the cellulosomal-
scaffolding protein A of the bacteria Clostridium thermocellum – also the in vivo 
biocompatibility of BC membranes treated with the RGD-CBM protein was investigated. 
Furthermore, the in vitro biocompatibility was evaluated using 3T3 mouse embryo fibroblast 
cultures. Viability, morphology and cell in-growth were analysed by MTS [3-(4,5-dimethylthiazol-
2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H- tetrazolium] assay, fluorescence and 
CryoSEM microscopy. 
 
Material and Methods 
Production of Bacterial Cellulose 
Gluconacetobacter xylinus (ATCC 53582) purchased from the American Type Culture 
Collection was grown in Hestrin-Schramm medium, pH 5.0. The medium was inoculated with 
the culture, added to the 24-well polystyrene plate (1 ml per well) and incubated statically at 
30 oC, for 5 days. BC pellicles were purified by 2% SDS treatment at 60 oC, for 12 h, washed 
with distilled water until complete removal of SDS and immersed in 4% NaOH at 60 oC, for 90 
min. After neutralization with distilled water the samples were autoclaved and stored in 
phosphate buffered solution (PBS) pH 7.4, at 4ºC, prior to use. The pellicle produced in a 24-
well polystyrene plate presented a diameter of 15.5mm. 
Preparation of tubular BC: the experimental set-up used for the production of BC tubes 
(FIGURE 1) was autoclaved and the Hestrin-Schramm medium was inoculated and added to 
the system. A layer of sterilized oil was placed surfacing the culture medium, to reduce the 
growth of the bacteria at the air-liquid interface. The silicon tube is permeable to oxygen, 
allowing the growth of the strictly aerobic bacteria next to the tub wall. To avoid the formation 
of air bubbles on the surface of the silicon tube – leading to irregularly shaped BC tubes – the 
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system was first connected to an air bomb during 4 days in an open circuit. After the formation 
of a thin BC pellicle, the air bomb was disconnected and pure oxygen was injected at 0,5 bar 
for 14 days and allowed the production of a BC tube with (3mm of inner diameter). Then, the 
BC tubes were removed from the silicon mould and treated with a 4% NaOH solution, at 60 oC, 
for 12 hours. The purified BC was then neutralized with filtered distilled water, autoclaved and 
stored in phosphate buffered solution (PBS) pH 7.4, at 4ºC, prior to use. 
 
 
Figure 1. Bacterial cellulose produced by G. xylinus (ATCC 53582) grows around the silicon tube, 
when an air flow is injected through the tube. a) Schematic picture of the cultivation system; b) 
Bacterial cellulose tube. 
 
Surface modification of BC with RGD-CBM protein 
The recombinant protein RGD – CBM has been formerly cloned in Escherichia coli and its 
production and purification was conducted as described in our previous work [37] (chapter 2). 
For surface modification of BC, the purified recombinant protein was added to the wells of 24-
well polystyrene plates (0.25mg of protein/per well), coated with bacterial cellulose sheets 
produced in similar 24-well polystyrene plates. The plates were incubated overnight at 4 ºC. 
Unbound protein was removed and the BC pellicles were washed with PBS and used in the in 
vitro and in vivo biocompatibility assays. 
 
Fibroblast adhesion and proliferation 
The mitochondrial activity of the cultured cells was determined using a colorimetric assay, 
commonly used as a measure of cell viability. The MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H- tetrazolium] assay was performed as follows: the 
purified recombinant proteins were added to the wells of the 24-well polystyrene plates (0.25 
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mg of protein/per well), coated with bacterial cellulose sheets. As referred earlier, the BC 
sheets were produced in similar 24-well polystyrene plates, such that they tightly fit in the 
wells, completely covering the bottom surface. The fibroblasts 3T3 were seeded at a density of 
12x 104cells/per well, in DMEM medium without serum. Two hours after the addition of the 
cells, the wells were washed with PBS and DMEM with serum (10%) was added. The MTS 
assay of the attached and spreading 3T3 fibroblasts was carried out at 2, 72 and 7 days after 
the addition of the cells. The plates were incubated at 37ºC, in atmosphere of 5% CO2 and 95% 
humidified air. The results were obtained from at least three different assays, each one with 
samples in triplicates. 
 
Morphological analysis by fluorescent microscopy 
After 2h, 72 and 7days of cell seeding on BC - untreated or treated with the RGD-CBM protein 
–the membranes were washed with pre-warmed PBS; then, the cells were fixed in 4% 
formaldehyde (Pierce, Rockford, IL, USA) in PBS, permeabilized with acetone (Sigma) at – 
20ºC, and stained with Alexa Fluor 546-phalloidin (Molecular Probes). Nuclei were visualized 
by staining with DAPI. Microscopy observations were performed using an Olympus BX51 
(Olympus Portugal SA, Porto, Portugal) fluorescence microscope. 
 
Cryo-Scanning Electron Microscopy (CryoSEM) 
CryoSEM presents a valuable technique for the visualization of materials that have a high water 
content, whose structure might be altered or destroyed by dehydration and cross linking. After 
14 days of cell seeding on BC – untreated or treated with the RGD-CBM protein – the 
membranes were washed with pre-warmed PBS; then, the cells were fixed in 2.5% 
glutaraldehyde in PBS. Samples were washed in ultrapure water and a piece of BC membrane 
was placed between two miniature rivets on a vacuum transfer rod and the sample was slam-
frozen in a nitrogen slush and transferred to the cryostat chamber, which was maintained at - 
150 °C. The top rivet was flicked off to produce a fractured surface, the ice was sublimed at - 
90 °C during 2 minutes (for visualization of fibers on the dense side of BC) or 4 minutes (for 
visualization of fibers on the porous side of BC), and then fractured surface was coated with 
gold/palladium. Afterwards, the sample was transferred to the microscope chamber, which 
was also maintained at - 150 °C and examined at 15 kV using a working distance of 15 mm. 
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The samples were analyzed by use of a CryoSEM (Model Gatan ALTO 2500) at CEMUP (Centre 
for materials characterization from the University of Porto). 
For visualization of the fibers from the BC tube, the tube samples were cut longitudinally and 
transversely. The transversal section was fractured and sublimed during 10 minutes. The 
longitudinal section was not fractured and the sublimation time was 30 minutes. 
 
Mechanical properties: Young´s modulus (E) tensile strength (TS) and elongation-
at-break (ε%) 
TS, E and ε% were measured with an Instron Universal Testing Machine (Model 4500, 
InstronCorporation, USA). The initial grip separation was set at 15 mm and the crosshead 
speed was set at 5 mm/min. TS is the stress needed to break a sample and was calculated by 
dividing the maximum load (N) by the initial cross-sectional area (m2) of the specimen, the TS 
is expressed in MPa. E is the initial slop of the stress-strain curve and expressed in MPa. ε% is 
the strain on a sample when it breaks. It was calculated as the ratio of the increased length to 
the initial length of a specimen (15 mm) and expressed as a percentage. BC tube was 
stretched in lengthwise direction and a total of fifteen tubes were used in the test. 
 
In vivo biocompatibility studies 
Experimental groups: 18 adult female white merino sheep weighing approximately 60 kg were 
random allocated to two groups of 6 animals each. One group (group 1) of animals was 
implanted with bacterial cellulose discs with 1.5 cm diameter and treated with the recombinant 
protein (RGD-CBM), a second group (group 2) was implanted with untreated BC discs. 
Anaesthesia and surgical procedures: The animals were solids fastened for 48 hours prior to 
the surgical procedure. An intravenous catheter of 20G was placed at the cephalic vein. The 
anesthetic protocol consisted in xylazine (0.2 mg/Kg, intravenous) as tranquilizer. For inducing 
anesthesia, sodium thiopental was used at a dosis of 15 mg/Kg intravenous. The anesthetic 
maintenance was done with isoflurane at 2% via endotracheal intubation carried by 100% 
oxygen with a flow of 2L/min. 
For surgery, sheep were placed in sternal recumbence over a tilted table so that the animal´s 
head and neck are always lower than the stomach to reduce risks of aspiration pneumonia. 
The wool was clipped in roughly square areas and the skin was aseptic prepared with 
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iopovidone. The incisions were made over the dorsal area, starting over the last ribs and 
ending just cranially to the sacrum. These 3 cm length incisions, 3 on the left side e two on the 
right one, were made parallel and 4 cm off the midline. A minimum distance of 3 cm was kept 
between incisions. After exposing the dorsal muscles, the BC tubes were inserted under the 
skin, distally to the midline, subsequently, the skin was closed with a Supramid® USP1 suture 
and the ewes were transferred to straw yards (4 m x 3 m) after surgery. The skin sutures were 
not removed in order to localize the implant site. 
Collection of implants and histological procedures: The implants and the surrounding tissue 
were collected after a peripheral infiltration of 2% lidocaine, at 1, 2, 4, 8, 16 e 32 weeks post-
implantation. Two samples were collected in each animal, randomly selected in each 
experimental group at the previously reported temporal points. The samples were fixed in 10% 
formalin, paraffin-embedded, cut in 2 µm and stained with hematoxylin and eosin (HE) for 
histological evaluation. 
Histological evaluation: The biological response parameters were assessed in the 
implant/tissue interface with three high power fields (x400) by at least two pathologists, for 
each sample and recorded in an appropriated formulary. Among the biological response 
parameters all were evaluated according to the ISO standard 10993-6 (annex E) and included: 
the extent of fibrosis/fibrous capsule (layer in micrometres) and inflammation; the 
degeneration as determined by changes in tissue morphology; the number and distribution 
from the material/tissue interface of the inflammatory cell types, namely polymorphonuclear 
neutrophilic leucocytes (PMN), lymphocytes, plasma cells, eosinophils, macrophages and 
multinucleated cells; the presence, extent and type of necrosis; other tissue alterations such as 
vascularization, fatty infiltration and granuloma formation; the material parameters such as 
fragmentation and/or debris presence, form and location of remnants of degraded material. 
 
Results and discussion 
In vitro studies on the BC-cell interactions 
When cultivated in static culture G. xylinus constructs a cellulose network much denser on the 
culture medium/air interface than on the opposite side [20, 41]. The results of the MTS test 
(FIGURE 2) showed that there were no significant differences on the fibroblast adhesion to the 
porous or dense side of BC and also that the cells proliferated equally well on both sides, as 
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previously reported by Backdahl and colleagues [41], in a study using human smooth muscle 
cells (SMC). The effect of the recombinant protein (RGD – CBM) on the adhesion of fibroblasts 
to BC was previously discussed [37] (chapter 2). Fluorescence microscopy allows, in this work, 
the observation of more details of the cell-BC interaction. Figure 3 show that, apart from 
increasing cell adhesion – as previously observed using the MTS assay – the presence of RGD 
stimulates a uniform distribution of the cells, important to improve the endothelialization of the 
graft, while cells coating the untreated BC seems to form aggregates (the images containing 
only the nuclei labelled on figure 3 allow a better visualization of this effect). There were no 
differences on the morphology of the fibroblast cultured on porous and denser side of the 
membrane.  
 
 
Figure 2. MTS assays of fibroblast cultures at the dense or porous side of BC membrane. The MTS 
assay was developed at 2, 72 and 7 days after cell seeding. Results are expressed as absorbance 
values at 490 nm. 
 
The CryoSEM results (FIGURE 4) showed that cells on RGD-treated BC present a more 
elongated morphology than the ones covering the untreated pellicle, irrespective of the side 
analysed. The more extended morphology of fibroblasts upon interaction with the adhesive 
peptides is likely driven by the greater number of focal contacts between integrins and RGD-
containing peptides linked to the BC surface. It is well known that a critical RGD density is 
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essential for the establishment of mature and stable integrin adhesions, which, in turn, induce 
efficient cell migration, spreading and formation of focal adhesions [42-45]. 
 
 
 
Figure 3. Fluorescent microscopy images showing fibroblast cultured 7 days on BC pellicle. (a) 
Dense and (b) porous side of RGD-treated BC; (c) Dense and (d) porous side of untreated BC. 
Nuclei were visualized by staining with DAPI (blue) and f- actin with Alexa Fluor 546-phalloidin 
(red). Actin and nuclei combined images were acquired using objectives 10x (scale 200µm); 
Nuclei images were acquired using objectives 20x (scale 100µm). 
 
The migration of cells is mediated by integrins, a diverse family of glycoproteins that form 
heterodimeric receptors for extracellular matrix (ECM) molecules. During migration, cells 
project lamellipodia that attach to the ECM and simultaneously break existing ECM contacts at 
their trailing edge. This allows the cell to pull itself forward [46]. Animal cells cannot degrade 
cellulose [39] and must push the nanofibrils aside while migrating into the cellulose network 
[41]. The CryoSEM technique was also used for visualization of cell ingrowth in BC scaffold. 
The results showed that after 14 days of culture the cells could not migrate through the BC 
fibers, once only cells on the surface were found. However, it has been demonstrated that cells 
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may migrate through BC membranes. Andrade et al. [38] (chapter 3) and Backdahl et al. [41] 
demonstrated the ingrowth of human microvascular endothelial cells (HMECs) and SMC, 
respectively, through BC network using an invasion chamber where an attractant (serum, 
growth factor, etc…) is used to stimulate the cells to grow into the BC - in both cases the cells 
were able to invade the fibrous cellulose matrix. 
 
 
Figure 4. CryoSEM micrographs of bacterial cellulose cultured with fibroblasts after 14 days. (a) 
Dense and (b) porous side of RGD-treated BC; (c) Dense and (d) porous side of untreated BC. Scale 
10µm. 
 
Mechanical properties of the BC tubes; structural details (CryoSEM) 
The production of BC tubes using different techniques has been described in the literature, for 
example:(1) a cylindrical glass matrix is immersed in a large volume and tubular BC is 
produced in the culture medium that enters between the outer and inner matrices. In this case 
the oxygen is supplied through the second opening that opens to the air surface [20]. This 
approach is not feasible for the production of long tubular BC structures. (2) Another technique 
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was developed by Putra et al. [47]; the authors used a silicone tube (an oxygen-permeable 
material) as a mould. The culture medium is poured into a silicone tube and the both edges 
were sealed. The G. xylinus produce BC gel all around the interface between the inner surface 
of silicone tube and the culture medium, which leads the formation of a BC tube with a more 
porous structure on the luminal side than the outer side. (3) Gatenholm and his group [41, 48, 
49] produced BC tubes submerging silicone tubes in a glass tube containing culture medium. 
One of the edges was sealed and at the other edge gas was inlet through the support. The G. 
xylinus produce BC gel all around the interface between the outer surface of silicone tube and 
the culture medium. The experimental set-up used in this work for the production of BC tubes 
(FIGURE 1) is similar to the one used by the Gatenholm group and produces a BC tube with a 
smoother and denser luminal side and a more porous outer side (FIGURE 5). According to 
Backdahl et al. [41] a smoother luminal surface, being similar to the basal membrane of the 
luminal side of blood vessels, is preferable for the attachment of endothelial cells while a 
porous outer side probably will facilitated the integration with the host tissue. The CryoSEM 
results also showed that, unlike the tubes produced by Putra et al. [47], no orientation of the 
fibrils network was observed. According to Putra and co-workers the degree of orientation of 
the fibrils depended on the diameter of the curvature of the silicone mould. An increase in the 
diameter of curvature led to a decrease in the degree of BC fibril orientation. Since, in the 
present study, the bacteria grow on the outer side of the silicone tube (hence, with lower 
curvature), this probably affected the direction of the fibril secretion by the G. xylinus. 
The Young´s modulus (E) of the BC tube was evaluated. Higher values of E are associated 
with a greater vessel wall stiffness. The BC tube produced in this work presented a more 
elastic structure in the lengthwise, i.e., lower E (0.25 ± 0.07 MPa) than human arteries and 
veins and much lower than collagen and PTFE, two common polymers used as vascular grafts 
(TABLE 1). The value reported by Putra and colleagues [47] is, also along the length of the 
tube, even more elastic (lower E), these differences are probably due to the different cellulose 
density/thickness. Typical plots of wall stress versus strain in BC tube segments are shown in 
Figure 6. The BC-tube produced in this work presented an ε% of 31± 4.4%, a value higher 
than presented by collagen (10%) and lower than PTFE (200–400).  
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Figure 5. CryoSEM micrographs of bacterial cellulose tubes. Visualization through a longitudinal 
cut of (a) Inner side (b) outer side. Visualization through a transversal cut of (c) Inner side (d) 
outer side. Scale 60µm (longitudinal images), scale 10µm (transversal images). 
 
The TS from our BC-tube was 0.19 ± 0.03 MPa, a value lower than the one obtained by Putra 
and colleagues (0.59 MPa) [47]. Again, although the values are in the same order of 
magnitude, the different properties may be assigned to variable thickness of the tubes. The TS 
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values for the BC tubes (obtained in our lab and described by Putra and colleagues [47]) are 
one order of magnitude lower than the ones reported for human arteries and veins (TABLE 1). 
 
Table 1. Comparison of the mechanical properties of BC tubes (3mm of inner diameter and 1mm 
of wall thickness) produced in this present work with BC tubes produced by Putra et al.[47], 
human arteries and veins and common polymers used as vascular grafts (collagen and PTFE). 
 Young´s Modulus 
(MPa) 
Tensile Strength 
(MPa) 
Elongation 
(%) 
References 
BC – tube 0.25 0.19 31 * 
BC – tube 0.06 0.59 - [47] 
Arteries 1.54 1.57 - [50, 51] 
Veins 3.11 2.65 – 3.3 - [50, 51] 
Collagen 1000 50 – 100 10 [52] 
PTFE 400 14 – 35 200 – 400 [52] 
* BC tubes produced in this work. 
- Not described. 
 
 
Figure 6. Tensile stress-strain curves of the lengthwise of BC tubes with an inner diameter and 
wall thickness of 3 mm and 1 mm, respectively. 
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According to Sanchavanakit and collegues, a BC dried film (from a 48h grown culture) with a 
thickness of 0.12 mm presents a tensile strength and break strain of 5.21 MPa and 3.75%, 
whereas for the reswollen films the values are 1.56 MPa and 8.0%, respectively [53]. McKenna 
and collegues reported a TS value of wet bacterial cellulose sheet grown between 48h – 96h  
of 1.1 - 2.2 MPa, ε% of 16 - 27% and E 10 - 14 MPa [54]. The BC production as well as the 
mechanical properties are influenced by the carbon and nitrogen sources and concentration, 
the pH and temperature, time of cultivation, the surface area of the fermentation system, the 
type of cultivation system (e.g. static or agitated cell culture) and differences in the bacterial 
strains. Also, the treatment after synthesis influenced the properties of BC membranes [8].  
The mechanical properties of the BC tubes produced using the method adopted in this work 
are inferior to the properties of both the commercial BC grafts available and of the natural 
blood vessels. Therefore, a different method for the production of the tubes, allowing a thicker 
BC wall is required (ongoing work). On the other hand, the impregnation of the porous 
cellulose matrix with blood before implantation may provide significant improvement on the 
mechanical properties. 
 
In vivo biocompatibility studies 
Implanted medical devices must perform, improving quality of life of the patients. However, 
some implants ultimately develop complications (adverse patient – device interactions) leading 
to the graft failure, and thereby may cause harm to or death of the patient. The complications 
associated to medical devices are largely due to the materials – tissue interactions, including 
both the effects of the implant on the host tissues, as well as the effects of the host tissues on 
the implant [52]. This way, much of the research is directed towards the search for 
biomaterials that are able to provide best performance. 
As a promising material for small vascular grafts, bacterial cellulose was evaluated in terms of 
its in vivo biocompatibility. The effect of the recombinant protein containing a bacterial domain 
on the biocompatibility of BC was also examined. Bacterial cellulose membranes with 1.5 cm 
diameter coated or not with the RGD-CBM, were subcutaneously implanted in the sheep. The 
implants and the surrounding tissue were collected at 1, 2, 4, 8, 16 e 32 weeks post-
implantation.  
The histological observation showed that at 1 week post-implantation there was a 
predominance of polymorphonuclear leukocytes (PMN) and macrophage infiltrate at the 
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implant – tissue junction in both groups 1 and 2, suggesting an acute/subacute inflammatory 
reaction (FIGURE 7a).  
In the 2nd week post-implantation an increase in macrophages, plasma cells and lymphocytes 
infiltration associated to a proliferation of small blood vessels was compatible with a chronic 
inflammation. The persistence of the inflammatory stimuli (BC membranes) led to a change 
from acute to chronic inflammation [55]. This chronic inflammation response was confined to 
the implantation site (FIGURE 7b). 
During the initial 4 weeks of observation, lymphocytes and macrophages were the most 
represented cells for both groups. The type of cell infiltrate and the increased 
neovascularisation, always surrounding the implant area were compatible with a chronic 
inflammation (FIGURE 7c). Macrophages must be considered in the development of immune 
responses to synthetic biomaterials by presenting antigen to immuno competent cells such as 
lymphocytes and plasma cells [56]. The macrophage is probably the most important cell in 
chronic inflammation because of the great number of biologically active products expressed by 
these cells [56]. Among these, growth factors are responsible for the growth of fibroblasts and 
blood vessels observed in both groups at the 4 week pos-implantation. 
8 weeks past implantation a marked decrease in inflammation grading was detected in both 
experimental groups (FIGURE 7d). These findings can be related to the formation of 
granulation tissue, the hallmark of healing inflammation, consisting in the proliferation of 
fibroblasts, macrophages and vascular endothelial cells and a decrease in inflammatory cells 
such as PMN and lymphocytes. 
The foreign body reaction (FBR), consisting mainly of macrophages and/or foreign body giant 
cells infiltration at the tissue-implant interface associated to the different degrees fibrosis (i.e. 
fibrous encapsulation) were observed at latter periods (16 and 32 weeks) of the experimental 
process (FIGURE 7e and 7f). With biocompatible materials, the composition of the foreign body 
reaction in the implant site may be controlled by the surface properties of the biomaterial, the 
form of the implant and the relationship between the surface area of the biomaterial and the 
volume of the implant [57, 58]. High surface-to-volume implants such as the BC membranes 
will have higher counts of macrophages and foreign body giant cells in the tissue-implant 
surface than will smooth-surface implants, which will have fibrosis as a significant component 
of the implant site.  
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Figure 7. Histomorphology of bacterial cellulose membrane implanted subcutaneously in sheep 
and surrounding tissue reaction. Once there were no significant differences in biological 
responses by the host, the images represent the results for both groups of the post-implantation 
times analyzed. (a) 1, (b) 2, (c) 4, (d) 8, (e) 16 and (f) 32 weeks post-implantation. (a, b, c, d), (e) 
and (f), 40x, 100x and 400x ampliation, respectively (Hematoxylin - eosin staining). The solid 
arrows indicate the fibrous capsule formation. The dashed arrow on image (f) indicates small 
blood vessels formation. (*) Bacterial cellulose. 
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Most biomaterials of potential clinical interest typically elicit the foreign body reaction, a special 
form of nonspecific inflammation. The major role of the neutrophil in acute inflammation is to 
remove foreign materials and bacteria from the injury site through phagocytose (engulfment, 
followed by the killing or degradation) [59]. The form and topography of the surface of the 
biomaterial determine the composition of the foreign-body reaction. Relatively flat and smooth 
surfaces such as that found on breast prostheses have a foreign body reaction that is 
composed of a layer of macrophages one to two cells in thickness. Relatively rough surfaces 
such as those found on the outer surfaces of expanded poly tetrafluoroethylene (ePTFE) or 
Dacron vascular prostheses have a foreign-body reaction composed of macrophages and 
foreign body giant cells at the surface. Fabric materials generally have a surface response 
composed of macrophages and foreign body giant cells, with varying degrees of granulation 
tissue subjacent to the surface response. A material in a phagocytosable form (i.e., powder or 
particulate) may provoke a different degree of inflammatory response than the same material 
in a nonphagocytosable form (i.e., film) [52]. 
Multinucleated giant cells (formed by the fusion of monocytes and macrophages in an attempt 
to phagocytose the material with a size greater then the own cell) in the vicinity of a foreign 
body are generally considered evidence of a more severe FBR, however it is not uncommon to 
see very large foreign-body giant cells containing large numbers of nuclei on the surface of 
biomaterials, in fact the components of the FBR (giant cells and granulation tissue) may persist 
at the tissue–implant interface for the lifetime of the implant [22, 52]. Sonohara and Greghi 
compared the biological response of Millipore membrane, Teflon and Gengiflex (a product 
based on bacterial cellulose) after subcutaneous implantation in rats for an experimental 
period of 30 days. The histological results showed that none of the material tested induced 
intense reaction with the host. The presence of a discrete to moderate giant cells infiltrate was 
observed for Millipore membrane and Teflon, in case of Gengiflex the framework was moderate 
to intense. [60] 
Märtson et al. [61] implanted a high purity cellulose sponge (Cellspon®) in the subcutaneous 
tissue of rats from 1 to 60 weeks. In that study, a mild foreign body reaction was observed at 
16 weeks post-implantation, in agreement with the observation made in the present study, at 
the same temporal point [61]. Märtson et al. described a decrease in the volume of 
amorphous cellulose implants that can be attributed to a degradation by, probably, a 
combination of chemical, biological and mechanical processes. At the latter stages of the 
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current assay (16 and 32 weeks), a change in the shape of the membrane was observed, 
which may be assigned to similar events, but our data do not allow an objective position 
regarding the possible degradation of the BC implants. 
Only a few studies addressed so far the in vivo biocompatibility of BC. Helenius and colleagues 
[39] reported the histological analysis of subcutaneously implanted BC, in mice, for a period of 
up to 12 weeks. BC was shown to integrate well into the host tissue, with cells infiltrating the 
BC network and no signs of chronic inflammatory reaction or capsule formation. The formation 
of new blood vessels around and inside the implants was also observed, evidencing the good 
biocompatibility of the biomaterial. 
Mendes and coworkers implanted BC subcutaneously in mice for 90 days, the results showed 
that the microbial cellulose membrane was found to be nonresorbable and induced a mild 
inflammatory response, suggesting that the membrane was well tolerated by the organism 
[62]. 
Esguerra and collegues used another animal model to evaluate the biocompatibility of BC, 
polyglycolic acid and expanded polytetrafluorethylene; these materials were implanted in a 
dorsal skinfold chambers of Syrian golden hamsters. The authors used intravital fluorescence 
microscopy, histology, and immunohistochemistry to analyze the biocompatibility, 
neovascularization, and incorporation of each material over a time period of 2 weeks. Histology 
results showed that the inflammatory response to BC is similar to that of ePTFE and PGA. 
However angiogenesis in BC is slower and less well developed than the other materials tested 
[63]. 
Testing always leads to experimental variability, particularly tests in living systems. It should be 
noted that the different results obtained until now with BC implants, may be explained by the 
different animal species used and the different methodology applied in assessing the 
inflammatory reaction. 
Generally, fibrosis (i.e., fibrous encapsulation) surrounds the biomaterial, isolating the implant 
and foreign-body reaction from the local tissue environment [52]. Our results showed that BC 
implants present a narrow fibrous capsule for both groups tested. The thickness of the fibrous 
capsule around implants placed subcutaneously has been used as a measure of the 
“biocompatibility” of materials. Hence, overall, from the present work, a classification of BC as 
a biocompatible material may be drawn. However, it is important to note that materials yielding 
acceptable tissue compatibility in one implantation site might yield unfavourable results in 
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another site [52]. Thus, to employ BC as a biomedical scaffold for artificial blood vessels 
requires additional compatibility studies, in which the BC is subjected to the environment that 
exists in the grafting site in the vasculature. 
Figure 7 shows the histological photographs of bacterial cellulose membrane implanted 
subcutaneously in sheep and surrounding tissue reaction. Once there were no significant 
differences in biological responses by the host for untreated or RGD-CBM treated BC, the 
images represent the results for both groups of the post-implantation times analyzed. Analysis 
of the histological sections by light microscopy shows the maturation of the granulation tissue, 
with a inflammatory infiltrate of mainly polymorphonuclear cells and lymphocytes and no 
capsule at 1 week pos-implantation, leading the formation of a mature fibrous capsule 
surround the implant and presence of newly formed vessels at 32 weeks pos-implantation. 
Significant differences of inflammation degree between the two groups were not observed. 
Although the adhesion peptide (RGD) present on BC membranes (group 2) could potentially 
interact with monocytes/macrophages (these cells express αVβ3 integrin) [22], influencing the 
adhesion and chemotaxis of these cells, a more intense infiltration of inflammatory cells was 
not observed. 
 
Conclusion 
Our data indicate that BC triggers a biological reaction typical of high surface-to-volume 
implants with an acute/subacute inflammatory reaction after 1 week pos-implantation that 
advance to a mild chronic inflammation confined to the implantation site and associated with 
neovascularisation. The presence of giant cells was observed at latter periods and a narrow 
fibrous capsule was present surrounding the implant. There were no significant differences on 
the inflammation degree between the BC coated with the recombinant protein RGD-CBM and 
the native BC. 
The CryoSEM analysis showed that the BC tubes present a denser luminal side and a porous 
outer side; no orientation of the fibrils network was observed. Fluorescence microscopy reveals 
that apart from increasing cell adhesion, the presence of RGD stimulates the elongation and an 
even cell distribution, while cells coating the untreated BC are rounded and seems to form 
aggregates. Mechanical test results showed that small-diameter BC tube produced by our 
group possess an elasticity higher than human arteries and veins. 
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General conclusions and future perspectives 
 
This work consisted in the functionalization of structures based on bacterial cellulose with 
recombinant proteins containing a cellulose-binding module fused to an adhesion peptide and 
the study of the potential application of this biomaterial as blood vessel replacement. The 
results obtained showed that the recombinant proteins containing the RGD or GRGDY 
sequences were cloned and successfully expressed in fusion with a family 3 CBM of 
Clostridium thermocellum in Escherichia coli expression system. The recombinant proteins 
containing the adhesion peptide were able to promote adhesion and spreading of the 
fibroblasts; besides, the presence of RGD stimulates the elongation and an even cell 
distribution, while cells coating the untreated BC are rounded and seem to form aggregates. 
Furthermore, the proteins containing the sequence RGD showed a stronger effect than GRGDY 
on these cells. However, it seems that the second RGD or GRGDY brings no further 
functionality to the proteins, probably because the RGD sequence at the C-terminus of the 
peptide was not exposed in such a way as to be recognized by integrins. The chimeric proteins 
were able to enhance endothelial cells adhesion to BC and stimulate angiogenesis. However, 
the ingrowth of the cell through cellulose was decreased. We believe that an improved 
migration of the cells on BC will be achieved with an intermediary concentration of the protein 
used in this work. Immunocytochemistry results showed that cells grown on BC maintained 
their positive staining for vWF. This glycoprotein is one of the various secretory and membrane-
bound molecules produced by the endothelium and has long been favored as an endothelial 
cell marker. 
Blood compatibility studies showed that BC presents good hemocompatibility. Namely, the 
whole blood coagulation studies shows that the results are comparable to those produced by 
currently available materials for blood replacements. Taking in consideration the – presumably 
– much larger surface area of BC, and the possibility of having this material endothelialized 
(not possible with Dacron or ePTFE), the results may be considered very promising. The 
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adsorption of total plasma protein was not influenced by the presence of recombinant proteins 
(RGD-CBM), although decreasing the adhesion of fibrinogen on pure solutions. Adsorption 
isotherm studies showed that BC presents a higher affinity for albumin than immunoglobulin or 
fibrinogen. The presence of RGD on BC polymer increased platelet adhesion; however, when 
endothelial cells were cultured on RGD-treated BC, a confluent cell layer was formed and 
almost no platelets adhered to the material. Thus, the improvement of BC blood-compatibility 
through modification with adhesion peptides seems to be an interesting strategy as long the 
cellulose grafts are previously covered with endothelial cells. Nevertheless, a further 
characterization of the hemocompatibility is advised for future work, namely using methods for 
the detection of the specific actvation of coagulation factors related to the contact activation 
pathway. 
In vivo biocompatibility studies indicate that BC triggers a biological reaction typical of high 
surface-to-volume implants. There were no significant differences on the inflammation degree 
between the BC coated with the recombinant protein RGD-CBM and the native BC. The 
CryoSEM analysis showed that the BC tubes present a denser luminal side and a porous outer 
side; no orientation of the fibrils network was observed. Preliminary mechanical test results 
showed that small-diameter BC tube produced by our group possess an elasticity higher than 
human arteries and veins. However, the tensile strength was significantly lower as compared to 
the one exhibited by natural vessels, and therefore a method to produce tubes with improved 
mechanical properties is already in progress in our laboratory. 
The modification of BC with the CBM technique is far from limited to the adhesion peptide. 
Other active groups and growth factors could be fused to the CBM domain. Also once platelets 
adhered to exposed RGD peptides, other peptides more specific to ECs, or different 
combinations of peptides should be explored. Future modifications of BC could include 
heparinisation to produce not only a blood compatible but also an antithrombogenic surface. 
Some research could be directed to the production of a more porous BC tubes that allows the 
in-growth of endothelial cells. In fact, our lab is currently developing a different method for the 
production of the tubes, with thicker and porous wall thus, improving the quality and 
mechanical properties of BC tubes. 
The realization of in vivo experiments is mandatory for the effective evaluation of BC as a blood 
vessel substitute. These assays started indeed in the curse of this work, however it has been 
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not possible to conclude the experiments in due time. Among other issues, evaluation of the 
thrombogenicity in in vivo conditions, suturability, mechanical performance, endothelialisation, 
etc, must be evaluated (assays are already ongoing). 
